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This project generated and characterized integration-free, episomal-derived induced pluri-
potent stem cell (E-iPSCs) lines from human somatic cell lines of different origins.
Two different somatic cell lines were used, the human fetal fibroblast cell line HFF1
and human umbilical vein endothelial cell line HUVEC. Both were reprogrammed into
integration-free iPSCs and were comparable amongst themselves and to human embry-
onic stem cells, the gold standard of pluripotent stem cells. Furthermore, the iPSCs
with different genetic background were differentiated to hepatocyte-like cells (HLCs).
With the use of iPSC-derived hepatocytes different stages during hepatogenesis and the
potential of maturation could be analyzed as well as compared to fetal liver and pri-
mary human hepatocytes (PHH). This study could uncover gene regulatory networks
which presence bipotential progenitor populations in HLCs. Additionally, comparable
transcriptome profile analyses revealed that the iPSC-derived HLCs are immature and
more similar to fetal liver. However, the HLCs hold typical functionality characteristics
of hepatocyte, e.g. glycogen storage, uptake and release of ICG and CDFDA, bile acid
and urea secretion. Furthermore, typical structures of hepatocytes such as bile canali-
culi with microvilli, lipid storage and tight junctions are visible. In order to analyze
the maturation potential of HLCs a long-term culture experiment was performed using
HUVEC-iPSC-derived HLCs which implies the possibility for long-term culture of HLCs
while increasing maturation. Additionally, HFF1-derived iPSCs were differentiated to
endodermal progenitors (EPs) to analyze the endodermal development before biliary tree
and hepatoblast which can give rise to hepatocytes, cholangiocytes and pancreatic cells.
The multipotent EPs hold a great potential to analyze the endodermal development of
intestine, lung, liver, bile duct and gallbladder, as well as pancreas.
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Zusammenfassung (German)
In dieser Studie wurden nicht-integrative Vektorkonstrukte zur Reprogrammierung von
zwei menschlichen Zelllinien (HFF1, HUVEC) verwendet, um integrations-freie, episo-
mal generierte iPSC Zelllinien (E-iPSCs) zu generieren. Darber hinaus wurden diese
iPSCs zu sogenannten Leberzell-hnlichen Zellen (HLCs) differenziert. Hierzu konnten
die verschiedenen Stufen der Hepatogenese und die potentielle Reifung zu Leberzellen un-
tersucht sowie mit ftalen und ausgereiften menschlichen Leberzellen verglichen werden.
Diese Studie konnte Gen-regulierende Netzwerke aufdecken, welche eine pi-potentiale
Vorluferpopulation in den HLCs prsentieren. Zustzlich deckte das Transkriptions-Profil
auf, dass die iPSC-generierten HLCs unreif und hnlicher den ftalen Leberzellen sind.
Dennoch weisen die HLCs typische funktionelle Charakteristika von Leberzellen auf, z.B.
Glykogen-Einlagerung, Aufnahme und Abgabe von Substanzen wie ICG und CDFDA,
Sekretierung von Gallensure und Harnstoff. Zustzlich konnten typische Leber-Strukturen
wie Gallenkanlchen mit Mikrovilli, Fettspeicherung und sogenannte tight junctions,
Verbindungsgnge zwischen den Zellen nachgewiesen werden. Um die potentielle Rei-
fung dieser HLCs voranzutreiben, wurde eine Langzeit-Kultivierung von HUVEC-iPSC-
generierten HLCs durchgefhrt. Dies sollte zugleich zeigen, ob die HLCs lnger kultiviert
und gleichzeitig reifen knnen. Ein zweiter Teil dieser Studie befasst sich mit der Gener-
ierung von endodermalen Vorluferzellen (EPs). Es wurden HFF1-iPSCs zu EPs dif-
ferenziert um die endodermale Entwicklung vor der Entstehung der Gallenwege und des
Hepatoblasten zu untersuchen. Die EPs zeigen Merkmale dafr, dass sie sowohl in Hepa-
tozyten, Cholangozyten und auch Pankreaszellen differenziert werden knnen. Mit Hilfe
dieser multipotenten EPs knnte es mglich sein die endodermale Entwicklung des Darmes,




The liver is the largest gland in the human body and plays the most important role in
regulation of metabolic pathways and detoxification. The liver regulates for example the
glucose levels through carbohydrate storage (Glycogen) and release. Lipids and proteins
are consistently rebuilt and degraded. Also, the production of bile and the metabolism
of dietary compounds take place in the liver. Substances which are foreign to the body
(e.g. drugs or toxicants) are inactivated and the blood homeostasis is controled by
the production of blood components (e.g. Albumin and clotting factors) (reviewed by
Duncan [2000]; Malarkey et al. [2005]).
In the postprandial state, glucose is taken up by the liver, is metabolized into glycogen
and stored. Glucose can also be metabolized into fatty acids or amino acids. Free
fatty acids are esterified with glycerol-3-phosphate to generate triacylglycerol (TAG) in
hepatocytes. This TAG is secreted into the circulation as very low-density lipoprotein
(VLDL) particles or can be stored in lipid droplets in hepatocytes. Amino acids (AA)
are used to synthesize e.g. proteins and glucose. In order to provide energy for the body
glucose and TAG are released from the liver into the circulation and metabolized by
muscle, adipose tissue, and other extrahepatic tissues. Liver-generated glucose provides
essential metabolic energy for extrahepatic tissues during fasting and activities (Rui
[2014]).
The liver is able to catabolize AA as alternative energy source for the body. AA
are oxidized by amino acid catabolizing enzymes (AACE) when other energy substrates
are low, especially circulating glucose and fatty acids. In this state the proteins in the
skeletal muscles is broken down, dissociated into AA, circulated in the blood and are
taken up by the liver where the oxidation of AA is taken place. Additionally, fatty acids
can be modulate to hepatic AA. Peroxisome proliferator-activated receptor-a (PPARa)
stimulates fatty acid β-oxidation. The liver is the main organ involved in the metabolism
of AA. This metabolism redounds to the generation of metabolic energy and supplies
substrates for gluconeogenesis to maintain blood glucose concentration. The main source
of glucose for the brain and other tissues is provided by gluconeogenic AA (Harper [1984],
Kaloyianni and Freedland [1990], Young and Marchini [1990]).
Another metabolic process which executes in the liver is the urea cycle, also known as
the ornithine cycle. The urea cycle enzymes convert the cytotoxic ammonia to the much
less toxic urea. This process has a net energy cost. Urea is eliminated via the kidney by
fluids in particular urine. The urea cycle activity regulates the nitrogen concentration in
the body. The synthesis of urea plays a key role in protein catabolism. Taken together,
the urea cycle is essential for life (Cushny [1917], Saheki et al. [1980], Hansen et al.
[1986], Meijer et al. [1990], Dimski [1994], Young et al. [2000]).
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The liver is a complex organ consisting of hepatocytes, which represent most of the
liver cell mass (Figure 1.1). Hepatocytes are arranged in so called hepatic plates sepa-
rated by sinusoid spaces. These hepatic plates are arranged star-like around a central
vein. The bile canaliculi on the surface of adjoining hepatocytes drain bile into the bile
ducts, which run parallel to portal veins and hepatic arteries to form the portal triad
(Shiojiri [1984]; Duncan [2000]; Lemaigre [2003]; Malarkey et al. [2005]; Godoy et al.
[2013]).
Figure 1.1: Cellular structure of the liver.
A) The adult human liver (red), with the gall bladder and extra hepatic ducts (green), in relation
to the stomach and intestine (yellow). B) The cellular structure of the liver showing the hepatocytes
(pink) arranged in hepatic plates separated by sinusoid spaces radiating around a central vein. Bile
canaliculi on the surface of adjoining hepatocytes drain bile into the bile ducts (green), which run
parallel to portal veins (blue) and hepatic arteries (red) to form the portal triad. Adapted from:
http://www.stembook.org/node/512; retrieved 09.06.2014.
The catabolism of cholesterol in the liver yields bile salts. The hepatocytes gener-
ate the primary bile in their canaliculi which transport the bile to the cholangiocytes
driven by an osmotic gradient. The cholangiocytes form the bile duct and metabo-
lize the canalicular bile by secretory and reabsorptive processes. The bile salt export
pump (BSEP, ABCB11) protein is located in hepatocytes and the ATP-binding cassette,
sub-family C (CFTR/MRP), member 4 (MRP4/ABCC4) are in charge of the bile salt
circulation from hepatocytes to the bile (Figure 1.2). Triggered by ingestion, the bile
duct opens and the bile circulates into the duodenum, where lipolysis with the help of
the bile takes place. The vast bulk of bile is recycled from the small intestine, where they
assist with the absorption of dietary fat and fat-soluble vitamins. Additionally, the bile
is important to eliminate cholesterol and various toxins. With the blood flow, the bile
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returns into the liver by the solute carrier family 10 (sodium/bile acid cotransporter),
member 1 (NTCP, SLC10A1) and solute carrier organic anion transporter family, mem-
ber 1A2 (OATP, SLCO1A2) where the circular flow starts again (Childs et al. [1995],
Bull et al. [1998], Childs et al. [1998], Kullak-Ublick and Meier [2000], Esteller [2008],
Ogimura et al. [2011], Garzel et al. [2014]).
Figure 1.2: Scheme of bile salt.
The catabolism of cholesterol in the liver yields bile salts (BS). The bile salt export pump (BSEP)
protein is located in hepatocytes and mediates the transport of BS from hepatocytes into the bile
canaliculi. Simultaneously, organic anion (OA) and organic cation (OC) were released to the bile
canaliculi. The ATP-binding cassette, sub-family C (CFTR/MRP), member 2 (MRP2) mediates the
OA release and ATP-binding cassette, sub-family B (MDR/TAP), member 1 (MDR1, ABCB1) mediates
the OC release. MDR3 is responsible for the transport of phosphatylcholine (PC) from hepatocytes
into the bile canaliculi. The uptake of BS into the liver sinusoid is dependent on an OA mechanism
and is mediated by the ATP-binding cassette, sub-family C (CFTR/MRP), member 4 (MRP4/ABCC4)
and MRP3. The solute carrier organic anion transporter family, member 1A2 (OATP, SLCO1A2) is in
charge of the sinusoidal uptake and release OA. The bile returns into the liver by sodium dependent
mechanism mediated by solute carrier family 10 (sodium/bile acid cotransporter), member 1 (NTCP,
SLC10A1).
Hepatocyte transplantation was pioneered 1967 when the first enzymatic isolation
of hepatocytes was performed successfully (Howard et al. [1967]). Two years later a
combined technique of mechanical and enzymatic isolation carried out by Berry and
Friend [1969] and was further developed by Seglen [1976]. From this followed that
the first attempts of hepatocyte transplantation were done at the same year. It took
untill 1992 when hepatocytes were successfully transplanted in a human body. To
date there is no other effective method for end stage liver patients and many ge-
netic liver disorders as orthotopic liver transplantation (OLT) (Matas et al. [1976];
Hess et al. [1976]; Searle and Flaks [1976]; Mito et al. [1992]; Fox and Chowdhury
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[2004]; Mazaris et al. [2005]; Mir et al. [2006]; Ishikawa et al. [2010]; Asgari et al.
[2013]; Utsumi et al. [2014]; Girometti et al. [2014]). However, this method includes
the risk of surgery and carries two major problems: first, the lack of a compatible
donor and, second, the risk of organ rejection (Lorenzini et al. [2008]). Additionally,
the number of people who need a liver transplantation increaes, but the number of
organ donors decreases since years. 1,305 new patients came on to the existing wait-
ing list for liver transplantation in Germany in 2013. Only 970 liver transplantations
took place, including 83 after living donation (Eurotransplant International Foundation
Annual Report 2013, https://www.organspende-info.de/sites/all/files/files/
Jahresbericht_Eurotransplant_2013.pdf, retrieved 25.11.2014; Deutsche Stiftung
Organtransplantation Jahresbericht 2013, http://www.dso.de/uploads/tx_dsodl/JB_
2013_Web_05.pdf, retrieved 25.11.2014). One million patients die each year from acute
and chronic liver diseases worldwide. The orthotopic liver transplantation (OLT) is still
the only effective cure for end-stage liver patients and many genetic disorders. OLT is
the transplantation of a healthy liver from a deceased person or the transplatation of
a part of a healthy liver from a healthy person into a liverish patient. This treatment
includes the risk of donor incompatibility, transplantation surgery and organ rejection
(Fox and Chowdhury [2004]; Mazaris et al. [2005]; Mir et al. [2006]; Ishikawa et al. [2010];
Lorenzini et al. [2008]; Gonzalez and Keeffe [2011]; Asgari et al. [2013]; Girometti et al.
[2014]; Utsumi et al. [2014]). In order to close the gap between needed and available
livers for transplantation alternative strategies are required. Therefore, one of the future
goals of regenerative medicine is to derive a whole liver from patient specific cells. With
the entering of induced pluripotent stem cells and differentiation of patient specific cells
great hopes emerged to tackle this challenge. Immunoreaction could be avoided and
thus the risk of rejection will drop dramatically. Soon this vision could become reality:
obtain some skin cells and make a whole liver from them. This idea is not new, but until
now it has not been carried out successfully. Before generating a whole liver in vitro the
liver as a whole including its development (hepatogenesis) needs to be understood.
1.1 Hepatogenesis
Hepatogenesis is best understood in mice and rats. The endodermal specification in the
mouse embryo starts at the six somite-stage from day seven to nine after fertilization.
At day 10 after fertilization (E10) the liver bud is formed by hepatoblasts, which fur-
ther differentiate into hepatocytes (Figure 1.3). The maturation of the liver continues
postnatally (Houssaint [1980]; Medlock and Haar [1983]; Cascio and Zaret [1991]; Watt
et al. [2001]; Tremblay and Zaret [2005]; Zhao and Duncan [2005]; Watt et al. [2007]).
Hepatocytes constitute the liver‘s biggest cell mass accounting for more than 75 % (Fig-
ure 1.1). The liver is able to regenerate itself in vivo. If two thirds are removed, the
cells start to proliferate immediately and the lost cell mass will be replaced. In vitro the
cells lose this ability and several experiments were conducted to activate the ability for
regeneration in vitro. Although, rodent hepatocytes can be expanded. It is not possi-
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ble to culture human hepatocytes in vitro highlighting the liver as a complex structure
(Richman et al. [1976]; Shimaoka et al. [1987]; Mitaka et al. [1991]; Block et al. [1996];
Mitaka [1998]; Runge et al. [2000]; Mizuguchi et al. [2001]; Uyama et al. [2002]; Zhao and
Duncan [2005]; Shan et al. [2013]). During development (hepatogenesis) many pathways
and cytokines are involved to generate this complex organ. Before generating a whole
liver in vitro the liver as a whole including the hepatogenesis needs to be understood.
Figure 1.3: Time line of mouse liver development.
Schematic of liver development in mouse. The endodermal specification in the mouse embryo starts at
the six somite-stage from E7 to E9. The endoderm is patterned along the anterior-posterior (A - P)
axis into foregut (fg), midgut (mg) and hindgut (hg) progenitor domains at E8. The liver diverticulum
(ld) forms by E9. At E10 the liver bud (lb) is formed. Around E15 hepatoblasts are differentiating into
hepatocyte and biliary cells. The maturation of the liver continue untill after birth. Adapted from:
http://www.stembook.org/node/512; retrieved 09.06.2014.
1.1.1 Embryogenesis - essential signaling pathways
Hippo pathway
One of the main pathways involved in early developmental processes is the Hippo path-
way. The Hippo pathway is responsible for early embryonic development, embryonic
and adult stem cells, cell proliferation, differentiation, apoptosis, organ size, specific
functions in adult organs, tissue regeneration and tumorgenesis (Pan [2007]; Camargo
et al. [2007]; Dong et al. [2007]; Zhao et al. [2007]; Zhao et al. [2011a]; Tremblay and
Camargo [2012]; Cockburn et al. [2013]; Harvey et al. [2013]; Li et al. [2013]; Lin et al.
[2013]; Yimlamai et al. [2014]).
The Hippo pathway operates as follows. The STE20-like protein kinase 1 (MST1) and
MST2 (known as Hippo in Drosophila melanogaster), their co-factor Salvador (SAV) as
well as the Large tumour suppressor homologue 1 (LATS1) and LATS2 (known as Warts
in D. melanogaster) are the core components of the mammalian Hippo pathway (Figure
1.4A). SAV activates MST and MST phosphorylates LATS. The activity of the Hippo
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pathway is mediated by the phosphorylation of LATS proteins. The LATS proteins
phosphorylate the yes-associated protein (YAP) and the transcriptional co-activator
with PDZ-binding motif (TAZ) on multiple sites. YAP and TAZ form a complex. This
phosphorylated YAP/TAZ complexes persist in the cytoplasm, accumulate and were
degraded by proteasomes. Dephosphorylation of YAP and TAZ inactivates the Hippo
pathway. The YAP/TAZ complex translocates into the nucleus, accumulates there and
regulates gene transcription combined with DNA-binding transcription factors as the
TEA domain family members (TEADs) (Figure 1.4A; Zhao et al. [2007]; Halder et al.
[2012]).
The Hippo signaling pathway influences fate and size of liver cells and it is essential
for the maintenance of the differentiated hepatocyte state. In vivo experiments in mice
show that inactivation of the Hippo signaling pathway adult hepatocytes dedifferentiate
and acquire progenitor characteristics. For example, the lack of NF2 results in over
expression of YAP in liver, which induces an overgrown liver. Over expression of the
oncoprotein Yes-associated protein 1 (YAP1) in mice leads to increased liver size of more
than 4-fold (Camargo et al. [2007]; Yimlamai et al. [2014]). The removal of MST1 and
MST2 function in mice leads to overgrown of organs such as liver and heart, as well as the
hyperproliferation of intestinal epithelium resulting from YAP hyperactivation. Another
experimental animal is Drosophila melanogaster. The overgrown of adult structures
in flies come from mutations in most components of the Hippo pathway (Halder and
Johnson [2011]; Halder et al. [2012]).
The core components of the Hippo pathway are regulated by several inputs such as
cell-cell adhesions and apicobasal polarity complexes. For example, angiomotin family
proteins are localized to junction proteins (e.g. adherens and tight junctions). An-
giomotin family proteins can bind to MST, LATS or YAP and activate the phosphory-
lation of the YAP/TAZ complex. Another example is neurofibromin 2 (NF2), which is
associated with the E-cadherin complex. E-cadherin is an important adhesion molecule.
NF2 can bind to SAV, the MTS or LATS proteins to activate the Hippo pathway and
phosphorylate the YAP/TAZ complex (Zhao et al. [2007]; Paramasivam et al. [2011];
Halder et al. [2012]; Cockburn et al. [2013]; Hirate et al. [2013]; Nakagawa et al. [2014]).
The YAP/TAZ complex acts as a transcriptional regulator and controls the activity of
TGF-β-SMAD signaling. The transforming growth factor (TGF)-β family phosphorylate
receptor-dependent SMAD2/3 which binds SMAD4. This complex translocates into the
nucleus and interacts with TAZ, which is responsible for the SMAD complex to stay
in the nucleus where it couples to the SMAD complex to the transcription structure
(Varelas et al. [2008]). As a result of the active Hippo pathway the YAP/TAZ complex
is phosphorylated and cannot shuttle into the nucleus. This leads to a suppression of
SMAD nuclear accumulation and cytoplasmatic stay of the YAP/TAZ complex (Varelas
et al. [2010]). In the cytoplasm the YAP/TAZ complex can also interact with the Crumbs
complex which contributes to the stabilization and maturation of junctional structures
(Varelas et al. [2010]). In mature hepatocytes the activity of YAP is more cytoplasmic
than nuclear because they show high Hippo pathway activity (Yimlamai et al. [2014]).
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Additionally, YAP plays an essential role in mammalian liver by cell fate decision
and affects the Notch signaling pathway (Yimlamai et al. [2014]). The Notch signal-
ing pathway plays an important role in ductal specification during development and is
transiently activated during liver regeneration (Khler et al. [2004]; Zong et al. [2009];
Hofmann et al. [2010]).
Figure 1.4: Scheme of the Hippo and Notch pathway.
A) The STE20-like protein kinase 1 (MST1) or MST2 together with their co-factor Salvador (SAV)
promote the phosphorylation of Large tumour suppressor homologue 1 (LATS1) and LATS2. MST
kinase phosphorylates LATS proteins. LATS proteins phosphorylate the yes-associated protein (YAP)
and the transcriptional co-activator with PDZ-binding motif (TAZ) on multiple sites. If the YAP and
TAZ are phosphorylated they stay in the cytoplasm, accumulate and were degraded by proteasome. YAP
and TAZ are dephosphorylated, if the Hippo pathway is inactivated. They translocate into the nucleus,
accumulate there and regulate gene transcription combined with DNA-binding transcription factors as
the TEA domain family members (TEADs). Adapted from: Halder et al. [2012]. B) The canonical
Notch signaling is characterized by the extracellular interaction of a Notch transmembrane receptor (in
mammalian Notch 1 - 4) with a canonical Notch transmembrane ligand (in mammalian Jagged (JAG) 1
- 2, Delta-like (DLL) 1 - 4). The contact between receptor and ligand initiates the proteolytic cleavage of
the receptor and the subsequent release of the Notch intracellular domain (NICD) of the receptor. The
NICD then translocates to the nucleus, where it interacts with a CBF1/Suppressor of Hairless/LAG-1
(CSL) family DNA-binding protein (C promoter-binding factor (CBF1)) and Mastermind-like protein





Notch signaling is an evolutionary conserved mechanism that plays amongst others an
important role in cell fate decisions in the early liver development. Multiple Notch lig-
ands, receptors and Hes/Hey family members are expressed in embryonic liver (Artavanis-
Tsakonas et al. [1999]; Louis et al. [1999]; Crosnier et al. [2000]; Jones et al. [2000]; Nijjar
et al. [2001]; Loomes et al. [2002]; McCright et al. [2002]; Flynn et al. [2004]; Kodama
et al. [2004]; Sumazaki et al. [2004]; Tanimizu and Miyajima [2004]; Zong et al. [2009];
Andersson and Lendahl [2014]). The Notch pathway can be divided into canonical
Notch signaling and non-canonical Notch signaling. The canonical Notch signaling is
characterized by the extracellular interaction of a Notch transmembrane receptor (in
mammalian Notch1 - 4) with a canonical Notch transmembrane ligand (in mammalian
Jagged (JAG) 1 - 2, Delta-like (DLL) 1 - 4) (Figure 1.4B). The ligand is on the cell
surface of a neighboring cell. The interaction between receptor and ligand initiates the
proteolytic cleavage of the receptor and the subsequent release of the Notch intracellular
domain (NICD) of the receptor. Then the NICD translocates into the nucleus. In the
nucleus the NCID interacts with a CBF1/Suppressor of Hairless/LAG-1 (CSL) family
DNA-binding protein, C promoter-binding factor (CBF1) and Mastermind-like protein
(MAML). The interaction initiates the transcription of Notch target genes. The non-
canonical Notch signaling can be initiated by a non-canonical ligand. In some forms
of non-canonical signaling there is no involvement of CSL (reviewed by D’Souza et al.
[2010]; Heitzler [2010]; Andersson et al. [2011]; Andersson and Lendahl [2014]).
During liver and biliary development Notch coordinates biliary fate and duct morpho-
genesis in a temporal- and dose-dependent way, which is a late event in liver development
(Figure 1.5). In addition, the Notch pathway regulates embryonic biliary fate and second
biliary layer formation as well as hepatobiliary remodeling after injury. Upregulation
of Notch signaling pathway components in undamaged adult liver result in several liver
diseases (Nijjar et al. [2001]; Nijjar et al. [2002]; Flynn et al. [2004]; Zong et al. [2009]).
Loss of Notch signaling induces developmental block of the bile duct. Already reduced
activity influences developmental processes negatively. In heterozygous mice a defect of
Notch2 and Jag1 is monitored as well as in patient with Alagille syndrome. After injury
the liver rejuvenate and the Notch signaling reprograms hepatocytes into endothelial
biliary cells. In the liver Notch signaling is also involved in lipid content regulation. The
inhibition of Notch signaling results in reduced hepatic glucose production and triggers
increased fatty liver (McCright et al. [2002]; Zong et al. [2009]; Yanger et al. [2013];
Pajvani et al. [2013]; Andersson and Lendahl [2014]). Increased Notch signaling causes
carcinoma in liver. The over expression of Notch1 ICD in mice results in several carci-
noma. This is also observed in human cholangiocarcinoma cells, the excessive availability
of NOTCH1, NOTCH3 and JAG1 could be monitored. The Notch signaling pathway is
a functional important effector downstream of the Hippo transducer YAP (Villanueva
et al. [2012]; Zender et al. [2013]; Yimlamai et al. [2014]).
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Figure 1.5: Scheme of bile duct formation by Notch signaling.
Endothelial-derived Jag1 positive cells activates Notch signaling and Hes1 expression in the neighboring
hepatoblasts in early liver development (E12.5 - 14.5). Afterwards formation of the first ductal plate
layer starts at E14.6 - 16.5. Tubulogenesis between E16.5 and E17.5 occurs at discrete sites of active
Notch signaling in neighboring hepatocytes and give rise to a primitive ductal structure. Cells com-
prising the second (outer) layer of this asymmetric tubule undergo biliary differentiation between E17.5
and P2 (not shown here). Consecutively growth of the portal mesenchyme and loss of unincorporated
biliary epithelial cells leads to the formation of a mature portal tract by P15. Biliary epithelial cells in
both layers of the ductal plate express Jag1, the endothelium cells (yellow) and biliary epithelial cells
(green cells with blue nuclei). Hepatocytes are the grey cells with red nuclei. Adapted from: Zong et al.
[2009].
TGFβ superfamily
The TGFβ superfamily is a huge protein group including the transforming growth factor
βs (TGFβs), the bone morphogenetic proteins (BMPs), Nodal, growth differentiation
factors (GDFs) and Activins. Members of the TGFβ superfamily are involved in embry-
onic development, maintenance and differentiation of embryonic stem cells, somatic stem
cells and cancer stem cells as well as in development and maintenance of various organs
(Massagu et al. [1987]; Massagu [1992]; Wilson and Hemmati-Brivanlou [1995]; Bran-
denberger et al. [2004]; Qi et al. [2004]; Clotman and Lemaigre [2006]; Xu et al. [2008];
Watabe and Miyazono [2009]; Wu and Hill [2009]). In general, TGFβ superfamily mem-
bers bind specific type I and II transmembrane serine threonine kinase receptors. This
leads to their activation and phosphorylation of intracellular receptor regulated Smad
proteins (R-Smad). The TGFβs, Nodal and Activins activate Smad2/3 by binding the
type I receptors ALK4/5/7. In contrast, BMPs and GDFs transduce their signal through
ALK2/3/6 and activating Smad1/5/8 (reviewed by Miyazono et al. [2005]; Schmierer
and Hill [2007]; Ross and Hill [2008]; Wrighton and Feng [2008]; Umulis et al. [2009];
Heldin and Moustakas [2012]; Massagu [2012]).
The TGFβ pathway is eponymous for this cytokine superfamiliy and is representative
of Activin and Nodal pathways (Figure 1.6). TGFβ binds to the TGFβ receptor II
(TβRII) which recruits the type I receptor TGFβ receptor I (TβRI/ALK5). Transphos-
phorylation of TβRI activates this process and initiates downstream signaling. The type
I receptor phosphorylates Smad2/3 and they form a heterotrimeric complex with the co-
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Smad, Smad4. This Smad complexs consists of two receptor-regulated Smad proteins
(R-Smad) and one co-Smad. In this case, two Smad2 or two Smad3 or one Smad2 and one
Smad3 with Smad4 (co-Smad) form a complex. This trimer (e.g. Smad2/Smad3/Smad4)
shuttles into the nucleus and regulates the transcription of various genes in collabora-
tion with other transcription factors, co-activators and co-repressors. When inhibitors of
Smad-activated proteins are active the inhibition results from a negative feedback by a
diversity of mechanisms. Here Smad7 works as the inhibitor (reviewed by Kretzschmar
and Massagu [1998]; Miyazono et al. [2005]; Derynck and Zhang [2003]; Schmierer and
Hill [2007]; Kang et al. [2009]; Vogt et al. [2011]).
Figure 1.6: Scheme of Nodal-Smad signaling.
Nodal binds to its receptors EGF-CFC. These receptors phospharylate Smad2 and Smad3. Smad2/3
builds a trimer complex with Smad4 and then shuttles into the nucleus where the complex binds to the
DNA. Together with co-factors this complex regulates the expression of various genes. Amongst others
the expression of Lefty1 and Lefty2 obtain activation. This induction activates a negative-feedback
circuit to the Nodal-Smad signaling pathway. Adapted from: Arnold and Robertson [2009].
In terms of signal transduction, the bone morphogenetic protein (BMP) pathway is
similar to the TGFβ pathway, but receptor binding is more diverse. The BMP ligands
BMP2 and BMP4 bind to type I receptor Alk3 and Alk6 which recruits the type II
receptor BMPRII/ActRII and ActRIIB. In contrast, BMP6 and BMP7 bind to type II
receptor ActRII/ActRIIB and recruit type I receptor Alk2, Alk3 and Alk6. In either
case, the type I receptor phosphorylates receptor regulated Smad proteins (R-Smad;
Smad1/5/8) and they form a heterotrimeric complex with the co-Smad, Smad4. This
Smad complex consists of two R-Smad and one co-Smad and shifts as a trimer into the
nucleus. There the complex binds to specific DNA sequences and regulates the tran-
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scription of various genes in collaboration with other transcription factors, co-activators
and co-repressors. The Smad-activated proteins are active as the inhibitors. The inhi-
bition results from a negative feedback by a diversity of mechanisms. Here Smad6 act
as a inhibitor in addition to Smad7 (reviewed by de Caestecker [2004]; Moustakas and
Heldin [2009]; Heldin and Moustakas [2012]).
In undifferentiated human embryonic stem cells (hESC) TGFβ, ACTIVIN and NODAL
signaling are observed by detection of phosphorylated and nuclear localized SMAD2.
Upon early differentiation their activity decreased and BMP signaling increased. De-
pending on the concentration ACTIVIN induces definitive endoderm (DE) or meso-
derm development. In mouse embryos loss of Smad2 activity results in early embryonic
lethality. The development of definitive endoderm is interrupted by the loss of Smad2,
Smad4 or primary targets of them: FoxH1, Foxa2 (HNF3β, Eomes) (Dufort et al. [1998];
Waldrip et al. [1998]; Tremblay et al. [2000]; Yamamoto et al. [2001]; Hoodless et al.
[2001]; Vincent et al. [2003]; Chu et al. [2004]; James et al. [2005]; Tada et al. [2005];
Arnold et al. [2008]). The development and specification of DE needs high Nodal activ-
ity, which is higher than for mesoderm development. The Activin/Nodal-Smad signaling
activates DE specific genes and Eomes. Eomes interacts with Smad2/3 and inhibits the
expression of mesoderm specific genes (Hart et al. [2002]; Shen [2007]; Teo et al. [2011]).
The development of DE is dependent on the concentration of ACTIVIN and NODAL.
BMP signaling induces differentiation of hESC as well as suppress E-Cadherin/CDH1
(E-CAD) and pluripotency for DE development (Xu et al. [2002]; Ying et al. [2003];
Pera et al. [2004]; Qi et al. [2004]; Teo et al. [2011]; Teo et al. [2012]; Lichtner et al.
[2013]). TGFβ is a key regulator of Epithelial-to-Mesenchymal Transition (EMT). Nu-
merous stimuli and cytokines can activate EMT, but TGFβ as SMAD-mediated and
Non-SMAD-mediated signaling seems to be the main regulator of EMT. Smad-dependent
signaling activates AKT and glycogen synthase kinase 3 beta (GSK3β) which leads to β-
catenin nuclear translocation, E-CAD and ZO-1 inhibition and EMT. Smad-independent
signaling activates e.g. RHOA, PAR6 and MAPK which leads to tight junction deple-
tion, cytoskeleton and cell-cell contact rearrangement, stress fiber formation as well as
activation of mesenchymal gene-expression (Miettinen et al. [1994]; Oft et al. [1998];
Fujita et al. [2000]; Bhowmick et al. [2001]; Rajasekaran et al. [2001]; Chen et al. [2002];
Kim et al. [2002]; Grille et al. [2003]; Masszi et al. [2003]; Barrios-Rodiles et al. [2005];
Ozdamar et al. [2005]).
1.1.2 Operative signaling pathways in Hepatogenesis
The TGFβ/Nodal signaling is one of the most important signaling pathways for the
entire development of an embryo. It activates Smad2/3 and induces directly the ex-
pression of the pluripotency factor Nanog. It is also required to increase and maintain
endodermal gene expression (Yasuo and Lemaire [1999]; Engleka et al. [2001]; Chang
and Hemmati-Brivanlou [2000]; Clements and Woodland [2003]; Xu et al. [2008]). At
E3.5 of mouse embryo development, when the inner cell mass (ICM) and the trophoec-
toderm (TE) has formed, the ICM consists of a mixture cell population (Figure 1.7A).
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There are cells which express GATA6 and cells which express Nanog. These cells are
not uniformly arranged, but they are positioned randomly and mosaic. Two lineages
segregate from the ICM, the primitive endoderm (GATA6-positive cells) and the pluripo-
tent epiblast (Nanog-positive cells) (Chazaud et al. [2006]). Mice experiments showed
that GATA6-knockout embryos died between E5.5 and E6.5 dpc. Expression of GATA6
starts around day 3.5 dpc in the ICM and mediate TGFβ/Nodal signaling during endo-
derm formation (Figure 1.7; Albano et al. [1993]; Hudson et al. [1997]; Morrisey et al.
[1998]; Koutsourakis et al. [1999]; Rossant et al. [2003]). Sox17a and HNF1β become
directly activated by GATA6. For the full induction of Sox17a and HNF1β the activaty
of GATA4, 5 and 6 is required whereby activation sequence is GATA6, GATA4 and then
GATA5. These is necessary for the full endodermal gene expression and gut formation
in vivo, too (Afouda et al. [2005]).
Figure 1.7: Nodal signaling in early mouse embryo.
A) At E3.5 of mouse embryo development the inner cell mass (ICM) and the trophoectoderm (TE)
has formed. The ICM is a mixture of GATA6 (cells with green nucleus) and Nanog (cells with pink
nucleus) expressing cells. From the ICM two lineages segregate, the primitive endoderm (GATA6-
positive cells) and the pluripotent epiblast (Nanog-positive cells). B) At E5.25 days post-coitum (dpc)
Nodal is expressed in the complete epiblast and induces the formation of anterior visceral endoderm
(AVE, step not shown). The Nodal signaling initiates the movement of the AVE (red area, movement
shown by purple arrow) to the anterior side at E5.75 dpc. In this area the Nodal antagonists Lefty and
Cer1 are expressed. A high expression level of Nodal in the posterior area induces the development
of the primitive streak (green area, shown at E6.75 dpc). Adapted from: Shen [2007] and Arnold and
Robertson [2009].
Liver development requires the interaction with mesenchymal tissue in the region
of the septum transversum (Figure 1.8). Liver-specific genes are not activated, if the
ventral foregut endoderm from 2 - 6 somite-stage embryo is cultured without cardiac
mesoderm or Fgf (Houssaint [1980]; Medlock and Haar [1983]; Deutsch et al. [2001];
Rossi et al. [2001]). Fgf signaling from the cardiogenic mesoderm induces the liver in
the ventral foregut endoderm. Mouse endoderm explants which were cultured without
cardiogenic mesoderm were treated only with Fgf. Other experiments could show that
mouse null mutations for individual components of the Fgf signaling pathway are lethal
before hepatic induction or have minimal phenotype (Yamaguchi et al. [1992]; Meyers
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et al. [1998]; Weinstein et al. [1998]; Jung et al. [1999]; Miller et al. [2000]). The septum
transversum mesenchyme (STM) cells derived from the lateral mesoderm plate (Figure
1.8). These cells were found in mouse explants of cardiogenic mesoderm and ventral
foregut endoderm. The bone morphogenetic proteins 2 and 4 (Bmp2 and Bmp4) are
strongly expressed in the STM before and during the induction of hepatic development.
The development of several ventral structures in an embryo is disturbed by the deletion
of Bmp4 (Jones et al. [1991];Furuta et al. [1997]; Hogan [1999]; Rossi et al. [2001]).
Figure 1.8: Signal and tissue interactions which regulate liver development.
A) At the 2 - 6 somite stage the expression of transcription factors specific for endoderm (Foxa) as
well as signals which affect the endoderm (BMP signaling) initiate the liver development. The bone
morphogenetic proteins (Bmp) emanate from the adjacent cells of septum transversum mesenchyme
(STM). B) Between the somite stages seven and eight the tissue specification take place. From the
cardiac mesoderm the fibroblast growth factor (Fgf) signal activates the liver gene program in proximal
endoderm and blocks gene program for pancreas. C) The signals which specified the hepatic endoderm
(HE) cells also initiate a morphological change of the cells during the 11 and 13 somite stage, the
HE become pillared in shape. Signaling molecules from the STM cells and primitive endothelial cells
(e.g. Bmp, Hgf and Vegfr2) and transcription factors (e.g. Hex, Prox1, Hlx and c-Met) are essential to
promote the morphogenesis of the liver bud itself (see D). D) By formation of the rostral diverticulum of
the gut the Liver-bud morphogenesis is build, the extracellular matrix around the hepatoblasts obtains
remodel and the E-cadherin-based connections between the cells is build, as well as the proliferation and
migration into the surrounding STM take place. The growing liver obtains invade by haematopoietic
cells and the organ becomes distinct from the gut epithelium. Abbreviation: Bmp = bone morphogenetic
protein; c-Met = Hgf receptor; Hgf = hepatocyte growth factor; Vegfr2 = vascular endothelial growth
factor receptor 2. Adapted from: Zaret [2002].
Haematopoietic area expressed homeobox (Hex ) and Prospero-related homeobox 1
(Prox1 ). These are two main homeodomain transcription factors which have the earli-
est known specific effects on hepatic endoderm (HE) and on liver-bud morphogenesis.
Before induction of hepatic endoderm Hex is expressed in mouse in the anterior visceral
endoderm and the anterior definitive endoderm (DE). Later on Hex is expressed in the
liver, thyroid and endothelial cells in adult vertebrates. Prox1 is involved in cell - cell in-
teractions and extra cellular matrix (ECM) remodeling and acts immediately after Hex
in hepatic morphogenesis (Crompton et al. [1992]; Hromas et al. [1993]; Oliver et al.
[1993]; Thomas et al. [1998]; Sosa-Pineda et al. [2000]).
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β1-integrin is part of a heterodimeric receptor for laminins and collagens. The loss of
β1-integrin results in failure to colonize hepatocytes in the liver of chimeric mouse (Hynes
[1992]; Fssler and Meyer [1995]). The hepatoblast growth the H2.0-like homeobox gene
(Hlx ) positively regulates the synthesis of paracrine factors (Figure 1.8). In Hlx knockout
mice the liver is a small bud (Hentsch et al. [1996]). The STM express the hepatocyte
growth factor (Hgf) and hepatoblasts express c-Met (the Hgf receptor). Hgf and c-Met
knockout mice result in apoptosis of the hepatoblasts. C-Met has a anti-apoptotic role
for Hgf signaling. Smad2 and Smad3 are involved in the Tgfβ signaling. Heterozygote
inactivation of both leads to fetal liver hypoplasia. In adult liver Tgfβ signaling inhibit
hepatocyte proliferation. Hgf and Tgfβ both are in charge of growth signals in liver
development. (Bladt et al. [1995]; Schmidt et al. [1995]; Amicone et al. [1997]; Isfort
et al. [1997]; Grasl-Kraupp et al. [1998]; Weinstein et al. [2001]).
WNT/β-Catenin pathway
WNT/β-Catenin is a conserved pathway which plays an important role during vertebrate
embryogenesis, tissue differentiation, organogenesis and regulates stem cell pluripotency.
This cascade cross-talks with other pathways, including retinoic acid, FGF, TGF-β
and BMP. WNTs are secreted glycoproteins which bind to Frizzled receptors, which
then triggers displacement of the multifunctional kinase GSK-3β from a regulatory
APC/AXIN/GSK-3β-complex (Figure 1.9). If the WNT signal is not operative (Off-
state) CK1 and the APC/AXIN/GSK-3β-complex bind to β-Catenin and become phos-
phorylated. β-Catenin is also an integral E-Cadherin cell-cell adhesion adaptor protein
and transcriptional co-regulator. The phosphorylation leads to its ubiquitination and
proteasomal degradation by the β-TrCP/SKP pathway (Li et al. [2012]; Wehrli et al.
[2000]; reviewed by MacDonald et al. [2009]; Clevers and Nusse [2012]).
Mouse studies show that the Wnt signaling is necessary for the extension of the
anterior-posterior axis in the primary embryo. During the patterning of the anterior-
posterior axis into forgut, midgut and hindgut the Wnt signaling is inhibited in the
forgut region by e.g. SFRP, but expressed in the hindgut region. Subsequently Wnt
signaling is required for hepatogenesis (Liu et al. [1999]; Yamaguchi et al. [1999]; McLin
et al. [2007]).
The Leucine-rich repeat-containing G-protein-coupled receptor (LGR) 5 is a WNT
target gene by binding the WNT agonist R-SPONDIN (RSPO) 1. LGR5 is part of the
Frizzled/LRP receptor complex and is responsible for the activation of the WNT signal-
ing in adult stem cells and hereby for the maintenance of the stem cells and progenitor
cells as liver progenitor cells (Jaks et al. [2008]; de Lau et al. [2011]; Sato et al. [2011];
ten Berge et al. [2011]; Barker et al. [2012]; Cheng et al. [2012]; Barker et al. [2013];
Gil-Sanchis et al. [2013]; Huch et al. [2013]).
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Figure 1.9: Activation and inactivation of the Wnt/β-catenin pathway.
If the Wnt-signal is inactive (Off-state) the destruction complex resides in the cytoplasm. There the com-
plex binds to β-catenin through β-TrCP. This raises that β-catenin is phosphorylated and ubiquitinated.
The proteasome recycles the complex by degrading β-catenin. Wnt binds to Frizzled receptors, which
then triggers displacement of the multifunctional kinase GSK3β from a regulatory APC/Axin/GSK3β-
complex and induces the association of the intact complex with phosphorylated LRP (low-density
lipoprotein (LDL)-receptor-related protein). The complex phosphorylates β-catenin, but the ubiquiti-
nation by β-TrCP is blocked. Synthesized β-catenin accumulates and translocates into the nucleus to
activate target genes. Adapted from: Clevers and Nusse [2012].
FGF pathway
The fibroblast growth factors (FGFs) play important roles during vertebrate develop-
ment, liver generation and in a wide array of biological processes like cell growth, dif-
ferentiation, angiogenesis and tissue repair, as well as maintenance of embryonic stem
cells. In general, FGF binds to the FGF receptor (FGFR) which induces FGFR dimeriza-
tion (Figure 1.10). Transphosphorylation triggers the kinase activation. Subsequently,
the FGFR kinase activates its intracellular substrates by phosphorylation. The FGFR
substrate 2α (FRS2α) is a major substrates of FGFR kinase, which is constitutively
associated with the receptor kinase, and phospholipase Cγ1 (PLCγ1). FRS2α binds to
the adaptor protein growth factor receptor-bound 2 (GRB2). GRB2 recruits the guanine
nucleotide exchange factor son of sevenless (SOS) and binds it to the signaling complex.
Then, SOS activates RAS GTPase, which initiates activation of the MAPK cascade.
MAPK translocates from the cytoplasm to the nucleus. There it phosphorylates and,
hence, activates immediate early gene transcription factors, such as FOS to induce tran-
scription of specific genes (Kouhara et al. [1997]; Carpenter and Ji [1999]; Bttcher and
Niehrs [2005]; Thisse and Thisse [2005]; Furdui et al. [2006]; Chen et al. [2008]; Turner
and Grose [2010]).
During mouse embryonic development (4 - 7 somites stage) Fgf signaling from the
developing heart (in addition of Bmp signaling from septum transversum mesenchyme
(STM)) induces hepatic development in the ventral foregut endoderm (Figure 1.8; Burgess




Figure 1.10: Scheme of FGF and MAPK/ERK signaling cascade.
A) FGF signaling: Fibroblast growth factor (FGF) binds to the FGF receptor (FGFR) which induces
FGFR dimerization. Transphosphorylation triggers the kinase activation. Subsequently, the FGFR ki-
nase phosphorylates its intracellular substrates which is activated by the phosphorylation. The FGFR
substrate 2α (FRS2α) is a major substrates of FGFR kinase, which is constitutively associated with
the receptor kinase, and phospholipase Cγ1 (PLCγ1). FRS2 binds the adaptor protein growth factor
receptor-bound 2 (GRB2)113. GRB2 recruits the guanine nucleotide exchange factor son of seven-
less (SOS) and binds it to the signaling complex. Then SOS activates RAS GTPase, which initiates
activation of the MAPK cascade. MAPK translocates from the cytoplasm to the nucleus. There it
phosphorylates and hence activates immediate early gene transcription factors, such as FOS to induce
transcription of specific genes. B) MAPK/ERK signaling: Mitogen-activated protein kinase (MAPK)
and the extracellular signal-regulated kinase (ERK) signaling cascade (MAPK/ERK) is activated by
several receptors which are involved in growth and differentiation including receptor tyrosine kinases
(RTKs). The architecture of the pathway usually includes a set of adaptors (Shc, GRB2, Crk, etc.)
linking the receptor to the guanine nucleotide exchange factor son-of-sevenless (SOS) transducing the
signal to the small GTP-binding proteins (RAS), which triggers the activation of MAPKKK (Raf).
Raf phosphorylates the MAPKK (MEK; MAPK and ERK kinase). Then activated MEK catalyses the
dual phosphorylation of the MAPK (ERK). Phosphorylated ERK translocates to the nucleus, where it
phosphorylates and activates transcription factors that control the expression of genes that are required




1.2 Human Embryonic Stem Cells (hESC) and induced
Pluripotent Stem Cells (iPSC)
Human embryonic stem cells (hESC) are derived from the inner cell mass (ICM) of blas-
tocyst stage embryos and can be cultured in vitro (Figure 1.11). hESC have two valuable
abilities which characterize these cell type. First, they have the capability to self-renew
indefinitely. Second, they are pluripotent. hESC can give rise to all cell lineages of
the three embryonic germ layers, which are endoderm (e.g. cells of the gastrointestinal
tract), ectoderm (e.g. cells of the nervous system), mesoderm (e.g. cells of bone and
muscle) and also germ cells. This pluripotent state is regulated by transcriptional and
epigenetic mechanisms. Self-renewal in embryonic stem cells is maintained by a gene
regulatory network orchestrated by the core transcription factors, OCT4, SOX2 and
NANOG in association with the FGF2, WNT, TGFβ signaling pathway (Albano et al.
[1993]; Hudson et al. [1997]; Morrisey et al. [1998]; Jung et al. [1999]; Koutsourakis et al.
[1999]; Liu et al. [1999]; Yamaguchi et al. [1999]; Yasuo and Lemaire [1999]; Rossant
et al. [2003]; Chazaud et al. [2006]; Greber et al. [2007]; McLin et al. [2007]; Chen and
Daley [2008]; Cheng et al. [2012]).
Murine embryonic stem cell lines were isolated from pre-implantation embryos in 1981.
17 years later, in 1998, James Thomson and colleagues derived the first human embryonic
stem cell lines also from pre-implantion embryos. By now, over 400 hESC lines exist, but
only a few of them are well characterized. H1 for example is one of the best characterized
hESCs lines. This line was derived by James Thomson and colleagues. The derivation,
characterization and cultivation of such cells was a milestone in human developmental
biology.
These cells paved the way for the modern drug discovery, and transplantation medicine.
The tissue rejection after implantation in patients constitutes a problem. Additionally,
to derive hESCs a blastocyst has to be destroyed, which raise ethical and moral concerns
(Figure 1.11; Evans and Kaufman [1981]; Thomson et al. [1998]; Jensen et al. [2009]).
These were solved when scientists succeeded found alternative ways to derive pluripotent
cells. At first, mouse somatic cells were reprogrammed successfully in 2006 by Takahashi
and Yamanaka. Shortly afterwards, two groups reprogrammed human adult fibroblasts
with viral transduction mediated over-expression of four transcription factors OCT4,
SOX2, KLF4 and c-MYC (Yamanaka-Cocktail) or OCT4, SOX2, NANOG and LIN28
(Thomson-Cocktail). The reprogramming of adult fibroblasts to induced pluripotent
stem cells (iPSCs) marked another milestone in human developmental biology and it is
used to shed light on the mechanisms of pluripotency and their maintenance. The iP-
SCs have the same capacities as human embryonic stem cells, including pluripotency and
self-renewal. Further they share the same morphology as well as they are able to differ-
entiate in all three germ layers in vitro (embryoid body formation) and in vivo (teratoma
formation in immune deficient mice). The integration of pro-viruses into genome of viral-
derived iPSCs is a risk factor for clinical applications in the future. Therefore, many
non-viral reprogramming methods were developed using non-integrating adenoviruses,
non-viral vectors, mRNA, miRNA or protein transfection. The major advantage of non-
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viral methods is the lack of integration into the genome of tranfected cells (Takahashi
and Yamanaka [2006]; Takahashi et al. [2007a]; Yu et al. [2007]; Chen and Liu [2009];
Yu et al. [2009]; Kiskinis and Eggan [2010]; Tavernier et al. [2012]). The derivation
of integration-free iPSC from somatic cells and differentiating them into a donor cell
type of interest are promising approaches for (i) future application in tissue replacement
therapies, (ii) generation of disease models in vitro, (iii) toxicology and drug screening.
Figure 1.11: Extraction and differentiation of ESC.
The first step of differentiation during the development of the mammalian embryo from the in-
ner cell mass is the formation of the blastocyst, when the morula differentiates to the trophoblast.
Embryonic stem cells (ESC) are derived from the inner cell mass of the blastocyst. ESC can
taken from the blastocyst, then can be cultured and differentiated in vitro. Adapted from: http:
//www.biologyjunction.com/stemcell_article.htm; Illustration by Cell Imaging Core of the Cen-
ter for Reproductive Science, retrieved 08.06.2014.
1.3 Methods for generating iPSCs
Amongst others, iPSCs are an alternative to hESCs without raising ethical and moral
concerns because they possess the same characteristics as hESCs. First Takahashi
and Yamanaka [2006] derived iPSCs from mouse somatic cells with a viral approach
(Yamanaka-Cocktail). One year later two groups successfully reprogrammed human
adult fibroblasts with viral transduction mediated over-expression of four transcription
factors using the Yamanaka-Cocktail or the Thomson-Cocktail (Takahashi et al. [2007a];
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Yu et al. [2007]). The efficiency of reprogramming human fibroblasts to iPSCs by using
retro-viruses is less than 1.0 % (Yamanaka 2007). The reprogramming of human fibrob-
lasts to iPSCs by transduction of lenti-viral constructs using the Thomson-Cocktail has
an efficiency of 0.02 – 0.0095 % (Yu et al. [2007]). Both methods are robust due to
the fact that viral transduction is highly efficient. This is confirmed by the ability of
numerous groups that have been able to reproduce these protocols (e.g. Prigione et al.
[2010]; Si-Tayeb et al. [2010]; Totonchi et al. [2010] Wolfrum et al. [2010]; Jozefczuk et al.
[2011]; Ohi et al. [2011]; Lichtner et al. [2013]). Derived by the fact that the efficiency
is too low to generate iPSCs routinely, additional different methods were developed to
reprogramm somatic cells (Hanna et al. [2007]; Nakagawa et al. [2008]; Woltjen et al.
[2009]). p53 inhibition enhances the efficiency of iPSCs generation of human fibroblasts
up to 100-fold. Furthermore, the transient inhibition of p53 can increase the efficiency
of reprogramming human dermal fibroblasts by approximately 7-fold. To increase the
efficiency of the viral reprogramming method additional factors have been used such as
the viral oncogene simian virus 40 large T antigen (SVLT40). SV40LT is a 708-amino
acid large oncoprotein. It is one of the two proteins expressed in infected cells by Simian
virus 40 to obtain alteration of the host cells. SV40LT is able to affect a multitude
of cells lines and it induces tumours in diverse animal models. The function of dedi-
cated indicator tumour suppressors and cell cycle regulatory proteins of the host cell by
binding it engineers. SV40LT inactivates the function of the tumor suppressor p53 and
members of the retinoblastoma family of proteins such as pRB, p107 and p130. If the
transcription of p53 is blocked the cell cycle cannot arrest and thereby the mechanism
of repairing DNA damages would be inhibited (Ali and DeCaprio [2001]; Zhao et al.
[2008]; Hong et al. [2009]; Kawamura et al. [2009]; Li et al. [2009]; Marin et al. [2009];
Utikal et al. [2009]; Wang and Adjaye [2011]).
To avoid mutagenesis by pro-virus integration and reactivation of oncogenic transgenes
non-viral methods have been designed. The main problem of non-viral methods is the
low efficiency of reprogramming. It is even lower compared to the retroviral methods.
Murine somatic cells were reprogrammed into iPSCs by the transfection of two plasmids,
carried the transgenes OCT4, KLF4, SOX2 and c-MYC. The reprogramming efficiency
ranged between 1 x 10−6 and 2.9 x 10−5 %. Another vector-used method used a piggyback
(PB) based vector system consisting of a vector and a transposon for doxycyclin inducible
expression of the reprogramming factors. The reprogramming efficiency amounts to >
2 %. Also, the transfection of somatic cells with the proteins of OCT4, SOX2, KLF4
and c-MYC generated iPSCs. Using proteins is a completely vector free method to
generate iPSCs. Unfortunately, the efficiency is low (around 0.001 %) and the import
into the cells is problematic. In addition, there is another method which generates iPSCs
that are free of vector and of transgene sequences by nucleofection of oriP/EBNA1
(Epstein-Barr nuclear antigen-1)-based episomal vectors that express reprogramming
factors. The transfection of oriP/EBNA1 vectors which are derived from the Epstein-
Barr virus happen without viral packaging. During culture the iPSCs which have been
reprogrammed by oriP/EBNA1 vectors, the cells remove the episomal vectors with a
rate of 5 % per cell division due to defective plasmid synthesis. The cis-acting oriP
element on the vector and the EBNA-1 gene which encodes a replication initiation
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factor the oriP/EBNA1-based vectors hold the ability of extra-chromosomal replication.
The efficiency of this method to generate iPSCs increased up to 0.003 – 0.006 % and
these iPSCs displayed ESCs characteristics. Analysis of whole-genome expression profiles
showed that the generated iPSCs by using oriP/EBNA1 vectors are more similar to ESCs
than iPSCs which were generated with other non-viral or viral methods. Moreover after
14 passages, the iPSCs had completely lost the episomal vectors (Yates et al. [1984];
Okita et al. [2008]; Chen and Liu [2009]; Kim et al. [2009a]; Woltjen et al. [2009]; Yu
et al. [2009]; Yu et al. [2011]).
Not all reprogrammed cells have ESCs morphology, but are different from the parental
cells. This kind of cells were described as partially reprogrammed cells. Due to impacted
targeting of the reprogramming factors OCT4, SOX2 and KLF4 the state of these cells
is in-between the parental cells and iPSCs. To obtain a higher efficiency of the pluripo-
tent state and shift the partially reprogrammed cells to the iPSCs state, the cells can
be treated with so-called small molecules, which are organic compounds, in order to
manipulate signaling pathways (Park et al. [2008]; Takahashi et al. [2007b]; Sridharan
et al. [2009]).
The inactivation of the TGFβ pathway (described in section 1.1.1) by using the small
molecule inhibitors SB431542 increase the efficiency and the kinetics of iPSCs generation
(Figure 1.12). An important process during the embryonic development is the induction
of epithelial to mesenchymal transition (EMT) which also has effects for iPSCs genera-
tion. Amongst others TGFβ has a growth inhibitor function and is also involved to that
process of EMT by e.g. decreasing expression of epithelial markers such as E-Cadherin
and ZO-1 as well as increasing expression of mesenchymal markers e.g. fibronectin.
Therefore, a temporal inhibition of the TGFβ pathway increases the reprogramming
efficiency. Later, the TGFβ inhibition has to be removed in particular when TGFβ
acquires the active role of pluripotentcy maintenance. The induction of pluripotency
is favoured by the change of mesenchymal to epithelial (MET) development (Miettinen
et al. [1994]; Hartsough and Mulder [1995]; Inman et al. [2002]; Barrios-Rodiles et al.
[2005]; Willis and Borok [2007]; Lin et al. [2009]; Wang et al. [2010]).
It is also evident that reprogramming using epithelial cells such as keratinocytes results
in an increased efficiency as compared with dermal fibroblasts or MSCs which are of
mesenchymal origin. The chemical compound PD0325901 an inhibitor of the MAP/ERK
kinase (MEK) pathway (described in section 1.1.2 and Figure 1.10). Extracellular signals
are activate the MAP kinase pathway which activates MEK. This pathway plays a major
role in the regulation of growth and differentiation of cells (Figure 1.12). The chemical
compound PD0325901 inhibits this pathway through blocking the phosphorylation of
ERK by MEK (Barrett et al. [2008]). The inactivation of the TGFβ and the MEK-ERK
pathways in fully reprogrammed iPS or ES cells by using the small molecule SB431542
and PD0325901, respectively, results in differentiation. Therefore, extended use of these
small molecules during reprogramming is not advisable.
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Figure 1.12: Inhibition of pathway by the use of small molecules.
To raise the efficiency of episomal based reprogramming of somatic cells chemical compounds so called
small molecules were used. In this case four different small molecules were used to block three different
signaling pathways. The small molecule SB431542 specifically inhibits the Type I receptors ALK4,
ALK5 and ALK7 and thus the inactivates the TGFβ signaling pathway. Additionally, the efficiency
and the kinetics of iPSCs generation increase due to the inhibition. The chemical compound PD0325901
inactivates the MAP/ERK kinase (MEK) by blocking the phosphorylation of ERK by MEK. Thereby
the MAP kinase pathway which plays a major role in the regulation of growth and differentiation of
cells. The small molecule CHIR9902 is blocking the glycogen synthase kinase-3 beta (GSK3β). GSK3β
is a multifunctional serine/threonine (Ser/Thr) kinase which regulates several physiological processes
such as apoptosis, metabolism, development, oncogenesis. Rho associated coiled-coil kinase (ROCK) is
a serine/threonine (Ser/Thr) kinase like GSK and regulates several cell processes such as cytokinesis,
proliferation, cell adhesion and motility. The ROCK inhibitor Y-27632 blocks this kinase.
The glycogen synthase kinase-3 beta (GSK3β) pathway (described in section 1.1.1)
regulates several physiological processes such as apoptosis, metabolism, development,
oncogenesis and is activated by cellular stress (ER stress, hyperosmotic stress, heat
shock, oxidative stress). To raise the efficiency of episomal based reprogramming the
small molecule CHIR99021 inhibits GSK3β (Figure 1.12; Chen et al. [2004]; Yu et al.
[2011]; Zhou et al. [2012]).
Another small molecule is a ROCK inhibitor named Y-27632 can be used. Rho as-
sociated coiled-coil kinase (ROCK) like GSKβ regulates several cell processes such as
cytokinesis, proliferation, cell adhesion and motility. The ROCK inhibitor increases the
reprogramming efficiency from 1 % to 27 % (Figure 1.12; Ishizaki et al. [2000]; Watanabe
et al. [2007]; Tsuchiya et al. [2011]).
All four small molecules together could be the best combination to reach a maximal
effect on episomal reprogramming (Yu et al. [2011]).
In general pluripotent cells are promising candidates for the application in tissue
replacement therapies and for the generation of disease models (Figure 1.13).
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However, there are still unresolved problems, such as the fact that KLF4 and c-MYC
are oncogenes that could be reactivated which pose risk factors for clinical applications
in the future. These conditions cause a high probability of genomic instability and
mutagenesis in iPSCs. Using fewer factors with OCT4, SOX2, KLF4 but without c-MYC
has been suggested to enable medical applications in the future and safer reprogramming.
Mouse neural stem cells which express endogenous level of c-MYC, SOX2 and KLF4 have
been reprogrammed by using one factor namely OCT4 (Nakagawa et al. [2008]; Chen
and Liu [2009]; Kim et al. [2009b]; Wang et al. [2010]).
Figure 1.13: Clinical application of iPSC.
Induced pluripotent stem cells (iPSC) were generated as a source for any cell type of interest. After
differentiation and functional analysis the cells can be transplanted in a patient. Adapted from: http:
//www.biologyjunction.com/stemcell_article.htm; Illustration by Cell Imaging Core of the Center
for Reproductive Science (retrieved 08.06.2014).
1.4 Hepatocyte differentiation of hESCs and iPSCs in
vitro
The transplantation of hepatocytes has been shown to be effective and minimally inva-
sive, but there is a worldwide shortage of human liver. In addition, limited willingness
of liver donation restricts the use of hepatocyte transplantation further. New methods
have to be generated to tackle these problems, for example a living related liver dona-
tion and cell therapy (Figure 1.13). Since 2005 human embryonic stem cells (hESCs)
were used to generate hepatocytes in vitro. Henceforward, this method was modified
and optimized repeatedly (Lee et al. [2004]; Mazaris et al. [2005]; Schwartz et al. [2005];
Soto-Gutierrez et al. [2006]; Hay et al. [2007]; Hay et al. [2008b]; Agarwal et al. [2008];
Hay et al. [2008a]). Independent from liver diseases and shortage of liver donors iP-
SCs were generated as a source for any cell type of interest. Therefore, iPSCs could be
used as a source to generate hepatocytes (Takahashi and Yamanaka [2006]; Takahashi
et al. [2007a]; Takahashi et al. [2007b]; Yu et al. [2007]; Yu et al. [2009]; Sullivan et al.
[2010]; Jozefczuk et al. [2011]; Yu et al. [2011]; Chiang et al. [2013]; Hoyer et al. [2013];




Figure 1.14: Different protocols of HLC-derivation.
Different protocol are shown to generate hepatocyte-like cells (HLC) from embryonic stem cells (ESC)
and induced pluripotent stem cells (iPSC). Adapted from: A) Hay et al. [2008b]; B) Asgari et al.
[2013]; C) Choi et al. [2013]; D) Mallanna and Duncan [2013]; E) Ogawa et al. [2013]; F) Kondo et al.
[2014a].
The current hepatocyte differentiation protocols are composed of cytokine cocktails
and stepwise approaches. The most hepatocyte differentiation protocols are composed
of three steps. First, the generation of definitive endoderm (DE), second, the hepatic
endoderm (HE) and finally the third step to generate the hepatocyte-like cells (HLCs).
Many different protocols exist to generate the HLCs (Figure 1.14). It seems that each
laboratory has its own specific protocol. The basal medium, the time period as well as
the cytokine composition of each step vary. The most important aspect is the cytokine
composition (Hay et al. [2008b]; Asgari et al. [2013]; Choi et al. [2013]; Mallanna and
Duncan [2013]; Ogawa et al. [2013]; Kondo et al. [2014a]). To generate DE the con-
centration and composition of the cytokines has to be defined. Activin A seems to be
essential to generate DE. All protocols which are listed here use Activin A to generate
DE (Figure 1.14). Depending on the concentration Activin induces DE or mesoderm de-
velopment. Activin and BMP4 synergistically promote the induction of DE stage (Hart
et al. [2002]; Tada et al. [2005]; Sulzbacher et al. [2009]; Teo et al. [2012]). Additionally,
the fibroblast growth factors (FGF) play an important role during liver generation, as
well as maintain embryonic stem cells (Jung et al. [1999]; Weinstein et al. [2001]; Greber
et al. [2007]). The pathways of these cytokines were described before (see on page 5).
Dimethylsulfoxide (DMSO) induces differentiation of various cells typs including stem
cells to endodermal cells and further to hepatic endoderm (HE), but the mechanism is
still unknown (Morley and Whitfield [1993]; Hay et al. [2008b]; Pal et al. [2012]; Chetty
et al. [2013]).
The hepatocyte growth factor (HGF) is essential for liver derivation. HGF binds to the
cell surface receptor c-Met. This initiates the phosphorylation of a receptor-dimer and
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activates amongst others the MAP/ERK signaling cascade (described in section 1.1.2).
HGF activates cell proliferation, cell survival and migration, which plays important roles
in liver development, maturation and regeneration. (Bottaro et al. [1991]; Bussolino et al.
[1992]; Ito et al. [2000]; Kamiya et al. [2001]).
Figure 1.15: Scheme of the Jak/Stat pathway.
Oncostatin M (OSM) binds to the subunit glycoprotein 130 (gp130) of a cell surface receptor com-
plex and specific to the subunit OSM Receptor β chain (OSMRβ) of the OSM specific Receptor type
II (OSMR). The receptors of gp130 and OSMRβ form a heterodimer which activates the receptor-
associated Janus kinase (JAK). JAK phosphorylates the signal transducer and activator of transcrip-
tion (STAT)1 and STAT3. An STAT1/3 heterodimer translocates to the nucleus, bind to specific DNA
sequences and activates the transcription of hepatic differentiation markers. Adapted from: Shuai and
Liu [2003].
As well as HGF the cytokine Oncostatin M (OSM) induces liver differentiation. OSM
is a member of the Interleukine 6 (IL-6) family of cytokines which all use gp130 as a
co-receptor (Figure 1.15). On the one hand OSM binds this subunit glycoprotein 130
(gp130) of a cell surface receptor complex with low affinity and on the other hand binds
specific the subunit OSM Receptor β chain (OSMRβ). The receptors of gp130 and
OSMRβ form a heterodimer which can activate two major pathways, the MAPK/ERK
pathway (described in section 1.1.2 and Figure 1.8) or the JAK/STAT pathway (Fig-
ure 1.15). In adult liver OSM induces amongst others low density lipoprotein recep-
tor (LDLR) expression, shown in human hepatoma cell line (HepG2), mice and rats.
Thereby OSM regulates the cholesterol metabolism. In rat was shown that OSM mediate
proliferation as well as anti-apoptosis of hepatocytes and, thereby, induces regeneration
of hepatocytes after liver injury (Grove et al. [1991]; Gearing et al. [1992]; Faris et al.
[1996]; Mosley et al. [1996]; Hirano et al. [1997]; Liu et al. [1997a]; Liu et al. [1997b];
Stancato et al. [1997]; Lindberg et al. [1998]; Tanaka et al. [1999]; Ito et al. [2000];
Kamiya et al. [2001]; Okaya et al. [2005]; Hamada et al. [2007]; Drechsler et al. [2012]).
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Dexamethasone (Dex) was used to complete the cocktail of supplements, which was
used in this work to generate hepatocytes in vitro. Dex is a synthetic glucocorticoid
which suppresses AFP expression and up-regulates albumin expression shown in rats
(Blanger et al. [1981]; Nawa et al. [1986]; de Juan et al. [1992]). Dexamethasone is
necessary for maturation of hepatocytes. OSM alone is not able to initiate this process
(Kamiya et al. [1999]; Kojima et al. [2000]; Matsui et al. [2002]; Agarwal et al. [2008]).
In the past, pharmaceutical companies used Primary human hepatocytes (PHH) for
toxicology test and drug screenings. The culturing of PHH is problematic because, firstly,
they cannot be expanded in vitro, secondly, PHH are difficult to obtain routinely and
thirdly, it is difficult to isolate them in sufficient quantities (Elaut et al. [2006a]; Elaut
et al. [2006b]; Fraczek et al. [2013]). Human hepatocarcinoma-derived and transformed,
permanent cell lines, including HepG2, THLE and HepaRG are used as alternatives, but
these cell lines have phenotypes significantly diverged from normal primary hepatocytes
(Hart et al. [2010]; Jennen et al. [2010]; Gerets et al. [2012]; Cuconati et al. [2013], Jetten
et al. [2013]).
The differentiation of iPSCs to hepatocyte-like cells (HLCs) could be a potential al-
ternative for pharmaceutical toxicology test and drug screenings. HLCs generated from
human iPSC have shown great promise as an inexhaustible source of cells that mirror the
genotype of the donor to satisfy this need. Multifunctional applicable HLCs generated
from iPSCs can serve as cellular models for drug screenings and toxicology studies, as
well as serve a source for disease modeling. Several groups have shown multifunctional
applicable HLCs already. Most studies using viral approach to derive iPSCs and further
to generate HLCs. However, these have drawbacks (e.g. genome integration) and most
studies focus on one aspect of the multifunctional application of the HLCs. These stud-
ies are focused on the generation of HLCs from iPSCs, the maturation, modeling liver
diseases or drug screening and toxicology (Greenhough et al. [2010]; Rashid et al. [2010];
Sullivan et al. [2010]; Hannan et al. [2013]; Jozefczuk et al. [2011]; Teo et al. [2011];
Yusa et al. [2011]; Asgari et al. [2013]; Choi et al. [2013]; Gieseck et al. [2014]; Subba
Rao et al. [2013]; Kondo et al. [2014a]; Kondo et al. [2014b]; Nakagawa et al. [2014];
Takayama et al. [2014]; Takebe et al. [2014]).
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1.5 Aim of this work
The liver is the largest gland in the human body and plays the most important role in
regulation of metabolic pathways and detoxification. Hepatocytes are the main cell type
supporting the detoxification function of the liver and as such they are already exten-
sively used for toxicology screens. Original primary human hepatocytes (PHH) cannot
be expanded in vitro, are difficult to obtain routinely and difficult to obtain in sufficient
quantities. Additionally, alternative hepatocarcinoma-derived and transformed, perma-
nent cell lines diverge significantly from normal primary hepatocytes. Due to these
stated facts another alternative must be found.
Induced pluripotent stem cells (iPSCs) have the same capacities as human embryonic
stem cells, including pluripotency, self-renewal, same morphology and they are able
to differentiate in all lineages of the three germ layers. The common way to generate
iPSCs from human somatic cells uses virus-approach. The integration of pro-viruses into
genome of viral-derived iPSCs is a risk factor for clinical applications in the future (Chen
and Liu [2009]). Therefore, this study demonstrates the generation and characterization
of integration-free, episomal-derived induced pluripotent stem cell (E-iPSCs) lines from
human somatic cell lines with different origin. The transcriptome of the E-iPSC lines
were compared to that of hESCs and to that of a viral-derived iPSC line (V-iPSC).
Additionally, the E-iPSCs were used to derive and characterize hepatocyte-like cells
(HLCs). Analysis about the functionality and life span were done. Additionally, the
transcriptome profile of these HLCs were compared to that of fetal liver and PHH to
identify commonalities and differences. Furthermore, an attempt was made to untangle
hepatogenesis-associated gene regulatory networks.
Due to the fact that the hepatogenesis is best understood in mice and rats so far, this
work also tried to gain insights into molecular and gene regulatory networks governing
the hepatogenesis in human.
This PhD thesis addresses four main goals:
• Generation of stable viral-free and integration-free human induced pluripotent
stem cells (E-iPSC).
• Differentiation of E-iPSCs to hepatocyte-like cells (HLCs) to model the hepatoge-
nesis.
• Generate HLCs with a higher functional quality and longer functional life span.
• Generation of endodermal progenitors (EP) from E-iPSCs to study the early time
span of hepatogenesis.
To achieve these goals, the following investigations were carried out:




• Full characterization of generated E-iPSC-lines and transcriptome analysis com-
pared to human embryonic stem cells (hESC.).
• Step-wise differentiation of E-iPSCs to HLCs and characterization of HLCs.
• Analyses of quality, functionality and life span of HLCs.
• Transcriptome profile analysis of HLCs compared to the transcriptome profile of
fetal liver and primary human hepatocytes (PHH).
• Generation and characterization of endodermal progenitors (EPs).
• Transcriptome profile analysis of EPs compared to HLCs, fetal liver and PHH.
27
2 Preliminary Work
Episomal-based reprogramming of HFF1-cells
In a previous study (my master thesis, 2012) I generated and characterized viral-free
induced pluripotent stem cells (iPSCs) (Figure 6.2). To achieve this, HFF1-cells were
transfected with oriP/EBNA1-based episomal vectors which are derived from the Epstein-
Barr virus without viral packaging and avoid genetic modification, because they do not
integrate into the genome. The vectors express the reprogramming factors OCT4, SOX2,
NANOG, KLF4, LIN28, c-MYC and SV40LT (Yu et al. [2009]; Figure 6.1). To enhance
the efficiency of reprogramming the following small molecules, (i) TGFβ-pathway in-
hibitor (SB431542), (ii) MEK-ERK pathway inhibitor (PD0325901) and (iii) GSK3β
inhibitor (CHIR99021) were supplemented one day after nucleofection for 23 days (Yu
et al. [2011]). Indeed, the iPSC-line (epiHFF1-iPS-B1) shown here is integration free
(Figure 2.1; Matz and Adjaye [2016]) and has the same characteristics as human embry-
onic stem cells (hESCs) lines (Figure 2.2 - 2.6; Matz and Adjaye [2016]; Supplementary
Figure S1 and S2).
Figure 2.1: PCR of plasmid detection in epiHFF1-iPS-B1.
A) Detection of the plasmid gene sequences of EBNA-1 and OriP which are included in each vector.
B) Detection of the plasmid gene sequences of LIN28 and SV40LT. C) Detection of the plasmid gene
sequences of NANOG and OCT4. D) Detection of the human genome gene sequence of OCT4. 100 bp
Marker was used. The vector ET2K, which is one of the three transfected vectors, was used as a positive
control, ddH2O was used as the negative control, as well as HFF1 the original cell line. Modified from
Matz and Adjaye [2016].
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The epiHFF1-iPS-B1 express pluripotent maker genes and amongst others the surface
marker genes AP, TRA-1-60, TRA-1-81, SSEA-4, but not SSEA-1. SSEA-1 is a marker
of differentiation in human ESC though a marker of the undifferentiated state in mouse
ESCs (Thomson et al. [1998]; Takahashi et al. [2007a]; Yu et al. [2007]) as well as
OCT4, NANOG, SOX2 (Figure 2.2 and 2.3; Matz and Adjaye [2016]). These iPSC-line
can differentiate in vitro in all three germ layers endoderm, ectoderm and mesoderm
by formation of embryoid bodies (Figure 2.4; Matz and Adjaye [2016]). The karyotype
analysis confirmed that epiHFF1-iPS-B1 is a human male iPSC-line, but Chromosome 12
contains an aberration. The DNA fingerprint is identical to the fingerprint of the human
fibroblast line HFF1, but different compared to the hESC lines H1 and H9 (Figure 2.5;
Matz and Adjaye [2016]). The expression pattern of pluripotency genes were measured
by quantitative real-time PCR (qRT-PCR) and compared to the pattern of H1 cells.
The expression pattern of the iPSC-line is similar to H1 and is stable over the time
(Figure 2.6).
Figure 2.2: Immunofluorescence-based detection of surface markers in epiHFF1-iPS-B1.
A) Staining of the surface protein alkaline phosphatase (AP) overview of the well, microscopy image and
live stained cells (from left to right). B) Immunofluorescence-based protein stainings for the surface
markers SSEA-4, TRA-l-60 and TRA-1-81 were positive, SSEA-1 was negative. DAPI stained the
nucleus. Scale bar: 200 µm, Alexa Flour 594 (red), Alexa Fluor 488 (green). Modified from Matz and
Adjaye [2016].
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Figure 2.3: Immunofluorescence-based detection of pluripotency markers in epiHFF1-
iPS-B1.
Immunofluorescence-based protein stainings for pluripotency markers OCT4, NANOG, SOX2, KLF4,
c-MYC, LIN28 and PODXL were positive. DAPI stained the nucleus. Scale bar: 200 µm, Alexa Flour
594 (red), Alexa Fluor 488 (green). Modified from Matz and Adjaye [2016].
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Figure 2.4: Immunofluorescence-based detection of germ-layer specific proteins EBs de-
rived from epiHFF1-iPS-B1.
All three germ layers mesoderm, ectoderm and endoderm were detected in vitro by formation of embry-
oid bodies. The detection of the proteins T and α-SMA are markers of mesoderm layer, PAX6, β-TUJ1
and NES detect the ectoderm layer and AFP, FOXA2, SOX17 are markers of endoderm layer. DAPI
stained the nucleus. Scale bar: 200 µm Alexa Flour 594 (red), Alexa Fluor 488 (green). Abbreviations:
T = brachyury homolog (mouse); α-SMA = Smooth Muscle Actin; PAX6 = Paired Box 6; β-TUJ1 =
class III β-Tubulin; NES = Nestin; AFP = α-Fetoprotein; FOXA2 = Forkhead box A2; SOX17 = SRY
(sex determining region Y)-box 17. Modified from Matz and Adjaye [2016].
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Figure 2.5: Karyogram and DNA fingerprinting of epiHFF1-iPS-B1.
A) Presence of a male karyogram 46,XY,add(12)(p13) from epiHFF1-iPS-B1. The Chromosome 12
containing additional material of unknown origin and different banding pattern. The additional material
has the size of a long arm of chromosome 6. mar = minimal altered region. B) Genomic DNA from
hESCs H1 and H9, HFF1 cells and the viral-free epiHFF1-iPS-B1 for PCR were used. 1: Genomic PCR
with the primer of D7S796. 2: Genomic PCR with the primer of D10S1214. 3: Genomic PCR with the
primer of D17S1290. 4: Genomic PCR with the primer of D21S2055. Modified from Matz and Adjaye
[2016].
Figure 2.6: Quantitative real-time PCR of epiHFF1-iPS-B1.
Expression pattern of pluripotency markers relative to HFF1 from hESC-line H1 and the iPSC-line
epiHFF1-iPS-B1 in passage 10 (P10) and passage 16 (P16) are shown. The standard deviation is de-
picted by the error bars. Abbreviations: HFF1 = human foreskin fibroblast; hESC = human embryonic
stem cell; iPSC = induced pluripotent stem cell.
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3.1 Episomal-based reprogramming of somatic cells
3.1.1 Characterization of human fetal fibroblast-derived iPSC line
The viral-free, episomal-based reprogramming of the human fetal fibroblast line HFF1
and most of the characterization was done in a previous work and is described in Chapter
2. However, the in vivo confirmation was not done. Therefore to complete the charac-
terization of the episomal reprogrammed induced pluripotent cell (iPSC)-line epiHFF1-
iPS-B1 teratoma formation in immunodeficient mice was performed. The presence of all
three germ layers in the teratoma were detected (Figure 3.1; Matz and Adjaye [2016]).
Hence, the final required step for demonstrating that epiHFF1-iPS-B1 is pluripotent has
been completed.
Figure 3.1: Teratoma of epiHFF1-iPS-B1.
In vivo teratoma formation of epiHFF1-iPS-B1 upon transplantation into NOD scid gamma mice. 1)
total tumor, histological structures corresponding to 2) ectoderm (pigmented neuronal epithelium),
3) endoderm (epithelium with goblet cells), 4) mesoderm (connective tissue) lineages are depicted.
Modified from Matz and Adjaye [2016].
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Global gene expression analyses
Reprogramming of somatic cells to iPSCs results in major changes in transcriptional
profile of the cells (Wolfrum et al. [2010]). To analyze potential changes of human fe-
tal fibroblasts (HFF1), episomal reprogrammed iPSC-line epiHFF1-iPS-B1 from HFF1
cells (E-iPSCs) and human embryonic stem cells (hESCs) the Illumina Bead-Studio
platform was used (Figure 3.2A). During the reprogramming process the transcriptome
profile of the parental cells shifted towards a hESC-like stage. The parental HFF1
cells lost their expression upon reprogramming while other sets of genes were activated
upon reprogramming. A third set of genes was maintained in both states (Figure 3.2A,
Supplementary Table 1). To visualize the distinct and overlapping genes expression
patterns in HFF1 versus E-iPSCs and hESCs a Venn diagram was generated (Figure
3.2B). We identified gene signatures representative of cellular housekeeping functions
(11994 genes; e.g. GAPDH, ACTB, PGK1, LDHA), donor cell (HFF1)-specific genes
(1373 genes; e.g. APOL3, CUX1, DOK1, EPS8, FOXF2 ), donor cell-memory genes
(213 genes; e.g. LAMA4, TERC ), self-renewal and pluripotent genes (1417 genes; e.g.
POU5F1, SOX2, NANOG, LIN28, GDF3 ), iPSC (E-iPSC)-specific gene expression sig-
nature (450 genes; e.g. DAZ4, FGD4, GJC3, LHX4, SDC3 ) and hESC-specific genes
(537 genes; e.g. FGFBP1, FGF9, GSC, WNT3A) (Figure 3.2B, the entire gene lists are
presented in Supplementary Table 2). The intersection of hESC and E-iPSC from the
Venn diagram contains genes (e.g. CDH1, EOMES, FGF8, HAND1, JAG2, LEFTY1,
LEFTY2, LIF, MIXL1, NODAL, SOX2, T, WNT10B) which are involved in biological
processes such as developmental signaling, pluripotency, self-renewal and embryogenesis
(Figure 3.2C - D).
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Figure 3.2: Microarray data analyses.
A) Heatmap visualizes expression pattern changes during cellular reprogramming. Expression pattern
of hESCs, episomal reprogrammed HFF1-cell line epiHFF1-iPS-B1 (E-iPSC), retro-viral reprogrammed
HFF1-cell line vHFF1-iPS-iPS4 (V-iPSC) and the somatic cell line HFF1 were compared. The top 24
genes with transcription activity either unchanged (Retained), low (Lost) or high (Acquired) expression
values of iPSCs relative to the parental cell line (HFF1) were selected. B) Venn diagram analysis of the
transcriptome profile from HFF1, E-iPSC and hESC portraying distinct and overlapping transcriptional
signatures. C) Graph of biological processes related to embryogenesis to percentage of genes from the
intersection of E-iPSC and hESC from the venn diagram (B). D) Graph of biological processes related
to embryogenesis signaling and pluripotency to percentage of genes from the intersection of E-iPSC
and hESC from the venn diagram (B). Abbreviations: hESCs = human embryonic stem cells; HFF1 =
human foreskin fibroblast 1; E-iPSC = episomal reprogrammed induced pluripotent stem cell; V-iPSC
= retro-viral reprogrammed induced pluripotent stem cell.
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Comparison of transcriptome profile from viral and non-viral reprogrammed iPSCs
In order to assess whether the episomal or viral reprogramming method induces weaker
or less alterations in gene expression we compared the gene gene expression signatures
of episomal-derived iPSCs (E-iPSCs), viral-derived iPSCs (V-iPSCs) and human em-
bryonic stem cells (hESCs) (Figure 3.3). E-iPSCs and V-iPSCs were derived from the
same genetic background, the human fetal fibroblast cell line HFF1. The retro-viral
reprogrammed iPSC-line vHFF1-iPS-iPS4, which was used for this study, was generated
in our laboratory and is fully characterized (Prigione et al. [2010]; Wang et al. [2010]).
RNA-based microarray analysis showed that the transcriptome profile of E-iPSCs is
closer to that of hESCs (R2 = 0.9363) than the transcriptome profile of V-iPSCs (R2
= 0.8176) (Figure 3.3A). The cluster analysis reinforced this result (Figure 3.3B). Fur-
ther, pluripotency gene expression levels were analyzed. The transcriptome profile of
E-iPSCs is closer to that of hESCs than V-iPSCs (Figure 3.3C). The expression pattern
of the viral reprogrammed cell line vHFF1-iPS-iPS4 is closer to the origin cell line HFF1.
Karyotype analysis demonstrated that epiHFF1-iPS-B1 contains an aberration on chro-
mosome 12 of unknown origin, but the karyotype of vHFF1-iPS-iPS4 has no aberration
(Figure 2.5; Prigione et al. [2010]). The RNA-based microarray data of the expression
level of the genes which are located on the short arm of chromosome 12 were analyzed
to clarify if the aberration is a duplication of the short arm (Figure 3.3C). The genes are
all most expressed in epiHFF1-iPS-B1 which could be an indication for a duplication.
However, the expression pattern of epiHFF1-iPS-B1 is closer to that of hESCs than to
the vHFF1-iPS-iPS4.
Further comparative analyses were performed to uncover difference and commonalities
between the different iPSC-lines and hESCs. A Venn diagram was generated to visualize
the distinct and overlapping genes expression patterns in V-iPSCs versus E-iPSCs and
hESCs (Figure 3.4). We identified gene signatures representative of cellular housekeep-
ing functions and pluripotency-associated genes (12,366 genes; e.g. GAPDH, ACTB,
OCT4/POU5F1, SOX2, NANOG), V-iPSC-specific genes (960 genes; e.g. IRAK4,
MASP1, SLMF7, TLR4 ), donor cell-memory genes (222 genes; e.g. LAMA4, TERC ),
E-iPSC-specific gene expression signature (441 genes; e.g. DAZ4, FGD4, GJC3, HSF1,
TDGF3, TCF15 ) and hESC-specific genes (621 genes; e.g. FGFBP1, GATA3, GSC,
PEG3, WNT3A) (Figure 3.4, the entire gene lists are presented in Supplementary Table
3). The intersection of hESC and E-iPSC from the Venn diagram contains genes (1,045
genes; e.g. BMP4, CDH1, CER1, DNMT3B, EOMES, FGF4, FGF8, HAND1, JAG2,
LEFTY1, MIXL1, NODAL, T, TDGF1 ) which are involved in biological processes such
as developmental signaling, pluripotency, self-renewal and gastrulation. The intersec-
tion of hESC and V-iPSC from the Venn diagram contains genes (607 genes; e.g. FGF9,




Figure 3.3: Transcriptome profiling of non-viral, episomal reprogrammed iPSC line
epiHFF1-iPS-B1.
A) Pearson correlation co-efficient of the entire expression data (Illumina microarrays) between indi-
cated cell types uncovered the similarity between E-iPSCs and hESCs (R2 = 0.9363). In comparison
the transcriptome profile of viral reprogrammed iPSCs deviated from hESCs to a greater extent (R2
= 0.8176). B) A dendrogram analysis confirmed that the transcriptome profile of epiHFF1-iPS-B1 is
similar to hESC (ES). C) Analysis of the transcriptome relations of pluripotency genes between hESC,
epiHFF1-iPS-B1, vHFF1-iPS-iPS4 and HFF1 (left hand). Analysis of the transcriptome relations at cell
cycle, pluripotency and development related gens located on the short arm of chromosome 12 between
hESC, epiHFF1-iPS-B1, vHFF1-iPS-iPS4 and HFF1 (right hand). Abbreviations: hESC = human
embryonic stem cell; iPSC = induced pluripotent stem cells; HFF1 = human foreskin fibroblast; epi =
episomal reprogrammed; v = viral reprogrammed.
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In order to analyze the similarity of viral- and episomal-derived iPSC as well as the
resemblance to hESCs a heatmap of pluripotent-associated and transcription factor genes
was created (Figure 3.4B). This heatmap underlines that E-iPSCs are more similar to
hESCs than V-iPSCs. Common pluripotent-associated genes and transcription factor
genes such as NANOG, LIN28, LEFTY1, DNMT3B, POU5F1 (OCT4 ) and KLF4 are
down regulated in V-iPSCs compared to E-iPSCs and hESCs (Figure 3.4B). Hence, this
underlines the similarity between E-iPSCs and hESCs as well as the difference between
E-iPSCs and V-iPSCs as well as hESCs and V-iPSCs.
Figure 3.4: Microarray-based gene expression profiling.
A) Venn diagram analysis of the transcriptome profile from vHFF1-B1 (V-iPSC), epiHFF1-B1 (E-iPSC)
and hESC portraying distinct and overlapping transcriptional signatures. B) Heatmap of pluripotent-
associated and transcription factor genes. Expression pattern of hESCs, episomal reprogrammed HFF1-
cell line epiHFF1-iPS-B1 (E-iPSC), retro-viral reprogrammed HFF1-cell line vHFF1-iPS-iPS4 (V-iPSC)
and the somatic cell line HFF1 were compared. Abbreviations: V-iPSC = viral reprogrammed induced
pluripotent stem cell; E-iPSC = episomal plasmid-based reprogrammed induced pluripotent stem cell;
hESC = human embryonic stem cell; HFF1 = human fetal fibroblasts.
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3.1.2 Characterization of human umbilical vein endothelial
cell-derived iPSC line
Reprogramming of the human fetal fibroblast cell line (HFF1) was shown already in this
study (Chapter 3.1.1). In addition, we could show that the episomal-based reprogram-
ming method results in induced pluripotent stem cells (iPSCs) which are more similar
to the characteristics of human embryonic stem cells (hESC) than the viral-based repro-
grammed iPSCs (Chapter 3.1.1). In order to assess whether cells of other origin can be
also reprogrammed with the episomal-based method, we used human umbilical vein en-
dothelial cells (HUVECs). HUVECs were reprogrammed using the same protocol which
was described in Chapter 2 for the reprogramming of HFF1. The nucleofection of a
GFP-vector showed in HUVECs a transduction efficency of 77.0 %. The reprogramming
efficiency ranged between 1.9 and 2.5 %, retrovirus reprogramming of HUVEC yield an
efficiency of 2.5 - 3.0 % (Supplementary Figure S7; Panopoulos et al. [2011]). After
picking of clones the master plates were stained positive for the pluripotency markers
OCT4 and PODXL as well as for the surface marker TRA-1-60, TRA-1-81 and SSEA-4.
The cells were negatively stained for CD31, a HUVEC marker, and SSEA-1, a marker
for differentiation in human pluripotent stem cells (Figure 3.6).
Figure 3.5: Illustration of HUVEC reprogramming.
Microscopy images showing morphology changes during the episomal reprogramming of HUVECs to
induced pluripotent stem cells (iPSC). The first image is HUVEC passage 3 before reprogramming. The
cells were episomal reprogrammed, cultured the first seven days in HUVEC-medium and were treated
with small molecules one day after reprogramming. The second image represent reprogrammed HUVEC
(iHuv-3a) on day 5. On day seven the cells were trypsinized and seeded on mouse embryonic fibroblasts
(MEFs). Eight days later iPSC-HUVEC-colonies were visible (Image 3), additional four days later the
iHUVEC-colonies seem stable and the small molecules were displaced (Image 4). Last image shows a
iHUVEC-colony which was selected and transferred after taking this picture.
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Figure 3.6: Immunofluorescence-based characterization of HUVEC-derived iPSCs.
Detection of the pluripotency marker OCT4, surface marker TRA-1-60, TRA-1-81, SSEA-4 and
PODXL, as well as the absence of the surface marker SSEA-1 and CD31. DAPI stained the nucleus.
Scale bar: 200 µm, Alexa Flour 488 (green), Alexa Flour 594 (red).
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The iPSC-line (epiHUV-iPS-3a) which was generated and characterized in this study
is genome integration free (Figure 3.7; Matz and Adjaye [2015]) and has similar char-
acteristics as hESC lines (Figure 3.9 - 3.12; Matz and Adjaye [2015]; Supplementary
Figure S1 and S2).
The epiHUV-iPS-3a expresses pluripotency associated makers, such as OCT4, SOX2,
NANOG and amongst others the surface markers TRA-1-60, TRA-1-81, SSEA-4, but
not SSEA-1 (Figure 3.8 and 3.9; Matz and Adjaye [2015]). SSEA-1 is a marker protein
of differentiation in human embryonic stem cells (hESCs) though a marker of the un-
differentiated state in mouse ESC (Thomson et al. [1998]; Takahashi et al. [2007a]; Yu
et al. [2007]). The karyotype analysis demonstrated that epiHUV-iPS-3a is a karyotypic
normal human female cell line. The DNA fingerprint is identical to the fingerprint of
HUVECs, but differs when compared to the hESC lines H1 and H9 (Figure 3.10; Matz
and Adjaye [2015]). The expression pattern of pluripotency genes was quantified by
qRT-PCR and compared to the pattern of H1 cells and the iPSC line epiHFF1-iPS-B1.
The expression pattern of the iPSC-line epiHUV-iPS-3a is similar to H1 and epiHFF1-
iPS-B1 (Figure 3.11). These iPSC line has the capacity differentiate in vitro in all three
germ layers endoderm, ectoderm and mesoderm by formation of embryoid bodies (Figure
3.12; Matz and Adjaye [2015]) and also in vivo by teratoma formation in imundificient
mice (Figure 3.13; Matz and Adjaye [2015]).
Figure 3.7: PCR of plasmid detection in epiHUV-iPS-3a.
A) EBNA-1 detection of the plasmid vector. B) OriP detection of the plasmid vector. C) SV40LT
detection of the plasmid ET2K vector. D) OCT4 detection of the plasmid ET2K and EN2K vectors.
E) LIN28 detection of the plasmid M2L vector. F) NANOG detection of the plasmid EN2K vector. G)
Detection of the human OCT4 genome gene sequence. 100 bp Marker was used. The vectors ET2K,
EN2K and M2L which were transfected into the HUVEC cells, were used as a positive control, the




Figure 3.8: Immunofluorescence-based detection of pluripotency markers in epiHUV-iPS-
3a.
All protein stainings for pluripotency markers OCT4, NANOG, SOX2, KLF4, c-MYC, LIN28 and
PODXL were positive. DAPI stained the nucleus. Scale bar: 200 µm, Alexa Flour 594 (red), Alexa
Fluor 488 (green). Modified from Matz and Adjaye [2015].
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Figure 3.9: Immunofluorescence-based detection of surface markers in epiHUV-iPS-3a.
Protein stainings for the surface markers SSEA-4, TRA-l-60 and TRA-1-81 were positive, SSEA-1 was




Figure 3.10: Karyogram and DNA Fingerprint of epiHUV-iPS-3a.
A) A normnal female karyogram 46,XX of HUVEC. B) A normnal female karyogram 46,XX of epiHUV-
iPS-3a derived from HUVEC. mar = minimal altered region. C) Genomic DNA from hESCs H1 and
H9, HFF1 cells, HUVEC and the viral-free epiHUV-iPS-3a for PCR were used. 1: Genomic PCR
with the primer of D7S796. 2: Genomic PCR with the primer of D10S1214. 3: Genomic PCR with
the primer of D17S1290. 4: Genomic PCR with the primer of D21S2055. 100 bp Marker was used.
Modified from Matz and Adjaye [2015].
Figure 3.11: Quantitative real-time PCR of epiHUV-iPS-3a.
Expression pattern of pluripotency markers relative to HUVEC from hESC-line H1, the iPSC-line
epiHFF1-iPS-B1 and the iPSC-line epiHUV-iPS-3a are shown. Three biological replicates in technical
triplicates of each sample were analyzed against HFF1 as control. The standard deviation is depicted
by the error bars.
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Figure 3.12: Immunofluorescence-based detection of germ-layer specific proteins EBs de-
rived from epiHUV-iPS-3a.
All three germ layers mesoderm, ectoderm and endoderm were detected in vitro by formation of em-
bryoid bodies. The detection of the proteins BRACHYURY and Smooth Muscle Actin (α-SMA) are
markers of mesoderm layer, Paired Box 6 (PAX6) and NESTIN detect the ectoderm layer and AFP,
SOX17, FOXA2 are markers of endoderm layer. DAPI stained the nucleus. Scale bar: 200 µm Alexa
Flour 594 (red), Alexa Fluor 488 (green). Modified from Matz and Adjaye [2015].
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Figure 3.13: Teratoma of epiHUV-iPS-3a.
In vivo teratoma formation of epiHUV-iPS-3a upon injection into NOD scid gamma mice. Represen-
tative images of histological structures corresponding to A) endoderm, B) ectoderm, C) mesoderm
lineages are depicted. Modified from Matz and Adjaye [2015].
Global gene expression analyses
The iPSCs derived from human umbilical vein endothelial cells (HUVECs) were derived
and fully characterized (Chapter 3.1.2). Reprogramming of somatic cells to iPSCs results
in major changes in transcriptional profile of the cells (Wolfrum et al. [2010]). To an-
alyze these changes during the reprogramming procedure of HUVECs RNA-microarray
analyses were performed by the use of the Illumina Bead-Studio platform. In addi-
tion, the transcriptome profiles of HUVECs and the episomal reprogrammed iPSC-line
epiHUV-iPS-3a from HUVEC (E-iPSCs) were confirmed to that of human embryonic
stem cells (hESCs) (Figure 3.14). During the reprogramming process the transcriptome
profile of the cell shifted from the parental towards a hESC-like stage. The parental
HUVECs lost their expression upon reprogramming while other sets of genes were acti-
vated upon reprogramming. A third set of genes was maintained in both states. This
expression pattern is comparable with other iPSC lines such as the HFF1-derived iPSC
lines (HFF1-iPSCs) in this study (Figure 3.14A). The transcriptome profile of the iP-
SCs departed from that of the donor cells and converged to the transcriptome profile of
hESCs (Figure 3.14B). To visualize the distinct and overlapping genes expression pat-
terns in HUVECs versus E-iPSCs and hESCs a Venn diagram was generated (Figure
3.14C). We identified gene signatures representative of cellular housekeeping functions
(11,000 genes; e.g. GAPDH, ACTB, PGK1, LDHA), donor cell (HUVEC)-specific genes
(630 genes; e.g. CDH5, FAT4, KLK3, PECAM1 ), donor cell-memory genes (246 genes;
e.g. AKT3, ENG, ICAM1, MLC1 ), self-renewal and pluripotent genes (2,027 genes; e.g.
POU5F1, SOX2, NANOG, LIN28, GDF3 ), iPSC (E-iPSC)-specific gene expression sig-
nature (750 genes; e.g. ART3, FGD4, GJC3, PLCE1, SDC3 ) and hESC-specific genes
(1,187 genes; e.g. DDX20, FGFBP1, FGF9, MIXL1, WNT3A, TP63 ) (Figure 3.14C,
the entire gene lists are presented in Supplementary Table 4). The intersection of hESC
and E-iPSC from the Venn diagram contains genes (e.g. CDH1, CER1, EOMES, JAG2,
KIT, LEFTY1, LEFTY2, NODAL, RSPO3, SOX2, WNT10B) which are involved in

















Figure 3.14: Microarray data analyses.
A) Heatmap visualizing principle of cellular reprogramming. Expression pattern of hESCs, episomal reprogrammed HUVEC-cell line epiHUV-iPS-
3a (HUVEC-iPSC), the somatic cell line HUVEC and two HFF1-derived iPSC lines were compared. Ten genes with transcription activity either
unchanged (Retained), low (Lost) or high (Acquired) expression values of iPSCs relative to the parental cell line (HUVEC) were selected. B) A
dendogram analysis confirmed that the transcriptome profile of epiHUV-iPS-3a (HUVEC-iPSC) is similar to hESC. C) Venn diagram analysis of
the transcriptome profile from HUVEC, HUVEC-iPSC (E-iPSC) and hESC portraying distinct and overlapping transcriptional signatures. D)
Graph of biological processes related to embryogenesis and pluripotency to percentage of genes from the intersection of E-iPSC and hESC from the
venn diagram (C). Abbreviations: hESCs = human embryonic stem cells; HUVEC = human umbilical vein endothelial cells; E-iPSC = episomal
reprogrammed induced pluripotent stem cell; HUVEC-iPSC = human umbilical vein endothelial cell-derived induced pluripotent stem cell.
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3.1.3 Transcriptome profile-based comparison of iPSCs
As described before during the reprogramming process the somatic cells change their
transcriptome profile in several sets of genes (Wolfrum et al. [2010]). It moves from so-
matic cell specifics and converges into a pluripotent stem cell-like stage, which is similar
to the transcriptome profile of hESCs. To show that this is also true for different somatic
cell types HFF1 and HUVEC were reprogrammed and compared. Human foreskin fi-
broblasts were isolated from neonatal foreskin (Gorman et al. [1979]). Human umbilical
vein endothelial cells (HUVECs) are cells derived from the endothelium of veins from
the umbilical cord (Park et al. [2006]). In order to visualize this transformation of the
two independent reprogrammed cell lines a dendogram was compiled of the transcrip-
tome profiles from HFF1, HFF1-iPSC, HUVEC, HUVEC-iPSC, hESC (Figure 3.15A).
Both iPSC lines differ from their parental cell type and from the other somatic cell type.
However, the transcriptome profiles of the two iPSC lines are similar to that of hESCs.
In order to deliver insight into details the pearson correlation co-efficient was evaluated
(Figure 3.15B). The transcriptome profile of HUVEC-iPSC correlated most with that
of hESC (R2 = 0.8989) and then with the transcriptome profile of HFF1-iPSC (R2 =
0.8957). Furthermore, to establish differences and commonalities between the parental
cell lines and the iPSCs a Venn diagram was conducted (Figure 3.15C, Supplementary
Table 5). HFF1-iPSCs share 417 genes with their parental cell line HFF1. The largest
percentage of these genes is involved in basic cellular processes, e.g. in organization and
assembling of chromosomes, chromatin and nucleosome, DNA packaging and metabolic
processes, cell cycle and cell devision (e.g. EPC2, FZR1, SEP15, TADA2A). HUVEC-
iPSCs share 94 genes with their parental cell line HUVEC. Most of these genes are
involved in homeostasis and homeostatic processes, ion transport, response to wounding
as well as defense and inflammatory response (e.g. C11ORF9, IL1A, P2RX1 ). However,
HFF1-iPSCs and HUVEC-iPSCs share most of the genes (1,074 genes, e.g. EOMES,
EPCAM, DPPA4, NODAL, POU5F1, SOX2, TNNT2, VGF ), which are involved in cel-
lular processes and homeostasis as well as embryogenesis and morphogenesis.
In order to analyze the differences and commonalities between the iPSC lines and hESC a
venn diagram of the three transcriptome profiles was generated (Figure 3.15D, the entire
gene lists are presented in Supplementary Table 6). The intersection of all three samples
contains genes which are involved in biological processes such as developmental signaling,
pluripotency, self-renewal and embryogenesis (e.g. CDH1, CER1, EOMES, JAG2, KIT,
LEFTY1, LEFTY2, NANOG, NODAL, POU5F1, RSPO3, SOX2, WNT10B). Analyses
of the intersections HEFF1-iPSC vs. hESC and HUVEC-iPSC vs. hESC as well as
genes expressed only in hESC uncovered the maximum difference was arranged in the
expression of genes which are involved in transcription and regulation of transcription
(intersection of HEFF1-iPSC vs. hESC 894genes, e.g. MIXL1, ZNF488, ZNF583 ; in-
tersection HUVEC-iPSC vs. hESC 520 genes, e.g. SOX17, ZFP14, ZNF536 ; section of
hESC 720 genes, e.g. CDX2, ZNF276, ZNF711 ).
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Figure 3.15: Comparison of the transcriptome profile from episomal reprogrammed iPSC
lines.
A) A dendogram analysis confirmed that the transcriptome profile of iPSC lines is similar to hESC. B)
Pearson correlation co-efficient of the entire expression data (Illumina microarrays) between indicated
cell types uncovered the similarity between HUVEC-iPSC and hESCs (R2 = 0.8989). In comparison
the transcriptome profile of HFF1-iPSC deviated from hESCs to a greater extent (R2 = 0.8776). C)
Venn diagram analysis of the transcriptome profile from HFF1, HFF1-iPSC, HUVEC and HUVEC-
iPSC portraying distinct and overlapping transcriptional signatures. D) Venn diagram analysis of the
transcriptome profile from HFF1-iPSC, HUVEC-iPSC and hESC portraying distinct and overlapping
transcriptional signatures. Abbreviations: hESCs = human embryonic stem cells; HFF1 = human
foreskin fibroblast 1; HFF1-iPSC = episomal reprogrammed induced pluripotent stem cell derived from
HFF1 cells, HUVEC = human umbilical vein endothelial cell.
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3.2 Derivation and characterization of hepatocyte-like
cells derived from iPSCs
3.2.1 Derivation of HLCs from HFF1-iPSC
We could show, that somatic cells can be reprogrammed with an episomal-based ap-
proach and the generated induced pluripotent stem cells (iPSCs) are similar to human
embryonic stem cells (hESCs) (Chapter 3.1). In general, hESCs and iPSCs can be dif-
ferentiated directly to the cell type of interest (Hay et al. [2007]; Sullivan et al. [2010];
Zhou et al. [2010]; Gherghiceanu et al. [2011]; Jozefczuk et al. [2011]; Barker et al. [2012];
Cheng et al. [2012]; Emdad et al. [2012]; Hannan et al. [2013]; Dianat et al. [2014]). In
earlier studies our laboratory generated hepatocyte-like cells (HLCs) from hESC and
viral reprogrammed iPSC lines (Jozefczuk et al. [2011]; Jozefczuk et al. [2012b]). In
this study HLCs were derived from the episomal reprogrammed cell line epiHFF1-iPS-
B1. The differentiation procedure consists of three stages (Figure 3.16). First, the
undifferentiated cells were differentiated to definitive endoderm (DE), second, to the
hepatic endoderm (HE) stage and third, to hepatocyte-like cells. Continuous morpho-
logical changes from the undifferentiated stage to HLCs were observed as discribed by
Jozefczuk et al. [2011].
Figure 3.16: Illustration of HLC differentiation derived from epiHFF1-iPS-B1.
Microscopy images depict morphological changes during the differentiation of epiHFF1-iPS-B1 (iPSC-
line) to HLCs. The iPSC-line were cultured in CM. The generation of the first stage DE takes five days.
HE is the second stage and takes four days. After 14 days the differentiation is completed and matured
HLCs is the endpoint of the third stage. Abbreviations: CM = conditioned medium; iPSC = induced
pluripotent stem cell; DE = definitive endoderm; HE = hepatic endoderm; HLC(s) = hepatocyte-like
cell(s).
During the first differentiation step from iPSC to DE the pluripotency marker OCT4
was down regulated (Figure 3.17). Forkhead box A2 (FOXA2) was expressed, usually
expressed by the DE progenitors, as well as SRY (sex determining region Y)-box 17
(SOX17), a marker of definitive endoderm. The Hepatocyte nuclear factor 4 alpha
(HNF4α) is an early marker of endoderm development and is expressed during the
whole HLC differentiation procedure (Greber et al. [2007]; Agarwal et al. [2008]).
Immunocytochemistry analysis of HE showed a positive staining of HNF4α, the early
marker alpha-Fetoprotein (AFP) and later-stage marker Albumin (ALB) for hepatic
commitment (Figure 3.18). HE cells were stained positive for Cytokeratin 18 (CK18),
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which is expressed at the end of the second stage of HLC differentiation. E-Cadherin
(E-CAD/CDH-1) marking the mesenchymal-to-epithelial transition (MET), established
cell-cell contacts and indicates the epithelial nature of the developing liver cells (Gouon-
Evans et al. [2006]; Cai et al. [2007]; Hay et al. [2008a]; Agarwal et al. [2008]; Choi and
Diehl [2009]; Schietke et al. [2010]; Mah et al. [2011]; Nakagawa et al. [2014]).
At the endpoint of HLC differentiation AFP, ALB, HNF4α and E-CAD are expressed
(Figure 3.19). CK18 is a marker of HE-stage and whose expression is decreased at HLC
stage. The expression of alpha-1 Antitrypsin (A1AT) detect the late stage of liver differ-
entiation and is involved in the maturation of the liver (Cai et al. [2007]; Agarwal et al.
[2008]; Takayama et al. [2012]).
Figure 3.17: Immunofluorescence-based detection of proteins in DE derived from
epiHFF1-iPS-B1.
Immunofluorescence for expression of a defining panel of proteins were examined. OCT4, pluripotency
marker; FOXA2, SOX17 markers for DE and the transcription factor HNF4α. DAPI stained the nu-
cleus. Scale bar: 200 µm Alexa Flour 594 (red). Abbreviations: DAPI = 4’,6-diamidino-2-phenylindole;
DE = definitive endoderm; FOXA2 = Forkhead box A2; HNF4α = hepatocyte nuclear factor 4 alpha;
OCT4 = POU5F1, POU class 5 homeobox 1; SOX17 = SRY (sex determining region Y)-box 17.
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Figure 3.18: Immunofluorescence-based detection of proteins in HE derived from
epiHFF1-iPS-B1.
The detection of the protein OCT4, pluripotency marker; AFP, ALB for early and later-stage hepatic
proteins, the transcription factor HNF4α, E-CAD and CK18. DAPI stained the nucleus. Scale bar: 200
µm Alexa Flour 594 (red). Abbreviations: AFP = alpha-Fetoprotein; ALB = Albumin; CK18 = Cy-
tokeratin 18; DAPI = 4’,6-diamidino-2-phenylindole; E-CAD = E-Cadherin; HE = hepatic endoderm;
HNF4α = hepatocyte nuclear factor 4 alpha; OCT4 = POU5F1, POU class 5 homeobox 1.
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Figure 3.19: Immunofluorescence-based detection of proteins in HLC derived from
epiHFF1-iPS-B1.
The detection of the protein OCT4, a pluripotency marker; AFP, ALB for early and later-stage hepatic
proteins, the transcription factor HNF4α, E-CAD, CK18 and A1AT. DAPI stained the nucleus. Scale
bar: 200 µm Alexa Flour 594 (red). Abbreviations: A1AT = Antitrypsin; AFP = alpha-Fetoprotein;
ALB = Albumin; CK18 = Cytokeratin 18; DAPI = 4’,6-diamidino-2-phenylindole; E-CAD = E-
Cadherin; HLC = hepatocyte-like cell; HNF4α = hepatocyte nuclear factor 4 alpha; OCT4 = POU5F1,
POU class 5 homeobox 1.
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In order to verify the immunocytochemistry results a quantitative real time PCR
(qRT-PCR) was performed. The qRT-PCR reflected the progress of expression pattern
obtained by the immunocytochemistry results during the HLC differentiation of liver
specific genes (Figure 3.20). The expression level of most liver markers increased from
the first stage DE to the HE stage (Figure 3.20A). SOX17, FOXA2 and HNF4a are
the only genes which are highly expressed at the end of stage I, the DE stage. SOX17
and FOXA2 are core genes of DE and are involved in hepatic maturation. HNF4α is a
key transcription factor and regulates different processes during the whole liver develop-
ment. AFP is classified as an early-stage marker of hepatocytes and ALB as a late-stage
marker, both expressions increased to the end of stage II of differentiation and increased
further to the endpoint of differentiation, stage III. A1AT is a serum glycoprotein, which
is synthesised and secreted by the liver. The level of gene expression changes during the
differentiation is comparable to AFP and ALB (Li et al. [2000]; Watt et al. [2003];
D’Amour et al. [2005]; McLean et al. [2007]; Agarwal et al. [2008]; Hay et al. [2008a];
Takayama et al. [2011]; Takayama et al. [2012]; Teckman and Jain [2014]). T-box 3
(TBX3 ) is an important regulator of liver development and maintains the expression
of hepatocyte transcription factors such as HNF4α (Figure 3.20B). The expression in-
creased from DE to HLCs. Fumarylacetoacetate hydrolase (FAH ) is involved in liver
maturation and function. The expression increased from DE to HE and stagnated to
HLCs. The Tryptophan 2,3-dioxygenase (TDO2 ) is a marker gene of mature hepa-
tocytes and catalyses the oxidation of tryptophan to N-formyl kynurenine. TDO2 is
mostly expressed in HLCs. Prominin 1 (PROM1/CD133 ) is a proginitor and stem cell
marker for embryonic and adult stem cells, but is also expressed in differentiated cells
and tumors. CD133 is detectable in fetal liver. At the endpoint of HLC differentiation
the expression level of CD133 is high. Another stem cell and progenitor marker for
liver cells is Leucine-rich repeat containing G protein-coupled receptor 5 (LGR5 ), which
is also mostly expressed in HLCs (Yin et al. [1997]; Florek et al. [2005]; Mizrak et al.
[2008]; Ldtke et al. [2009]; Schmidt et al. [2009]; Barker et al. [2012]; Cheng et al. [2012];
Huch et al. [2013]; Gil-Sanchis et al. [2013]; Prez-Carro et al. [2013]).
continued on next page
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Figure 3.20: Quantitative real-time PCR profile of liver specific maker.
A) qRT-PCR-derived expression changes of SOX17, FOXA2, HNF4α, AFP, ALB and A1AT in DE,
HE and HLC. B) qRT-PCR-derived expression changes of (TBX3 ), FAH, (TDO2 ), CD133 and LGR5
in DE, HE and HLC. Three biological replicates in technical triplicates of each sample were analyzed.
The standard deviation is depicted by the error bars. As control was used the RNA from HFF1-
iPSC line (epiHFF1-iPS-B1) which was differentiated. Abbreviations: A1AT = alpha-1 Antitrypsin;
AFP = alpha-Fetoprotein; ALB = Albumin; DE = definitive endoderm; FAH = Fumarylacetoacetate
hydrolase; FOXA2 = Forkhead box A2; HE = hepatic endoderm; HLC = hepatocyte-like cell; HNF4α =
hepatocyte nuclear factor 4 alpha; LGR5 = Leucine-rich repeat containing G protein-coupled receptor
5; qRT-PCR = quantitative real-time PCR; SOX17 = SRY (sex determining region Y)-box 17; TBX3
= T-box 3; TDO2 = Tryptophan 2,3-dioxygenase; PROM1/CD133 = Prominin 1.
Functional analysis of HFF1-iPSC-HLCs
To analyze whether or not the generated HLCs are functional several tests were con-
ducted. First, an immunofluorescence-based detection of the protein E-Cadherin (E-
CAD) was performed, which visualizes the typical polygonal morphology (Figure 3.21A).
Second, the Periodic Acid-Schiff (PAS) staining was done to prove the glycogen stor-
age, which underlines the functionality of HLCs (Figure 3.21B). Glycogen storage is
one of the main characteristics of hepatocytes (Greenberg et al. [2006]; Agarwal et al.
[2008]). Third, the functionality of the HLCs was confirmed by the detection of Bile
salt export pump (BSEP), Sodium-taurocholate cotransporting polypeptide (NTCP)
and Tight junction protein 1 (ZO-1) (Figure 3.21C). LGR5 was detected by qRT-PCR
as highest expressed in HLCs and could also be detected by immunofluorescence-based
protein detection in HLCs (Figure 3.21C). Fourth, the verification of the secretory func-
tion was done by using the nontoxic organic anion Indocyanine green (ICG) (Berk and
Stremmel [1986]; Mller and Jansen [1998]; Ho et al. [2012]). The uptake of ICG as
well as the release six hours later was documented (Figure 3.22A). The incubation with
5 (and 6)-Carboxy-2,7-dichlorofluorescein diacetate (CDFDA) is another test to show
the functionality. CDFDA will passively taken up and actively deliver by the liver cells
(Zamek-Gliszczynski et al. [2003]; Nezasa et al. [2006]). This process was visualized by
immunofluorescence microscopy (Figure 3.22B).
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Figure 3.21: Morphological and functional analysis of HLCs derived from epiHFF1-iPS-
B1.
A) Immunofluorescence-based detection of E-Cad and detection of the typical polygonal morphology
of HLCs. B) Periodic acid-Schiff assay was used to demonstrate Glycogen storage as indicated by
pink or dark red-purple cytoplasm. C) Immunofluorescence-based detection of BSEP, LGR5, NTCP
and ZO-1. DAPI stained the nucleus. Scale bar: 200 µm, Alexa Flour 594 (red), Alexa Flour 488
(green). Abbreviations: BSEP = Bile salt export pump; DAPI = 4’,6-diamidino-2-phenylindole; E-Cad
= E-Cadherin; HLCs = hepatocyte-like cells; iPSC = induced pluripotent stem cell; LGR5 = Leucine-
rich repeat containing G protein-coupled receptor 5; NTCP = Sodium-taurocholate cotransporting
polypeptide; ZO-1 = Tight junction protein 1.
58
Chapter 3. Results
Figure 3.22: Functional analysis of HLCs derived from epiHFF1-iPS-B1.
A) ICG uptake and release by HLCs at the end of differentiation. Image of HLCs direct after incubation
with ICG (left panel uptake) and six hours later (right panel release). B) Visualization of CDFDA.
Immunofluorescence-based image of HLCs direct after incubation with CDFDA (left panel) and six hours
later (right panel). Abbreviations: CDFDA = 5 (and 6)-Carboxy-2,7-dichlorofluorescein diacetate; ICG
= Indocyanine green; HLCs = hepatocyte-like cells.
To complete the functional analysis of hepatocytes the secretion of bile acids, urea
and CYP3A4 were measured (Figure 3.23). HepG2 was used as a reference. Bile acid
measurement showed the excretion of primary bile acids in HLCs and in HepG2 (Figure
3.23A). The levels of urea production in HepG2 and epiHFF1-B1-HLC were quantified.
The epiHFF1-B1-HLCs produced the highest amount of urea (Figure 3.23B). HLCs
derived from viral-free, episomal reprogrammed iPSC-line epiHFF1-iPS-B1 (E-iPSC)
also produced CYP3A4, but HepG2 cells secrete double amounts of CYP3A4 (Figure
3.23C). Quantitative RT-PCR confirmed the CYP3A4 expression as well as the expres-
sion of other members of the cytochrome P450 superfamily of enzymes (Figure 3.23D),
which are involved in drug metabolism and synthesis of cholesterol, steroids and other
lipids (Lamba et al. [2014]). The expression level of these enzymes were measured in all
three steps of HLC differentiation generated from E-iPSCs and were compared to that
of HepG2 cells as well as HLCs derived from H1 and H9, made by Justyna Jozefczuk
(Jozefczuk et al. [2011]). These results were substantiated by electron microscopy evi-
dence and shows the structural condition of the derived HLCs (Figure 3.23E). Typical
structures of hepatocytes such as bile canaliculi with microvilli, lipid storage and tight
junctions are visible in one image.
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Figure 3.23: Quantification of functionality in HLC derived from epiHFF1-iPS-B1.
A) Analysis of bile acid production in HepG2 and epiHFF1-B1-HLC (HLC). The levels of bile acids are
presented in pmol/ml/24h. B) Analysis of urea production in HepG2 and epiHFF1-B1-HLC (HLC).
Three biological replicates in technical triplicates of each sample were analyzed. The levels of urea
are measured in mg/dl/24h. C) Analysis of CYP3A4 production in epiHFF1-B1-HLC (HLC) and
HepG2. Three biological replicates in technical triplicates of each sample were analyzed. The levels
of CYP3A4 are presented as relative light units per milliliter (R.L.U./ml). D) Expression pattern
of cytochrome P450 genes relative to iPSC-control from the three stages of HLC differentiation are
shown by qRT-PCR. HepG2 was used as a positive control. The standard deviation is depicted by the
error bars. Three biological replicates in technical triplicates of each sample were analyzed. E) The
detection of hepatocyte specific structures and organelles in HLCs derived from iPSC-line epiHFF1-
iPS-B1 by electron microscopy. Abbreviations: BC = bile canaliculi; CCP = clathrin coated pits;
CYP3A4 = cytochrome P450, family 3, subfamily A, polypeptide 4; DE = definitive endoderm; HE =
hepatic endoderm; HLC(s) = hepatocyte-like cell(s); iPSC = induced pluripotent stem cell; L = Lipid




Comparative RNA-based microarray analysis of HFF1-iPSC-HLCs
Upon showing the biochemical characteristics of the iPSC-derived HLCs and the ultra-
structure analysis by electron microscopy we performed comparative microarray-based
gene expression profiling. Therefor RNA was isolated from E-iPSCs and from their
differentiated DE, HE, HLCs. In order to assess whether the HLCs are more similar
to fetal liver or adult liver RNA was isolated from fetal liver and primary human hep-
atocytes (PHH). The transcriptome profiles of all samples were compared. A cluster
dendrogram demonstrates the high similarities of the transcriptome profiles between the
biological replicates. The iPSCs, DE and HE formed a cluster which is then extended
by HLCs. Furthermore, fetal liver and PHH formed a cluster (Figure 3.24A). K-means
clustering identified 100 clusters (Supplementary Figure S3A and Supplementary Table
7). In these K-means cluster developmental stage-specific groups of genes were found
(Supplementary Figure S3B and Supplementary Table 8), e.g. OCT4, NANOG, SOX2
expression at the undifferentiated stage, SOX17 marking DE stage, HNF6 at the HE
stage, PROX1 at the HLC stage, AFP marking the fetal liver stage and ALB marking
the mature liver (PHH) stage (Figure 3.24B). Transcription factor over-representation
analysis using the oPOSSUM data base identified upstream regulators of genes within
the six selected clusters were identified (Supplementary Figure S4, Supplementary Ta-
ble 8 and 9; Kwon et al. [2012]). The iPSCs network shows the well known regulatory
relations between OCT4 (POU5F1 ), SOX2, NANOG, KLF4. Most significant factors
from the oPOSSUM analysis were STAT1, MZF1 and KLF4 (Z-Score > 10). The DE
network demonstrates SP1, INSM1, MZF1, KLF4, REST as most significant (Z-Score
≥ 10), in HE LHX3, MIZF, CTCF, in HLC PLAG1, EWSR1-FLI1 and IRF2, in fe-
tal liver TAL1::GATA1, HNF1A, ZFN143, GATA1 as well as HNF1B and in PHH
HNF1A, CTCF, ZFX, HNF4A, FOXA2, FOXA1 and CEBPA. The microarray data
were confirmed by qRT-PCR experiment (Figure 3.24C). KRT17 and CXCR4 are rep-
resentatives of the definitive endoderm stage (DE), ANXA1, TTR and TBX3 represent
the hepatocyte-like cell stage (HLC), AFP marking the fetal liver stage and ALB substi-
tutes the mature liver (PHH) stage. Furthermore, in order to visualize the development
of the expression pattern during the differentiation from iPSCs to HLCs a heatmap was
generated of the top 30 most abundantly expressed genes in each differentiation stage
of the selected k-means clusters (Figure 3.24D and Supplementary Table 10).
Comparative transcriptome profile analysis of HLCs, fetal liver and PHH samples
using a venn diagram shows the numbers of expressed genes (Figure 3.25A). The HLC-
related genes ANXA1, TTR and TBX3 as well as the fetal liver-related gene AFP and
ALB represent the matured liver stage PHH and are detected in the intersection of all
three samples as well as are included in the 11,506 genes (Supplementary Table 11). A
closer look into the exclusively expressed genes in the HLCs (1,808 genes) uncovered
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Figure 3.24: Transcription profile analyses of HLC derivation.
A) Cluster dendrogram of E-iPSC, DE, HE, HLC, fetal liver and PHH. Fetal liver and PHH formed a
cluster as well as E-iPSCs, HE and DE formed a cluster which is then extended by HLCs. B) K-means
cluster 68 contained OCT4 marking undifferentiated stage (iPSC), cluster 81 (sub-cluster 1) contained
SOX17 marking DE stage (DE), cluster 37 (sub-cluster 2) represents HE stage, cluster 51 represents HLC
stage, cluster 72 contained AFP marking fetal liver stage and cluster 91 contained mature liver marker
ALB (PHH). C) Confirmation of microarray data by qRT-PCR. On the left the array expression data
and on the right the qRT-PCR expression data are depicted. The standard deviation is depicted by the
error bars. D) The top 30 expressed genes from each K-means cluster in B were combined in a heatmap.
Abbreviations: AFP = alpha-Fetoprotein; DE = definitive endoderm; HE = hepatic endoderm; HLC(s)
= hepatocyte-like cell(s); iPSC = induced pluripotent stem cell; E-iPSC = endodermal reprogrammed
iPSC; PHH = primary human hepatocytes; OCT4 = POU5F1, POU class 5 homeobox 1; SOX17 =
SRY (sex determining region Y)-box 17.
The expression of tight junction genes is one marker for the maturation of the HLCs.
In order to analyze maturation level of the iPSC-derived HLCs a Venn diagram was
generated from HLC vs. fetal liver, HLC vs. PHH and fetal liver vs. PHH (Figure
3.25C, Supplementary Table 12). DAVID analysis of Hippo signaling-related genes from
the intersection of HLC vs. PHH and HLC vs. fetal liver uncovered the activity of
cell-cell contact related pathways, adherent and tight junction pathway. A chart of
these Hippo pathway related genes underlines the predominant expression of cell-cell
contact related genes in HLCs (Figure 3.25D). The Hippo pathway is responsible for
maturation and stabilization of the tight junctions in hepatocytes. Furthermore, the
ABC transporters are expressed, which are accountable for the uptake and efflux of e.g.
bile acids and metabolites. These are over represented in HLCs, fetal liver and PHH
(Figure 3.26A and 3.26B). Bile acid-related transporter genes such as NTCP, MRP2,
ASBT and MDR2/3 are highly expressed in HLCs compared to the DE and HE stage
(Figure 3.26C). The expression of bile acid-related transporters substantiates the func-
tionality of HLCs. In addition, the heat map in Figure 3.26D containing genes of the
cytochrome p450 superfamily uncovered the commonalities between HLCs, fetal liver
and PHH (Varelas et al. [2010]; Osman-Ponchet et al. [2014]; Chavan et al. [2015]).
To detect the relationship between the stages of the HLC differentiation, a Venn
diagram analysis was performed, and further to analyze which genes were expressed and
distinct in DE, HE, HLCs as well as in between (Figure 3.27A, Supplementary Table
13). These gene were analyzed in DAVID. It uncovered genes which are related to
pathways that define the functionality of the liver such as drug metabolism, metabolism
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Figure 3.25: Comparative transcription profile analyses.
A) Venn diagram of HLC, fetal liver and PHH. B) David analysis: GO cellular components of HLC
exclusively expressed genes (Fisher extract p < 0.01). C) Venn diagram of fetal liver vs. PHH anova,
HLC vs. fetal liver anova and HLC vs. PHH anova. D) David analysis: GO cellular components of
HIPPO pathway genes exclusively expressed genes (Fisher extract p < 0.01) in the intersection of HLC
vs. fetal liver anova and HLC vs. PHH anova (intersection with 1,958 genes). The following samples
were used for the heatmaps: E-iPSC, DE, HE, HLC, fetal liver and PHH, except for G were used
E-iPSC, DE, HE and HLC. Abbreviations: DE = definitive endoderm; HE = hepatic endoderm; HLC
= hepatocyte-like cells; iPSC = induced pluripotent stem cells; PHH = primary human hepatocytes.
Until now most studies on liver cell fate decision have been conducted in mice (Tani-
mizu et al. [2003]; Fougre-Deschatrette et al. [2006]; Vanderpool et al. [2012]). This type
of analyses can be applied to human using iPSCs. Therefore, we used the transcriptome
profile of all stages of HLC derivation (undifferentiated iPSC, DE, HE and HLCs) and
generated a heatmap consisting of key genes which are related to hepatocytes, cholan-
giocytes as well as progenitor-associated gens (Figure 3.27B). Progenitor-related genes
such as HNF1A and HNF1B are expressed in HE and HLCs whereas the liver progen-
itor specific gene PROX1 is expressed exclusively in HLCs. ALB, AFP, ABCB4 and
CYP3A7 as hepatocyte-specific genes are expressed in the HLC samples. Furthermore,
there exists a group of hepatocyte-related genes which is expressed in HLCs and HE,
e.g. ABCC2, RARB and TTR. Cholangiocyte-related genes such asWNT3A, SOX9 and
KRT7 are expressed in both HE and HLCs, whereas AQP1 and DLK1 are expressed
exclusively in HLCs. To analyze the relation between these genes for cell fate decision, a
transcription factor network was created using the data base oPOSSUM (Figure S6). To
make it more manageable transcription factors with a Z-score > 10 (green circles) and
downstream regulating transcription of the progenitor genes (red circles) are shown (Fig-
ure 3.27C, Supplementary Table 9). MYC, HNF1A, SP1, MZF1 5-13, HNF4A, KLF4
were the most significant upstream transcription factors (Z-score > 10, p < 1e−15).
This demonstrates the associated functionalities of this core regulatory network, HNF1A
and HNF4A determine the liver fate by regulating ALB and AFP while KLF4 regulates
SOX17. The bipotential markers DLK1 and NOTCH3 are both regulated by MYC,
KLF4, SP1 and MZF1 5-13. All cholangiocyte marker genes are regulated by KLF4,
SP1 and MZF1. SOX9 is only regulated by these three while ONECUT1, ONECUT2
and SALL4 are regulated by these three and additionally by MYC and HNF4A. MYC
was the most prominent transcription factor in this network (Z-score of 12.54) and regu-
lates PROX1 and the transcription factor HNF1A, which is also regulated by HNF4A, as
well as the cholangiocyte-related gene WNT3A (Hay et al. [2008b]; Dianat et al. [2014];
















Figure 3.26: Heatmap-based transcription profile analyses.
A) Heatmap of HIPPO pathway-related genes and a scheme of the HIPPO signaling pathway. B) Heatmap of ABC transporter-related genes. C)
Heatmap of bile acid transporter-related genes. D) Heatmap of cytochrome P450 superfamily-related genes. The following samples were used for
the heatmaps: E-iPSC, DE, HE, HLC, fetal liver and PHH, except for G were used E-iPSC, DE, HE and HLC. Abbreviations: DE = definitive
endoderm; HE = hepatic endoderm; HLC = hepatocyte-like cells; iPSC = induced pluripotent stem cells; PHH = primary human hepatocytes.
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Figure 3.27: Cell fate decision during HLC derivation.
A) Venn diagram of DE, HE and HLC. B) Heatmap of bipotential progenitor-associated, hepatocyte-
related and cholangiocyte-associated genes. The following samples were used iPSC-B1, DE, HE and
HLC. C) An induced network of transcription factors with a Z-score > 10 (green, size of circle corre-
sponds to Z-score) and associated genes (red). Abbreviations: DE = definitive endoderm; HE = hepatic




3.2.2 Generation and characterization of hepatocyte-like cells
derived from HUVEC-iPSC
To generate hepatocyte-like cells (HLCs) from the episomal reprogrammed cell line
epiHUV-iPS-3a the protocol from Sullivan et al. [2010] was used (as described in section
6.4). All stages of the differentiation procedure were monitored (Figure 3.28). The same
differentiation protocol was used due to the fact that comparable analyses were planed.
Figure 3.28: Illustration of HLC development derived from epiHUV-iPS-3a.
Microscopy images showing morphology changes during the differentiation of epiHUV-iPS-3a (iPSC-
line) to hepatocyte-like cells (HLC). The iPSC-line were cultured in conditioned medium (CM). The
generation of the first stage definitive endoderm (DE) takes five days. Hepatic endoderm (HE) is
the second stage and takes four days. After 14 days the differentiation is completed and matured
Hepatocyte-Like Cells (HLC) is the endpoint of the third stage.
During the first step of the protocol the iPSCs differentiated to definitive endoderm
(DE) (Figure 3.29). The expression of the pluripotency associated marker OCT4 was
down regulated. Forkhead box A2 (FOXA2) is expressed, which is expressed by the
definitive endoderm progenitors, as well as SRY (sex determining region Y)-box 17
(SOX17), which is a marker of definitive endoderm (Greber et al. [2007]; Agarwal et al.
[2008]). The hepatocyte nuclear factor 4, alpha (HNF4α) is an early marker of en-
doderm development and is expressed during the whole HLC differentiation (Agarwal
et al. [2008]). Immunocytochemistry analysis of hepatic endoderm (HE), the second
stage during HLC differentiation, showed a positive staining of HNF4α, the early marker
alpha-Fetoprotein (AFP) and later-stage marker Albumin (ALB) for hepatic commit-
ment (Figure 3.30; Gouon-Evans et al. [2006]; Hay et al. [2008a]; Agarwal et al. [2008]).
Additionally, HE cells were stained positive for Cytokeratin 18 (CK18), which is ex-
pressed at the end of the second stage of HLC differentiation (Cai et al. [2007]). The
hepatoblast marker CK19 was also proved by immunofluorescence-based protein detec-
tion (Cai et al. [2007]; Dianat et al. [2014]). E-Cadherin (E-CAD/CDH-1) was detected,
which marks the mesenchymal-to-epithelial transition (MET), established cell-cell con-
tacts and indicates the epithelial nature of the developed liver cells (Choi and Diehl
[2009]; Schietke et al. [2010]; Mah et al. [2011]; Nakagawa et al. [2014]). Vimentin
(VIM), a mesenchymal marker, identifies also the epithelial-to-mesenchymal-transition
(EMT) and was expressed while the expression of E-CAD was down-regulated (Lan et al.
[2013]; Mitra et al. [2014]; Nakagawa et al. [2014]). At the endpoint of HLC differenti-
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ation AFP, ALB, HNF4α and E-CAD were expressed, as well as VIM in regions where
E-CAD was expressed (Figure 3.31). The expression of CK18 and CK19 as markers of
the HE stage were decreased. (Cai et al. [2007]; Agarwal et al. [2008]; Takayama et al.
[2012]; Dianat et al. [2014]).
Figure 3.29: Immunofluorescence-based detection of proteins in DE derived from
epiHUV-iPS-3a.
Immunofluorescence for expression of a defining panel of proteins were examined. OCT4, pluripo-
tency marker; FOXA2, SOX17 markers for DE and the transcription factor HNF4α. DAPI stained
the nucleus. Scale bar: 200 µm Alexa Flour 488 (green). Abbreviations: DAPI = 4’,6-diamidino-2-
phenylindole; DE = definitive endoderm; FOXA2 = Forkhead box A2; HNF4α = hepatocyte nuclear




Figure 3.30: Immunofluorescence-based detection of proteins in HE derived from
epiHUV-iPS-3a.
The detection of the protein OCT4, pluripotency marker; AFP, ALB for early and later-stage hep-
atic proteins, the transcription factor HNF4α, E-CAD, VIM, CK18 and CK19. DAPI stained the
nucleus. Scale bar: 200 µm Alexa Flour 594 (red), Alexa Flour 488 (green). Abbreviations: AFP =
alpha-Fetoprotein; ALB = Albumin; CK18 = Cytokeratin 18; DAPI = 4’,6-diamidino-2-phenylindole;
E-CAD = E-Cadherin; HE = hepatic endoderm; HNF4α = hepatocyte nuclear factor 4 alpha; OCT4
= POU5F1, POU class 5 homeobox 1; VIM = Vimentin.
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Figure 3.31: Immunofluorescence-based detection of proteins in HLC derived from
epiHUV-iPS-3a.
The detection of the protein AFP, ALB for early and later-stage hepatic proteins, the transcription
factor HNF4α, E-CAD, VIM, CK18 and CK19. DAPI stained the nucleus. Scale bar: 200 µm Alexa
Flour 594 (red), Alexa Flour 488 (green). Abbreviations: AFP = alpha-Fetoprotein; ALB = Albu-
min; CK18 = Cytokeratin 18; DAPI = 4’,6-diamidino-2-phenylindole; E-CAD = E-Cadherin; HLC =
hepatocyte-like cell; HNF4α = hepatocyte nuclear factor 4 alpha; VIM = Vimentin.
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To track the development of the expression pattern during the HLC differentiation of
liver specific genes qRT-PCR was performed (Figure 3.32). The expression of pluripo-
tency associated genes such as OCT4, SOX2 and NANOG were decreased and liver
stage specific genes increased (Figure 3.32A). SOX17, FOXA2 and HNF4a are the only
genes which are highly expressed at the end of stage I, definitive endoderm (Figure
3.32B). SOX17 and FOXA2 are core genes of DE and are involved in hepatic matura-
tion (D’Amour et al. [2005]; McLean et al. [2007]; Takayama et al. [2011]; Takayama
et al. [2012]). Keratin 17 (KRT17) is involved in the JAK/STAT pathway, induces pro-
liferation as well as differentiation markers and is expressed in DE only (Shuai and Liu
[2003]; Kim et al. [2006]; Lan et al. [2013]; Sankar et al. [2013]; Pattarachotanant et al.
[2014]). HNF4α is a key transcription factor and regulates different processes during the
liver development (Li et al. [2000]; Watt et al. [2003]; Agarwal et al. [2008]; Takayama
et al. [2011]; Takayama et al. [2012]). The expression of most liver markers suddenly
rose from the first stage DE to the hepatic endoderm stage. AFP is classified as an
early-stage marker of hepatocytes and ALB as a late-stage marker, both expressions
were increased to the end of stage II of differentiation and rose further to the endpoint
of differentiation, hepatocyte-like cells (HLCs) stage III (McLean et al. [2007]; Agarwal
et al. [2008]; Hay et al. [2008a]; Takayama et al. [2011]; Takayama et al. [2012]. A1AT is
a serum glycoprotein which is synthesised and secreted by the liver (Teckman and Jain
[2014]). The expression development during the differentiation is comparable to AFP
and ALB (Figure 3.32B).
To analyze the influence of the cytokine treatment with HGF, OSM and DEX, which
induce liver differentiation and maturation (1.4), and further the state of maturation of
the generated HLCs two more experiments were conducted. First, HLCs were generated
as described before, however, the derivation of the third stage varied. HLCs were gener-
ated a) with cytokines (HLC 5d), which is the common procedure, b) without cytokines
(HLC 5d -Cytokines) as well as c) with the small molecules FH1 and FPH1 (HLC SM
5d). FPH1 induces proliferation of PHH and FH1 maturation of iPSC-derived HLCs
(Shan et al. [2013]). The small molecules FH1 and FPH1 were used in a concentration
of 15 µM. The RNA was isolated and qRT-PCRs were performed. The expression level
of HNF4α was comparable in all three samples. The HLCs generated without cytokines
showed the highest expression level of A1AT, AFP and ALB (Figure 3.32C). Second,
HLCs were generated with cytokine treatment and were cultured further. RNA was
isolated from five days HLCs (common age and endpoint of differentiation), ten days,
15 days and 18 days. The expression level of HNF4α, A1AT and ALB were increased
until the differentiation endpoint. AFP had the expression maximum at ten days old
HLC and then decreased. Immunofluorescence-based protein stainings confirmed the




Figure 3.32: Quantitative real-time PCR profile of liver specific maker.
A) The expression pattern of pluripotency associated genes during the liver differentiation of epiHUV-
iPS-3a were decreased. B) Development of the expression pattern of liver specific markers during the
HLC differentiation are shown. Definitive endoderm (DE) specific marker genes SOX17, FOXA2 and
KRT17 were highly expressed in DE stage and decreased during liver differentiation. HNF4α as a key
transcription factor is highly expressed in all three stages. The liver specific genes AFP, ALB and
A1AT were most expressed at the end stage of liver differentiation, hepatocyte-like cells (HLCs) stage
III. C) Comparison of liver specific gene expression levels in HLCs generated under different conditions.
HLCs were generated with the treatment of cytokines (epiHUV-3a HLC 5d), without cytokines and
small molecules (epiHUV-3a HLC SM 5d) or without cytokines (epiHUV-3a HLC 5d -Cytokines). The
expression level of HNF4α comparable in all three samples. In HLCs generated without Cytokines
showed the highest expression level of A1AT, AFP and ALB. D) The expression level of HNF4α,
A1AT and ALB were increased till the endpoint. AFP had the expression maximum at HLC ten days
old and decreased then. Three biological replicates in technical triplicates of each sample were analyzed.
The standard deviation is depicted by the error bars. As control was used the RNA from HUVEC-iPSC
line (epiHUV-iPS-3a) which was differentiated.
Functional analysis of HUVEC-iPSC-HLCs
To analyze whether or not the derived HLCs are functional several tests were con-
ducted. First, E-Cadherin (E-CAD, CDH-1) marks the epithelial-to-mesenchymal tran-
sition (EMT) and indicating the epithelial nature of the developed liver cells and visual-
ized the typical cell shape of liver cells (Figure 3.33A) (Choi and Diehl [2009]; Schietke
et al. [2010]; Nakagawa et al. [2014]). Second, we tested whether or not our gener-
ated HLCs store glycogen as hepatocytes do (Greenberg et al. [2006]; Agarwal et al.
[2008]). To detect the glycogen in epiHUV-iPS-3a derived HLCs Periodic Acid-Schiff
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(PAS) staining was performed (Figure 3.33A). Third, we tested the secretory func-
tion using the nontoxic organic anion Indocyanine green (ICG) (Figure 3.33B) and 5
(and 6)-Carboxy-2,7-dichlorofluorescein diacetate (CDFDA) (Figure 3.22C), (Berk and
Stremmel [1986]; Mller and Jansen [1998]; Zamek-Gliszczynski et al. [2003]; Nezasa et al.
[2006]; Ho et al. [2012]).
Figure 3.33: Functional analysis of HLC derived from epiHUV-iPS-3a.
Functional analysis of induced pluripotent stem cell (iPSC)-derived hepatocyte-like cells (HLC).
A) Immunofluorescence-based detection of E-Cad is depicted on the left hand side and thereby detection
of the typical polygonal morphology of HLC. DAPI stained the nucleus. Scale bar: 100 µm, Alexa Flour
594 (red). To detect Glycogen storage a periodic acid-Schiff (PAS) assay was used and is depicted on the
right hand side. Glycogen storage is indicated by pink or dark red-purple cytoplasms. B) Indocyanine
green (ICG) uptake and release. HLC at the end of differentiation was used. Image of HLC direct after
incubation with ICG (left panel uptake) and six hours later (right panel release). C) Visualization of 5
(and 6)-Carboxy-2,7-dichlorofluorescein diacetate (CDFDA). Immunofluorescence image of HLC direct




Fourth, bile acid production was measured in epiHUV-3a-HLC (iHUV3a HLC), epiHUV-
3a-HLC three days older (iHuv3a HLC +3d), epiHUV-3a-HLC treated with small molecules
FH1 and FPH1 (iHuv3a HLC SM), epiHUV-3a-HLC without cytokines (iHuv3a HLC
-Cytokines) and HepG2. The measurement shows the excretion of primary bile acids
and are presented in pmol/ml/24h (Figure 3.34A). Fifth, the measurement of urea pro-
duction was performed in epiHUV-3a-DE (DE), epiHUV-3a-HE (HE), epiHUV-3a-HLC
five days (HLC 5d), epiHUV-3a-HLC ten days (HLC 10d), epiHUV-3a-HLC 13 days
(HLC 13d), epiHUV-3a-HLC 18 days (HLC 18d) and HepG2. The levels of urea was
measured in mg/dl/24h. The cells of epiHUV-3a-HLC 13 days produced most of urea
(Figure 3.34B). All these results together substantiated the similarity of these iPSC-
derived HLCs to hepatocytes in morphology and biochemical matter.
Figure 3.34: Measurement of functionality in HLC derived from epiHUV-iPS-3a.
A) Analysis of bile acid production in epiHUV-3a-HLC (iHUV3a HLC), epiHUV-3a-HLC three days
older (iHuv3a HLC +3d), epiHUV-3a-HLC treated with small molecules (iHuv3a HLC SM), epiHUV-3a-
HLC without cytokines (iHuv3a HLC -Cytokines) and HepG2. The levels of bile acids are presented in
pmol/ml/24h. B) Analysis of urea production in epiHUV-3a-DE (DE), epiHUV-3a-HE (HE), epiHUV-
3a-HLC five days old (HLC 5d), epiHUV-3a-HLC ten days old (HLC 10d), epiHUV-3a-HLC 13 days
old (HLC 13d), epiHUV-3a-HLC 18 days old (HLC 18d) and HepG2. Three biological replicates in
technical triplicates of each sample were analyzed. The levels of urea was measured in mg/dl/24h.
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Microarray analysis of HUVEC-iPSC-derived HLCs
As described before during the reprogramming process the somatic cells change their
transcriptome profile dramatically (Wolfrum et al. [2010]). It moves from characteristic
of a somatic cell and converges to a pluripotent stem cell-like stage, which is similar to the
transcriptome profile of hESCs. Differentiation of iPSCs to HLCs results in a directed
change of the transcriptome. It should converged to the transcriptome of human pri-
mary hepatocytes (PHH). In order to visualize this transformation of the reprogrammed
HUVEC line and further differentiated to HLCs a cluster dendogram was complied of
the transcriptome profiles from HUVEC, HUVEC-iPSC, hESC, HUVEC-derived HLCs
at different time points (HLC 14d, HLC 19d, HLC 27d), fetal liver and PHH (Figure
3.35A). The HUVEC-iPSC lines differ from their parental cell type and has a transcrip-
tome profile similar to hESC. HLCs derived from HUVEC-iPSC cluster all together and
differ from the HUVEC-iPSC line as strong as from the transcriptome profile of fetal
liver and PHH. In order to show the precise distinction between the samples Pearson
correlation co-efficient was evaluated (Figure 3.35B). The most similarity was located
between 14 days and 19 days HLCs followed by the transcriptome profile between 19
days and 27 days HLCs. The transcriptome of 19 days HLCs holds the highest similarity
to that of fetal liver and PHH in comparison to the other HLCs.
Figure 3.35: RNA-based microarray analyses HUVEC-iPSC-derived HLCs.
A) A dendogram analysis of the transcriptome profiles from hESC, HUVEC, HUVEC-iPSC, HLC-
derived from HUVEC-iPSC at different time points (HLC 14d, HLC 19d, HLC 27d), fetal liver and
PHH.B) Pearson correlation co-efficient of the entire expression data (Illumina microarrays) of HUVEC,
HUVEC-iPSC, HLC 14d, HLC 19d, HLC 27d, fetal liver and PHH. Abbreviations: hESCs = human
embryonic stem cells; HUVEC = human umbilical vein endothelial cell; HUVEC-iPSC = episomal
reprogrammed induced pluripotent stem cell derived from HUVECs; HLC = hepatocyte-like cell; PHH
= primary human hepatocytes.
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Comparative transcriptome profile analysis of HLCs of three different time points
(HLC 14d, HLC 19d, HLC 27d), fetal liver and PHH samples using Venn diagram anal-
yses show the numbers of expressed genes (Figure 3.36). First, a Venn diagram was
created using the expressed genes of 14d, 19d and 27d HLCs (Figure 3.36A, Supplemen-
tary Table 14). The HLC-related genes ANXA1, TTR and TBX3 as well as the fetal
liver-related gene AFP which marks the early liver development and ALB represent
the matured liver stage are expressed in all three samples (12,380 genes). Proliferation-
associated genes are exclusively expressed in 14 days old HLCs (663 genes, e.g. BCL2,
FGF2, NOG, TEK ). 19d HLCs express genes which are associated e.g. to cell survival
and recognition (342 genes, e.g. FGF9, GAP43, HOXB7, RDH12 ). Defense, inflam-
matory, immune and wound response-associated genes are exclusively expressed in 27d
HLCs (265 genes, e.g. CXCL3, LYZ, SP100, TLR4 ).
Second, a comparison was conducted of expressed genes in 14 days HLCs (HLC 14d)
with fetal liver and PHH (Figure 3.36B, Supplementary Table 15), in 19 days HLCs
(HLC 19d) with fetal liver and PHH (Figure 3.36C, Supplementary Table 16) and in 27
days HLCs (HLC 27d) with fetal liver and PHH (Figure 3.36D, Supplementary Table
17). The HLC-related genes ANXA1, TTR and TBX3 as well as the fetal liver-related
gene AFP and ALB as a matured liver stage marker are expressed in all samples.
Additionally, in all samples are expressed bile acid-related transporter genes such as
SLC10A1 (NTCP) and ABCC2 (MRP2 ), Hippo signaling-related genes e.g. BBC3,
TEAD3 and TAZ, cell-cell contact-related genes such as CDH1 (E-CAD), CLDN1 and
TJP1 (ZO-1 ) as well as cytochrome p450 superfamily-related genes such as ACYP2,
and CYP27A.
Third, the intersections were analyzed between the HLCs vs. PHH and HLCs vs. fetal
liver. Analysis of PHH vs. HLC 14d (350 genes, Figure 3.36B) by DAVID uncovered the
expression of drug metabolism-related genes (e.g. NAT2, TYMP) and NOTCH signaling
pathway-related genes (e.g. JAG, MESP) as well as cell-cell signaling-related genes (e.g.
FGF2, PANX1, WNT5A). Intersection analysis of fetal liver vs. HLC 14d (1,768 genes,
Figure 3.36B) by DAVID uncovered the expression of WNT signaling pathway-related
genes (e.g. FZD9, LEF1, RAC2 ), embryonic development-related genes (e.g. DLC1,
PTK7, SOX8 ) and cell proliferation-related genes (e.g. LGR4, KIT, VEGFC ). Inter-
section analysis of PHH vs. HLC 19d (369 genes, Figure 3.36C) by DAVID uncovered
the expression of drug metabolism-related genes (e.g. TYMP, UMPS ) and cytochrome
p450 superfamily-related genes (e.g. CYP1A1, CYP2E1 ) as well as regulation of cell
growth-related genes (e.g. ABTB2, HNF4α, SEMA4F ). Intersection analysis of fetal
liver vs. HLC 19d (1,653 genes, Figure 3.36C) by DAVID uncovered the expression of
cell adhesion molecules-related genes (e.g. CLDN4, PECAM1, VCAM1 ), developmen-
tal maturation-related genes (e.g. GDF11, RUNX3, SOX8 ) and cell cycle-related genes
(e.g. CHEK2, E2F2, TTK ). Intersection analysis of PHH vs. HLC 27d (358 genes,
Figure 3.36D) by DAVID uncovered the expression of drug metabolism-related genes
(e.g. TYMP, UMPS ) and cytochrome p450 superfamily-related genes (e.g. CYP1A1,
CYP2E1, CYP3A4 ) as well as regulation of body fluid levels-related genes (e.g. ANXA8,
HNF4α, SERPINE1 ). Intersection analysis of fetal liver vs. HLC 27d (1,350 genes,
Figure 3.36D) by DAVID uncovered the expression of cell adhesion molecules-related
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genes (e.g. CLDN4, MPZ, VCAM1 ), gap junction-related genes (e.g. ADCY3, GJA1,
PDGFB) and cell cycle-related genes (e.g. CHEK2, MCM2, TTK ).
To sum up these transcriptome profile analysis of HLCs with three different time
points (HLC 14d, HLC 19d, HLC 27d), fetal liver and PHH samples all three HLC
samples were similar and clustered together. Each sample expressed genes comparable
to fetal liver and PHH. However, the transcriptome profile of HLC 14d showed the most
overlap with that of fetal liver and HLC 19d with that of PHH.
Figure 3.36: Venn diagram analyses.
A) Venn diagram analysis of the transcriptome profile from HUVEC-iPSC-derived HLC at different
time points (HLC 14d, HLC 19d, HLC 27d) portraying distinct and overlapping transcriptional signa-
tures. B) Venn diagram analysis of the transcriptome profile from PHH, fetal liver and HLC-derived
from HUVEC-iPSC at day 14 (HLC 14d) portraying distinct and overlapping transcriptional signa-
tures. C) Venn diagram analysis of the transcriptome profile from PHH, fetal liver and HLC-derived
from HUVEC-iPSC at day 19 (HLC 19d) portraying distinct and overlapping transcriptional signa-
tures. D) Venn diagram analysis of the transcriptome profile from PHH, fetal liver and HLC-derived
from HUVEC-iPSC at day 27 (HLC 27d) portraying distinct and overlapping transcriptional signa-
tures. Abbreviations: HUVEC = human umbilical vein endothelial cell; HUVEC-iPSC = episomal
reprogrammed induced pluripotent stem cell derived from HUVECs; HLC = hepatocyte-like cell; PHH
= primary human hepatocytes.
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3.2.3 Comparison of transcriptome profiles from different HLCs
In order to visualize and analyze the distinctions and commonalities in certain areas
heatmaps were generated to show the Hippo, Notch and TGFβ pathway (Figure 3.37)
as well as ABC transporter-related, cytochrome P450 superfamiliy-related (Figure 3.38),
liver development-related, bile acid transporter-related and tight junction-related genes
(Figure 3.39).
The Hippo signaling pathway influences fate and size of liver cells and it is essential for
the maintenance of the differentiated hepatocyte state. Additionally, the Hippo pathway
is responsible for maturation and stabilization of the tight junctions. The expression pat-
tern of hippo pathway-related genes in HUVEC-derived HLCs is comparable to that in
HFF1-derived HLCs (Figure 3.37A). Notch signaling is an evolutionary conserved mech-
anism that plays amongst others an important role in cell fate decisions in the early
liver development. During liver and biliary development Notch coordinates biliary fate
and duct morphogenesis in a temporal- and dose-dependent way, which is a late event
in liver development. HFF1-derived HLCs and HUVEC-derived HLCs show a compa-
rable expression pattern of Notch signaling-related genes and cluster together (Figure
3.37B). In liver development the TGFβ pathway is involved in tight junction depletion,
cytoskeleton and cell-cell contact rearrangement. The samples of HFF1-derived HLCs
and HUVEC-derived HLCs cluster together and reveal comparable expression pattern
of TGFβ pathway-related genes (Figure 3.37C).
ABC transporters are accountable for the uptake and efflux of e.g. bile acids and
metabolites. The expression pattern of HUVEC-derived HLCs differs from HFF1-derived
HLCs and form their own cluster. The iPSC sample expression pattern cluster together
and this cluster is extended by the HFF1-derived HLCs (Figure 3.38A). The same re-
sult is shown by the heatmap of cytochrome P450 superfamily-related genes, which
are involved in drug metabolism and synthesis of cholesterol, steroids and other lipids.
The iPSC sample expression pattern cluster together and this cluster is extended by
the HFF1-derived HLCs. The expression pattern of HUVEC-derived HLCs differs from
HFF1-derived HLCs and form their own cluster (Figure 3.38B). This indicates that
HUVEC-derived HLCs are more hepatocyte-like than HFF1-derived HLCs.
A short insight into the liver development was summarized in a heatmap (Figure
3.39A). The expression pattern HFF1-derived HLCs and HUVEC-derived HLCs are com-
parable and form a cluster. The expression of pluripotent-associated genes (POU5F1,
SOX2 and NANOG) are down-regulated and mature liver-related genes (ALB, CYP1A1
and TTR) as well as hepatoblast-related genes (e.g. DLK1, HNF1B, NOTCH3 ) are up-
regulated. The iPSC sample expression pattern of bile acid transporter genes cluster
together and this cluster is extended by the HFF1-derived HLCs. The expression pat-
tern of HUVEC-derived HLCs differs from HFF1-derived HLCs and form their own
cluster (Figure 3.39B). Due to the fact that the Hippo pathway and TGFβ pathway are
involved in the tight junction formation and the expression pattern of Hippo pathway-
and TGFβ pathway-related genes were comparable in HFF1-derived HLCs and HUVEC-
derived HLCs a heatmap of tight junction related-genes was compiled (Figure 3.39C).
The HFF1-derived HLCs expression pattern is not comparable with that of HUVEC-
82
Chapter 3. Results
derived HLCs. The samples of HUVEC-derived HLCs do not cluster together. Tight
junction related-genes ar most expressed in HFF1-derived HLCs.
In order to analyze the transformation of somatic fibroblast cell lines during the re-
programming process and further differentiating to HLCs a cluster dendogram was com-
plied of the transcriptome profiles from HUVEC, HUVEC-iPSC, HFF1-iPSC, HUVEC-
derived HLCs at different time points (HLC 14d, HLC 19d, HLC 27d), fetal liver and
PHH (Figure 3.40A). The cluster dendrogram demonstrates the high similarities of the
transcriptome profiles between the biological replicates. The iPSCs formed a cluster
which is then extended by HFF1-HLCs. The HUVEC-derived HLCs of different time
points formed a cluster. Furthermore, fetal liver and PHH formed a cluster.
To detect the relation between HFF1-HLCs and HUVEC-HLCs a venn diagram analy-
sis was conducted (Figure 3.40B, Supplementary Table 18). Most liver-related genes are
expressed in both samples (12781 genes, intersection of HFF1-HLCs and HUVEC-HLCs
venn diagram). The expression of the HLC-related genes ANXA1, TTR and TBX3 as
well as the fetal liver-related gene AFP and mature liver-related gene ALB are located in
the intersection. Additionally, in both samples are expressed bile acid-related transporter
genes such as SLC10A1 (NTCP) and ABCC2 (MRP2 ), Hippo signaling-related genes
e.g. BBC3, TEAD3 and TAZ, cell-cell contact-related genes such as CDH1 (E-CAD),
CLDN1 and TJP1 (ZO-1 ) as well as cytochrome p450 superfamily-related genes such
as ACYP2, CYP1A1 and CYP26A1. However, they also expressed markers which in-
dicates that these HLCs are immature. Both expressed progenitor-related markers such
as PROM1 (CD133 ), LEFTY2, DNMT3B, SOX2, NOTCH3, DLK1, intestine-related
gene CDX2, cholangiocyte-related genes e.g. AQP1 KRT7, SOX9 and pancreas-related
genes MEIS2, ISL1 (Ahlgren et al. [1997]; Smith et al. [1997]; Swift et al. [1998], Cheng
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continued from previous page
Figure 3.37: Comparative pathway analyses.
The expression pattern of the following samples were compared: HFF1-iPSC, HFF1-HLC, HUVEC-
iPSC and HUVEC-HLC. A) Heatmap of Hippo pathway-related genes. B) Heatmap of Notch pathway-
related genes. C) Heatmap of TGFβ pathway-related genes. Abbreviations: HUVEC = human umbili-
cal vein endothelial cell; HUVEC-iPSC = episomal reprogrammed induced pluripotent stem cell derived
from HUVECs; HLC = hepatocyte-like cell.
Figure 3.38: Comparative heatmap analyses.
The expression pattern of the following samples were compared: HFF1-iPSC, HFF1-HLC, HUVEC-
iPSC and HUVEC-HLC. A) Heatmap of ABC transporter-related genes. B) Heatmap of cytochrome
P450 superfamily of enzymes-related genes. Abbreviations: HUVEC = human umbilical vein endothelial
cell; HUVEC-iPSC = episomal reprogrammed induced pluripotent stem cell derived from HUVECs;
















Figure 3.39: Comparative heatmap analyses of liver specificities.
The expression pattern of the following samples were compared: HFF1-iPSC, HFF1-HLC, HUVEC-iPSC and HUVEC-HLC. A) Heatmap of
liver development-related genes. B) Heatmap of bile acid transporter-related genes. C) Heatmap of tight junction-related genes. Abbreviations:
HUVEC = human umbilical vein endothelial cell; HUVEC-iPSC = episomal reprogrammed induced pluripotent stem cell derived from HUVECs;
HLC = hepatocyte-like cell.
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To analyze whether or not one of the generated HLCs is more mature than the other
DAVID analyses of the single sections were performed. The HUVEC-iPSC-derived HLCs
exclusively expressed genes e.g. of drug metabolism, cytokine-cytokine receptor inter-
action, ABC transporters, Metabolism of xenobiotics by cytochrome P450, chemokine
signaling pathway and MAPK signaling pathway (1212 genes, Figure 3.40B, Supplemen-
tary Table 18). This indicates that HLCs derived from HUVEC-iPSCs are more mature
and functional hepatocyte-like cells compared to HFF1-iPSC-derived HLCs. However,
HUVEC-iPSC-HLC expressed progenitor-related genes such as CXCR4, CER1, PROX1
and PDX1 indicating that these cells are immature (Cheng et al. [2012]; Hannan et al.
[2013], Seth et al. [2014]). The HFF1-iPSC-derived HLCs exclusively expressed genes
related to e.g. cell adhesion molecules, cell-cell signaling and tight junction indicating
that these cells are more mature on a structural level compared to HUVEC-iPSC-derived
HLCs (1284 genes, Figure 3.39C and 3.40B).
In order to analyze the relation between the iPSC-derived HLC lines compared to fetal
liver and PHH a venn diagram analysis of these samples was conducted (Figure 3.40C,
Supplementary Table 19). The transcription profiles of the HLCs are more similar to
that of fetal liver than to PHH. Both HLC lines and the fetal liver expressed genes related
to cell-cycle, DNA replication and cell adhesion molecules as well as progenitor-related
genes (e.g. DLK1, DNMT3B, DPPA4, NOTCH3, PODXL, PROM1 ).
87
Chapter 3. Results
Figure 3.40: Comparative cluster analyses.
A) A dendrogram analysis of the transcriptome profiles from HUVEC, HUVEC-iPSC, HLC-derived
from HUVEC-iPSC at different time points (HLC 14d, HLC 19d, HLC 27d), HFF1-iPSC, HLC-derived
from HFF1-iPSC, fetal liver and PHH. B) Venn diagram analysis of the transcriptome profile from
HFF1-iPSC-derived HLC (HFF1-HLC 14d) and HUVEC-iPSC-derived HLC (HUVEC-HLC 14d) por-
traying distinct and overlapping transcriptional signatures. C) Venn diagram analysis of the transcrip-
tome profile from HFF1-iPSC-derived HLC (HFF1-HLC 14d), HUVEC-iPSC-derived HLC (HUVEC-
HLC 14d), fetal liver and PHH portraying distinct and overlapping transcriptional signatures. Abbre-
viations: HUVEC = human umbilical vein endothelial cell; HUVEC-iPSC = episomal reprogrammed




3.3 Derivation and characterization of endoderm
progenitor cells derived from HFF1-iPSC
Human pluripotent stem cells, including human embryonic stem cells (hESCs) and in-
duced pluripotent stem cells (iPSCs), have the capacity to self-renew and give rise to all
tissue types. During the differentiation in vitro to mature cell types these pluripotent
stem cells traverse the early embryonic development (Murry and Keller [2008]). The
liver and pancreas are examples for endodermal-derived tissues. To address the early
embryonic development of endodermal-derived tissues and to analyze cell fate decisions
during this process we derived endodermal progenitors (EPs) from iPSCs.
Generate iPSCs is primarily to archieve immunocomparbility and also to avoid eth-
ical and moral issues. The viral reprogramming is the most commonly used method
(Prigione et al. [2010]; Wang et al. [2010]; Somers et al. [2010]; Jozefczuk et al. [2011];
Ban et al. [2011]; Cheng et al. [2012]; Sekine et al. [2012]; Takebe et al. [2014]). Here,
in this project another method was used which was published by Yu et al. [2009]. The
episomal-derived iPSCs, which were used for this study were derived from human fibrob-
lasts (HFF1 cells), are viral-free and integration-free (see Chapter 2).
The endodermal progenitors (EPs) were derived from the iPSC-line epiHFF1-iPS-B1
followed the protocol by Cheng et al. [2012] with slight modifications. The differenti-
ation procedure is split into four stages (Figure 3.41). First, the definitive endoderm
(DE), which is also the first stage of HLC differentiation. Second, an intermidiate stage
between definitive endoderm and endoderm progenitors, labeled as transient cells (TC).
Third, the stage of pre-endoderm progenitors (pre-EP), when the maintenance medium
is applied and fourth, when 3D-colonies are formed the EP stage is accomplished. The
original protocol describes the second stage as a period of four weeks. In this study,
the procedure was modified and reduced to three and two weeks. The procedure could
be successfully shortened. Before the cells were split the first time, minor changes were
observed, but no colonies were formed. After the first split the culture was homogenous.
At passage 4 the first colonies were observed. The cells which were cultured two weeks
as TCs (2 week cells) had formed big colonies at passage 8, as well as the three weeks
TC cultured cells. The original treated cells which were four weeks at the TC stage (4
week cells) had small colonies at passage 8 in comparison to the other procedures (two
and three weeks cultured TCs). During the culture the size and number of EP colonies
from the 4 weeks TCs adapted to that of the other conditions (Figure 3.41).
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Figure 3.41: Illustration of EP development derived from epiHFF1-iPS-B1.
Microscopy images showing morphology changes during the differentiation of epiHFF1-iPS-B1 (iPSCs)
to endodermal progenitors (EPs). The iPSC-line were cultured in conditioned medium (CM). The
generation of the first stage definitive endoderm (DE) takes five days. The intermediate stage (TC)
were generated in two, three and four weeks. Following the cells were split the first time to pre-
EPs (P0). At passage eight (P8) the two and three week cells have big colonies, the four week cells
have minor colonies in comparison. In the course of passages the cells adapt, shown in passage 16
(P16). Abbreviations: DE = definitive endoderm; EP(s) = endoderm progenitor(s); iPSC = induced
pluripotent stem cell; P0 = passage zero; TC = transient cells.
After five days DE stage related maker proteins were detected (Figure 3.42). Antibody
stainings showed that the expression of the pluripotency marker OCT4 was down reg-
ulated, the definitive endoderm marker chemokine (C-X-C motif) receptor 4 (CXCR4),
as well as HNFα, E-Cadherin (E-CAD), the stem cell/progenitor markers leucine-rich
repeat containing G protein-coupled receptor 5 (LGR5) and PROM1 (CD133) were de-
tectable (McLean et al. [2007]; Mizrak et al. [2008]; Wang et al. [2013b]). At the end
of the intermediate stage TC the expression of OCT4 was deactivated and HNF4α, E-
Cadherin (E-CAD), CXCR4 and LGR5 were still detectable (Figure 3.43). At passage
4 the first EP colonies were detectable. The treatment with trypsin or accutase failed to
split the colonies, therefore the colonies grew bigger. At passage 8 activated leukocyte
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cell adhesion molecule (ALCAM), HNF4α, LGR5 and CXCR4 were identifiable (Figure
3.44). Due to the fact that the colonies increased in size, but not in number two nee-
dles were used to split the colonies mechanically. The colonies became smaller, more
and the stainings got more pronounced intense (Figure 3.45). These progenitor cells
express the self-renewal marker LGR5 and markers associated with the foregut (SOX2),
midgut/hindgut (caudal type homeobox 2, CDX2), pancreas (pancreatic and duodenal
homeobox 1, PDX1), liver (Albumin, ALB), definitive endoderm (chemokine (C-X-C
motif) receptor 4, CXCR4) and stem cell (LGR5, CD133) (Cheng et al. [2012]; Hannan
et al. [2013]).
Figure 3.42: Immunofluorescence-based detection of proteins in DE derived from
epiHFF1-iPS-B1 to generate EP.
The detection of the protein OCT4, pluripotency marker; the transcription factor HNF4α, E-CAD,
CXCR4, LGR5 and CD133. DAPI stained the nucleus. Scale bar: 200 µm, Alexa Flour 594 (red),
Alexa Flour 488 (green).
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Figure 3.43: Immunofluorescence-based detection of proteins in intermediate stage from
DE to EP derived from epiHFF1-iPS-B1.
OCT4 as a pluripotency marker was not detectable; endodermal marker such as the transcription factor
HNF4α, E-CAD, CXCR4, as well as the stem cell markers LGR5 and CD133 were detectable. DAPI
stained the nucleus. Scale bar: 200 µm, Alexa Flour 594 (red), Alexa Flour 488 (green).
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Figure 3.44: Immunofluorescence-based detection of proteins in EP passage 8 derived
from epiHFF1-iPS-B1.
The detection of the protein ALCAM, HNF4α, LGR5 and CXCR4. DAPI stained the nucleus. Scale
bar: 200 µm, Alexa Flour 594 (red), Alexa Flour 488 (green).
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Figure 3.45: Immunofluorescence-based detection of proteins in EP passage 16 derived
from epiHFF1-iPS-B1.
The detection of the protein LGR5 (self-renewal marker), PDX1 (pancreas marker), ALBUMIN (liver
marker), SOX2 (foregut marker), CDX2 (hindgut marker), CD133 (stem cell marker) and CXCR4
(definitive endoderm marker). DAPI stained the nucleus. Scale bar: 200 µm, Alexa Flour 594 (red),
Alexa Flour 488 (green).
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Figure 3.46: Quantitative real-time PCR profile of EP derivation.
A) The expression pattern of pluripotency associated genes during the endodermal progenitor (EP)
derivation from epiHUV-iPS-3a were decreased. B) Development of the expression pattern of specific
markers during the EP differentiation are shown. Definitive endoderm (DE) specific marker genes
CER1, EOMES, MIXL1 and GATA6 were expressed in DE stage, decreased during EP differentiation
and were highly expressed in EPs. CD133 was not expressed in DE and transient cells (TC) but
increased in preliminary stage of EPs (pre-EP) and was highly expressed in EPs. HNF4α and FOXA2
as key transcription factors of liver development were most expressed in EPs. The liver specific genes
AFP, ALB and TBX3 were most expressed at the end stage of EP derivation. The stem cell/progenitor
marker LGR5 and intestine-specific marker CDX2 were also most expressed in EPs. Three biological
replicates in technical triplicates of each sample were analyzed against the undifferentiated state of
induced pluripotent stem cells (epiHFF1-iPS-B1) as the control. The standard deviation is depicted by
the error bars.
QRT-PCR analyses of all stages during EP derivation revealed the expression profile of
each stage relative to the undifferentiated state of the iPSC-line which was differentiated
to EPs (Figure 3.46). The expression of pluripotency-associated genes such as OCT4,
SOX2 and NANOG decreased during the differentiation to DE and transient cell (TC)
stage and increased to the pre-EP and EP stage, but was still decreased compared to
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the expression level of iPSCs. Immunofluorescence-based antibody staining of EPs for
SOX2 uncovered the expression (Figure 3.45). However, the expression level of GDF3
and DNMT3B in EPs is increased or comparable to the iPSCs (Figure 3.46A). Primitive
streak-/endoderm-specific genes such as CER1, EOMES, MIXL1, GATA6, FOXA2 and
HNF4α are expressed most at the EP stage (Rosa [1989]; Afouda et al. [2005]; Hart et al.
[2005]; Agarwal et al. [2008]; Arnold and Robertson [2009]; Takayama et al. [2011]; Teo
et al. [2011]; Takayama et al. [2012]). Early and late liver specific genes such as AFP,
ALB and TBX3 are expressed most at the EP stage as well as the progenitor-related
genes CD133, LGR5 and the intestinal-associated gene CDX2 (Figure 3.46B) (Renard
et al. [2007]; Hay et al. [2008b]; Cheng et al. [2012]; Hannan et al. [2013]).
Figure 3.47: Functional assays of EP cells-derived from epiHFF1-iPS-B1.
A) Analysis of bile acid production in endodermal progenitors (EP) and epiHUV-3a-HLC (HLC). The
levels of bile acids are presented in pmol/ml/24h. B) Analysis of urea production in EP, epiHFF1-B1-
DE (DE), epiHFF1-B1-HE (HE), epiHFF1-B1-HLC. Three biological replicates in technical triplicates
of each sample were analyzed. The levels of urea was measured in mg/dl/24h.
In order to study functional characteristics of the EPs secretion assays for bile acid
and urea were done (Figure 3.47). Compared to the HLCs generated from the same
iPSC-line the EPs secreted more primary bile acids (Figure 3.47A). The urea secretion
was lower than the secretion level of DE cells (Figure 3.47B).
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Comparative Microarray analysis of HFF1-iPSC-EP
A comparative transcriptome analysis was done by using the transcriptome profile of
viral- and integration-free iPSCs as the original sample with all steps of the EP gener-
ation and the transcriptome profile of HLCs. The EPs and HLCs were generated from
the same iPSC line (iPSC-B1). A cluster dendrogram was created (Figure 3.48A). The
transcriptome of the EPs is distinct separated from the others. A principal component
analysis of the samples was done and confirmed the result of the dendogram (Figure
3.48B). The transcriptome profile of EPs is distinct and separated from the other sam-
ples. The TC and pre-EP were clustered together.
Further analyses of the expression level of selected gene sets were done (Figure 3.49).
Definitive endoderm and primitive streak related genes were expressed most in DE and
pre-EP samples (Figure 3.49A-B). However, in EPs were most expressed GATA binding
protein 6 (GATA6 ) and HNF4α of definitive endoderm-related gene set and and T-box
6 TBX6 of primitive streak-related gene set. All are transcription factors which are
important for the embryogenesis (Morrisey et al. [1998]; Yi et al. [1999]; Li et al. [2000];
Tomizawa et al. [2013]). Another gene set of transcription factors were most expressed
in EPs (Figure 3.49C). These are all involved in developmental processes. Later on,
Meis homeobox 2 (MEIS2 ) is involved in activating of different gene sets in the pan-
creas and ISL LIM homeobox 1 (ISL1 ) regulates the generation of all endocrine islet
cells (Ahlgren et al. [1997]; Smith et al. [1997]; Swift et al. [1998]). T-box 3 (TBX3 )
regulates β-catenin activity in liver cell proliferation and survival (Bamshad et al. [1999];
Renard et al. [2007]). The Regulatory factor X, 6 (RFX6 ) directs β cell differentiation
and keeps the matured cells in their functional activity (Aftab et al. [2008]; Piccand et al.
[2014]). Forkhead box P2 (FOXP2 ) regulates lung epithelial gene transcription and is
requires to generate early pulmonary endoderm cells (Shu et al. [2001]; Hannan et al.
[2015]). Another set of genes includes progenitor-related genes (Figure 3.49D). Regard-
ing to this list only two genes were most expressed in EPs, Forkhead box A1 (FOXA1 ;
also known as Hepatocyte nuclear factor 3 alpha HNF3α) and Albumin (ALB). FOXA1
is involved in maturation of liver and regulates the expression level of e.g. Transthyretin
(TTR), which is a pre-albumin gene (Lai et al. [1990]; Domanskyi et al. [2014]; Heddad
Masson et al. [2014]). ALB is involved in maturation of hepatocytes and maintains their
functional activity (Muglia and Locker [1984]; Shiojiri et al. [1991]; Hay et al. [2008b]).
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Figure 3.48: Comparative cluster analysis of stepwise EP generation.
A) A cluster dendrogram comparison of the the transcriptome of viral- and integration-free iPSC as the
original sample with all steps of the EP generation and the transcriptome of HLC. The EP and HLC were
generated from iPSC (iPSC B1). The Transcriptome of the EP is distinct separated from the others.
B) Principal component analysis of same samples in A. As shown in A the transcriptome of the EP is
distinct and separated from the other samples. The TC and pre-EP are more similar. Abbreviations:
iPSC = induced pluripotent stem cells, DE = definitive endoderm, TC = transient cells, pre-EP =
















Figure 3.49: Comparative cluster analysis of stepwise EP generation.
A) Definitive endoderm related genes were expressed most in DE and pre-EP samples. B) Primitive streak related genes were expressed most in
DE and pre-EP samples. C) Transcription factors related to early liver (TBX3), pancreas (ISL1, RFX6), lung (FOXP2) as well as ID2 and MEIS2
were overexpressed in EP. D) The heat map of progenitor related genes identified the EP as a panendoderm progenitor. Abbreviations: iPSC
= induced pluripotent stem cells, DE = definitive endoderm, TC = transient cells, pre-EP = pre-endodermal progenitor cells, EP = endodermal
progenitors, HLC = hepatocyte-like cells.
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3.4 Mouse embryonic fibroblasts replaced by human
fetal mesenchymal stem cells
In 1998, when Thomson et al. [1998] isolated and cultured human embryonic stem cells
(hESCs) for the first time they used mouse embryonic fibroblasts (MEFs) as a supportive
surface for the hESC culture. Under these conditions the hESCs were able to maintain
their undifferentiated stage. By replacement of fetal calf serum with Knockout Serum
Replacement (SR) and the use of the basic fibroblast growth factor (FGF2) could reduce
the spontaneous differentiation level (Amit et al. [2000]). Later on a culture method was
developed, which does not use MEFs (feeder-free culture system), to advance the safety
profile. The feeder-free system allows to isolate pure DNA, RNA and protein from
hESCs and other human cell types. However, MEFs were still used for the production
of conditioned medium (CM). Xu et al. [2001] developed a feeder-free system using the
medium conditions of Amit et al. [2000] to integrate the soluble factors into the medium
secreted by the MEFs. To obtain MEFs a pregnant mouse has to be sacrificed and
the embryos have to be harvested (see page 123). Additionally, CM complicate clinical
applications of hESCs due to the potential contamination by animal pathogens. Other
feeder-free media were developed and are commercial available (Liu et al. [2006]; Lu
et al. [2006]; Yao et al. [2006]; Chen et al. [2011]; Beers et al. [2012]; Frank et al. [2012];
Wang et al. [2013a]). Not all media are appropriate for all cell lines. MEF conditioned
medium works very well, but it is not defined, followed by mTeSR and TeSR-E8 medium
(Stemcell technologies), which are defined but expensive.
To avoid overspending and killing of mice this study analyzed the use of human fetal
femur mesenchymal stem cells (fMSCs) as an alternative for MEFs. Serveral studies
showed the successful use of human cells as feeders to culture hESCs, e.g. human dermal
fibroblasts, human amniotic epithelial cells or human adult bone marrow mesenchymal
stem cells (Hovatta et al. [2003]; Cobo et al. [2008]; Lee et al. [2010]; Chen et al. [2013];
Mobarra et al. [2014]; Ghasemi-Dehkordi et al. [2015]).
First, hESCs and iPSCs were cultured on feeders (MEFs or fMSCs) with normal
medium and 8 ng/ml FGF. The culture with MEFs was comparable to the culture
method with fMSCs. Immunofluorescence-based antibody stainings of pluripotency as-

















Figure 3.50: Immunofluorescence-based detection of pluripotency markers in epiHFF1-iPS-B1.
All protein stainings for pluripotency markers OCT4, SOX2, NANOG, and the surface marker TRA-1-60 were positive. The culture of epiHFF1-
iPS-B1 on mouse embryonic fibroblasts (MEFs) is depicted on the left hand side and the culture of epiHFF1-iPS-B1 on human fetal mesenchymal




Second, conditioned medium was made from fMSCs as described for MEFs (see page
124). For both variations of CM (MEF-CM and fMSC-CM) an Activin A test was done
to analyze how much and how stable Activin A was produced in each CM. The Activin
A production from fMSCs were 1.7 fold higher than from MEFs and remained at a
relative constant level (Figure 3.51). Before using the CM all days were mixed and the
final concentration was measured. The concentration of Activin A in the CM made from
fMSCs was 2.5 fold higher than in the CM made from MEFs (data not shown).
Third, hESCs and iPSCs were cultured on Matrigel with CM made from MEFs or
fMSCs and with or without additional FGF (8 ng/ml). After four passages RNA was
isolated and qRT-PCRs were done. Generally, no significant differences were found.
In all conditions the cells kept their pluripotency. All cell lines expressed pluripotency
associated genes such as OCT4, SOX2, NANOG and GDF3 (Figure 3.52 and S12).
Immunofluorescence-based detection of pluripotency associated proteins confirmed the
qRT-PCR results (Figure 3.53, 3.54 and S13 - S16).
Figure 3.51: Measurement of Activin A in CM made from MEFs and fMSCs.
A) Analysis of Activin A production in conditioned medium (CM) made from MEFs. B) Analysis of
Activin A production in CM made from fMSCs. Three biological replicates in technical triplicates of
each sample were analyzed. The levels of Activin A are presented in ng/ml.
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Figure 3.52: Quantitative real-time PCR of pluripotency markers.
Expression pattern of pluripotency markers relative to HFF1 from hESC-line H1, the iPSC-line
epiHFF1-iPS-B1 and the iPSC-line epiHUV-iPS-3a are shown. The cells were cultured in conditioned
medium (CM) made from mouse embryonic fibroblats (MEFs), which is the common used CM, and
fetal mesenchymal stem cells (fMSCs) made CM (fMSC-CM). Three biological replicates in technical
triplicates of each sample were analyzed against HFF1 as control. The standard deviation is depicted
















Figure 3.53: Immunofluorescence-based detection of pluripotency markers in epiHFF1-iPS-B1.
All protein stainings for pluripotency markers OCT4, SOX2, NANOG, and the surface marker TRA-1-60 were positive. The culture of epiHFF1-
iPS-B1 on Matrigel with mouse embryonic fibroblasts (MEFs) made conditioned medium (CM) with additional FGF is depicted on the left hand
side (B1 MEF-CM +FGF) and the culture of epiHFF1-iPS-B1 on Matrigel with human fetal mesenchymal stem cells (MEFs) made CM with
additional FGF is depicted on the right hand side (B1 fMSC-CM +FGF). DAPI stained the nucleus. Scale bar: 200 µm, Alexa Flour 594 (red),
















Figure 3.54: Immunofluorescence-based detection of pluripotency markers in epiHFF1-iPS-B1.
All protein stainings for pluripotency markers OCT4, SOX2, NANOG, and the surface marker TRA-1-60 were positive. The culture of epiHFF1-
iPS-B1 on Matrigel with mouse embryonic fibroblasts (MEFs) made conditioned medium (CM) without additional FGF is depicted on the left
hand side (B1 MEF-CM -FGF) and the culture of epiHFF1-iPS-B1 on Matrigel with human fetal mesenchymal stem cells (MEFs) made CM
without additional FGF is depicted on the right hand side (B1 fMSC-CM -FGF). DAPI stained the nucleus. Scale bar: 200 µm, Alexa Flour 594
(red), Alexa Fluor 488 (green).
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4 Discussion
4.1 Generation of iPSCs
Reprogramming of somatic cells is not a trivial task. Major roadblocks must be over-
come. The cell identity that has been determined by previous cell fate decisions and
subsequent epigenetic patterns that lock the cell identity in its current state have to be
reset. Also pluripotency genes have to be activated and their expression maintained (Fig-
ure 4.1). Since 2006, when Takahashi and Yamanaka [2006] successfully reprogrammed
somatic cells by ectopic expression of pluripotent transcription factors (TFs), several
methods of reprogramming were published. The principle is the same, the methods
are based on the ectopic expression of pluripotent TFs (Okita et al. [2008], Stadtfeld
et al. [2008], Sridharan et al. [2009], Woltjen et al. [2009], Yu et al. [2009], Zhou et al.
[2009], Plews et al. [2010], Sommer et al. [2010], Warren et al. [2010], Miyoshi et al.
[2011], Nishimura et al. [2011]). The ectopically expressed TFs form complexes with co-
regulatory factors, bind to specific DNA sequences across the genome and then modify
transcriptional and epigenetic regulation. This results in changes of histone modifica-
tions at somatic genes, mesenchymal to epithelial transition (EMT) is initiated, as well
as increased proliferation. Second, specific remodeling of chromatin causes the expres-
sion of genes in the pluripotency network to be activated and the expression of genes
which promote differentiation to be suppressed. Third, the recruitment of diverse epige-
netic enzymes supports the establishment of pluripotency-specific signal transduction,
as well as transcriptional and epigenetic patterns. Fourth, the iPSCs are stabilized
while the transgenes are silenced, the endogene core pluripotency circuit is activated,
the epigenome is reset and the cytoskeleton is remodeled to an ESC-like state (Taka-
hashi and Yamanaka [2006], Takahashi et al. [2007b], Zhao et al. [2011b], Buganim et al.
[2012], Golipour et al. [2012], Hansson et al. [2012], Polo et al. [2012]).
The viral-approach is still the classic method of reprogramming human adult fibrob-
lasts by over-expression of four transcription factors OCT4, SOX2, KLF4 and c-MYC
(Yamanaka-Cocktail) or OCT4, SOX2, NANOG and LIN28 (Thomson-Cocktail) (Taka-
hashi et al. [2007a]; Yu et al. [2007]). The efficiency amounts to 1 %. The integration
of pro-viruses into genome of viral-derived iPSCs is a risk factor for clinical applications
in the future. The major advantage of non-viral and non-integrating methods is the
lack of integration into the genome of tranfected cells (Chen and Liu [2009]; Yu et al.
[2009]). A very elegant method is the mRNA transfection. However, it is very inefficient

















Figure 4.1: Scheme of reprogramming process.
The reprogramming of somatic cells can be done by different methods (vrial-, plasmid-, protein or RNA-based). The principle of the methods
is the same, they based on the ectopic expression of pluripotent transcription factors (TFs). The ectopic expressed TFs form complexes with
coregulatory factors and bind to specific DNA sequences across the genome and obtain transcriptional and epigenetic regulation. It is activated
the endogenous expression of genes in the pluripotency network by specific remodeling of the chromatin. Additionally, the expression of genes
which promote differentiation is suppressed. The iPSCs are stabilized while the transgenes are silenced, the endogene core pluripotency cycle is
activated, the epigenome is reset and the cytoskeleton is remodeled to an ESC-like state (reviewed by Buganim et al. [2013] and Ma et al. [2013b]).
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Hence, a non-viral, episomal-based approach described by Yu et al. [2009] was used
in this study. The efficiency of this method to generate iPSCs ranges between 0.003 %
and 0.006 % (Yu et al. [2009]). We improved it with human fetal fibroblasts (HFF1)
cells, using the oriP/EBNA1 (Epstein-Barr nuclear antigen-1)-based episomal vectors
which express reprogramming factors, with an efficiency of 0.03 %. Later on, we used
human umbilical vein endothelial cells (HUVECs) with an efficiency of 2.5 %. This is
an increase of more than 83 %. The retrovirus reprogramming of HUVECs results in
an efficiency between 2.5 % and 3.0 % (Panopoulos et al. [2011]). The episomal-based
reprogramming is able to generate an efficiency comparable to the viral-approach us-
ing HUVECs. Additionally, the efficiency of reprogramming HUVECs was much higher
compared to the HFF1 reprogramming. After three weeks iPSC colonies from HUVEC
reprogramming were available. Using HFF1 cells for reprogramming took four months
to generate iPSCs. There are several other factors which influence the reprogramming
efficiency, e.g. the age of the donor cells itself and the passage number of in vitro culture,
the ability to undergo replication and cell cycle status, the variability in factor reactiva-
tion, and other stochastic events. (Aasen et al. [2008]; Maherali et al. [2008]; Ho et al.
[2010]; Lagarkova et al. [2010]; Schlaeger et al. [2015]). One major explanation of the
higher and faster reprogramming efficiency could provide the mesenchymal to epithelial
transition (MET) process. The induction of pluripotency is favoured by the change of
MET development. It is evident that reprogramming using epithelial cells such as ker-
atinocytes or in this case HUVECs results in an increased efficiency as compared with
dermal fibroblasts (e.g. HFF1) or MSCs which are of mesenchymal origin (Yang and
Weinberg [2008]; Wang et al. [2010]). Another advantage over HFF1 cells is the expres-
sion of decay-accelerating factor (DAF) in HUVECs. DAF is a membrane protein which
protects the cells from own complement-mediated injury, DNA damage and karyotype
changes. It is expressed in endothelium, epithilium and hematopoetic cells. HUVECs
own the highest DAF expression of all human cells that have been studied (Asch et al.
[1986]; Bryant et al. [1990]; Tsuji et al. [1994]; Mason et al. [2002]; Lagarkova et al.
[2010]).
The episomal-derived iPSCs (E-iPSCs) from both cell types were fully characterized
and are comparable to human embryonic stem cells (hESCs). During the culture of the
iPSCs all have completely lost the episomal vectors after 12 passages and no integration
was detectable. The E-iPSC lines express pluripotency markers such as OCT4, NANOG
and SOX2 also the surface marker proteins SSEA-4, TRA-l-60, TRA-1-81 and TRA-
2-49 but not SSEA-1. Additionally, they have the ability to differentiate to cell types
of the three germ layers endoderm, ectoderm and mesoderm in vitro (by formation of
embryoid bodies) and in vivo (by formation of teratoma in immunodeficient mice).
The teratoma assay is part of the ”golden standard” to characterize iPSCs. Nowadays,
teratoma assay should no longer used for basic characterization of iPSCs. There are too
many drawbacks. The most important teratoma counter-argument is the procedure by
itself. iPSC are transplanted into minimum one immunodeficient mouse to form spon-
taneously a teratoma which should include tissue from all three germ layers. Then, the
mouse will be killed and the teratoma will be analyzed (Okita et al. [2007]). Usually,
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more than one mouse will used for one iPSC line. Our laboratory made the experience
that the assay do not always works and it is more or less by chance that tissues of all
three germ layers are included in one teratoma. That is because during the teratoma
formation the iPSCs differentiate spontaneously. It is no direct differentiation to one or
the other germ layer tissue. This procedure is comparable to the embryoid body (EB)
formation with the difference that EB formation happen in a dish and can be repeat
as often as necessary. The EB assay is not only low priced, it is done much faster and
mice are not needed. Surprisingly, it is still existing a strong market for teratoma as-
say. Once again, this year a protocol for teratoma assay was published (Nelakanti et al.
[2015]). In this age alternatives should be used to perform the basic characterization of
iPSCs. On the one hand, to show by EB assay in vitro the ability to differentiate in
all three germ layers of a new iPSC line should be sufficient. On the other hand, direct
differentiation assays for tissues of all three germ layers could be performed in vitro and
gene expression transcriptome profile-based analysis can be conducted. Since 2011, a
robust open access bioinformatic assay of pluripotency in human cells is available and
called PluriTest (Mller et al. [2011]). With this tool the gene expression pattern of the
new iPSC line will be compared to the expression profile of several hundreds hESC and
iPSC lines from multiple laboratories all over the world. With the microarray data set
the PluriTest requires as less as 10 minutes to validate the pluripotency of the cell line.
We have performed the PluriTest with two iPSC lines and differentiated iPSC line to
definitive endoderm (DE), which is the first step of hepatocyte differentiation (Figure
4.2). As the other performed assays this tool confirms the pluripotency of the iPSC
lines and declares the DE sample as not-pluripotent as it should. To conclude, for basic
characterization it is no longer necessary to perform a teratoma assay. In the future our
laboratory will pass on teratoma assay to verify pluripotency.
The episomal reprogramming approach holds a high aneuploidy rate of 11.5 % and
ranks on the second position when compared to other reprogramming methods. Only
retroviral reprogramming approach holds a higher aneuploidy rate of 13.5 % (Schlaeger
et al. [2015]). The HFF1-derived E-iPSC line we used for this study contains addi-
tional material on Chromosom 12 at the short arm 12p. This is a hot spot of gain.
The hallmark pluripotency genes NANOG and GDF3 are located there and are over
expressed (NANOG 3.32-fold and GDF3 1.29-fold) compared to hESCs as demonstrated
by quantitative real-time PCR (qRT-PCR) and transcriptome analysis (Figure 2.5; 2.6
and 3.3). This aberration does not exist in the somatic cells (HFF1). Presumably, this
is a result of the selective force during the reprogramming procedure and culture adap-
tion (Mayshar et al. [2010]; Prigione et al. [2010]). In this sector the reprogramming
of HUVECs also performed better. The HUVEC-derived E-iPSC line holds a normal
karyotype as the original cell line and expresses pluripotency-associated genes as hESCs




Comparable analysis of pluripotency in new human iPSC lines and one differentiated iPSC line to
definitive endoderm (DE).A) Novelty Score. Green colored samples are pluripotent. The orange colored
sample HFF1-iPSC-DE is not-pluripotent, it is more dissimilar to the pluripotent samples in the model
matrix than the other pluripotent samples. B) Hierarchical Clustering. The pluripotent samples HFF1-
iPSC-1 and HFF1-iPSC-2 cluster together. HFF1-iPSC-DE differs from the pluripotent samples and do
not cluster with them (Mller et al. [2011], http://www.scopus.com/inward/record.url?eid=2-s2.
0-79953267538&partnerID=40&md5=7108a16c223225f3d2443f06cbba4ace, retrieved 08.04.2015).
In order to analyze the difference and commonalities between the iPSCs and compared
to hESCs microarray-based analyses of the transcriptome profiles were performed. The
transcriptome profile of the HUVEC-iPSC line is similar to that of hESCs and the
HFF1-iPSC line. The transcriptome profile differences between the HUVEC-iPSC line
and HFF1-iPSC line are minimal (Figure 3.15).
In general, the derivation of integration free iPSCs from somatic cells and differen-
tiating them into a donor cell type of interest are promising approaches for (i) future
application in tissue replacement therapies, (ii) generation of disease models in vitro,
(iii) toxicology and drug screening.
However, episomal-based reprogramming will never become the ”golden standard” of
reprogramming. For that the reprogramming efficiency is too low and an element of
risk remains that foreign particles could integrate into the host genome (Schlaeger et al.
[2015]). The future belongs to methods which using human mRNA or small molecules for
reprogramming somatic cells. The main advantage to other methods is that they avoid
using foreign particles which could potentially integrate into the host genome and pro-
voke gene mutation. These methods will be used for clinical approaches (Bernal [2013];
Yoshioka et al. [2013]). Reprogramming of human somatic cells with small molecules
has not been developed yet, but it is merely a matter of time. Over the past years, the
method using mRNA to reprogram human somatic cells has further developed. More
and more companies sale mRNA-based reprogramming kits (e.g. Miltenyi Biotec, ams-
bio, Lonza, Stemgent, Mandal and Rossi [2013]). In the early stages it was necessary to
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conduct the RNA transfection 10 times. Though, it seemed that this protocol was not
reproducible. Among other laboratories ours was not able to reproduce this protocol.
One explanation could be that the cytotoxicity of mRNA transfected cells is very high by
trigger a strong innate immune reaction. Due to that after ten transfections almost all
cells were dead. Today, the number of mRNA days has not decreased rather increased.
However, the mRNA was modified so that the RNA do not trigger an immune reaction
(Warren et al. [2010], Drews et al. [2012], Tavernier et al. [2012], Mandal and Rossi
[2013]). Due to the fact that more and more mRNA-based iPSC lines were published
and companies offer mRNA reprogramming kits it seems to be reproducable. The fu-
ture step in our laboratory will be to establish a competitive mRNA-based method for
reprogramming human somatic cells and further analyze the power of small molecules
to reprogram human somatic cells on their own.
4.2 Generation of Hepatocyte-like cells from E-iPSCs
Hepatogenesis is best understood in mice and rats (Houssaint [1980]; Medlock and Haar
[1983]; Cascio and Zaret [1991]; Watt et al. [2001]; Tremblay and Zaret [2005]; Zhao and
Duncan [2005]; Watt et al. [2007]). The liver is able to regenerate itself in vivo. However,
in vitro the cells lose this ability and several experiments were conducted to activate the
ability for regeneration in vitro. It is not possible to culture human hepatocytes in
vitro highlighting the liver as a complex structure (Mitaka [1998]; Runge et al. [2000];
Mizuguchi et al. [2001]; Zhao and Duncan [2005]; Shan et al. [2013]; Chapter 1).
One million patients die each year from acute and chronic liver diseases worldwide.
The orthotopic liver transplantation (OLT) is still the only effective cure for end-stage
liver patients and many genetic disorders (Girometti et al. [2014]; Chapter 1).
This gives an impression how important the research of alternatives is. The deriva-
tion of integration free iPSCs from somatic cells and differentiating them into liver cells
is a promising approach for (i) future application in tissue replacement therapies, (ii)
generation of disease models in vitro, (iii) toxicology and drug screening.
In the past, our lab differentiated hESCs and viral reprogrammed iPSC lines to
hepatocyte-like cells (HLCs) (Jozefczuk et al. [2011]; Jozefczuk et al. [2012b]). In this
study viral- and integration-free episomal-based iPSCs (E-iPSCs) from human neonatal
foreskin fibroblast (HFF1) cells and human umbilical vein endothelial cells (HUVECs)
could differentiate to HLCs (Chapter 3.2). The differentiation procedure consist of three
stages (Figure 3.16 and 3.28). First, the undifferentiated cells were differentiated to the
defnitive endoderm (DE), second, to the hepatic endoderm (HE) stage and third, to
hepatocyte-like cells. Continued changes of the morphology from undifferentiated stage
to HLCs were observed as discribed by Jozefczuk et al. [2011]. Immunofluorescence-
based protein stainings and qRT-PCRs confirmed the stages of differentiation from each
step. All in all both lines differentiate similar (Figure 3.17 - 3.19 and 3.29 - 3.31). Both
stored glycogen and showed the uptake and release of ICG and CDFDA (Figure 3.22
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and 3.33). They secrete bile acid and urea in a similar level (Figure 4.3). Both cell lines
are able to differentiate into HLCs. They can be used for drug screenings and toxicology
studies.
Figure 4.3: Measurement of secretion levels in HLCs.
A) Analysis of bile acid production in epiHUV-3a-HLC and epiHFF1-B1-HLC. The levels of bile acids
are presented in pmol/ml/24h. B) Analysis of urea production in epiHUV-3a-HLC and epiHFF1-B1-
HLC during differentiation from definitive endoderm (DE), hepatic endoderm (HE) and hepatocyte-like
cells (HLCs). Three biological replicates in technical triplicates of each sample were analyzed. The levels
of urea was measured in mg/dl/24h.
In order to analyze the difference and commonalities between the generated HLCs and
compared to the transcriptome profile of fetal liver and PHH microarray-based anaylses
were performed. The transcriptome profiles of both iPSC-derived HLC lines are com-
parable. Most liver-related genes are expressed in both samples. The expression of
endoderm progenitor-related genes indicates that these HLCs are immature. The com-
parative transcriptome profile analysis to fetal liver and PHH confirmed the indication
of immaturity of the HLCs (Figure 3.40).
However, the used protocol has to be optimized to generate mature HLCs. In order to
achieve the maturation small molecules treatment could be used or 3D culture systems
could be the right direction. There are a lot of 3D cell culture systems based on an
external scaffold, which can allow the formation of 3D structures in hepatocyte cultures.
Another approach is the liver bud formation without any scaffold (Godoy et al. [2013],
Shan et al. [2013], Takebe et al. [2014]). The idea of liver bud formation is that mimic
functional liver in vitro due to the fact that a liver in vivo do not only consists of
hepatocytes. Hepatocytes are arranged in so called hepatic plates separated by sinusoid
spaces. These hepatic plates are arranged star-like around a central vein. The bile
canaliculi on the surface of adjoining hepatocytes drain bile into the bile ducts, which
run parallel to portal veins and hepatic arteries to form the ”portal triad” (Shiojiri
[1984]; Duncan [2000]; Lemaigre [2003]; Malarkey et al. [2005]; Godoy et al. [2013]). The
formation of a 3D liver bud depends on the interaction of signals between endodermal
epithelial, mesenchymal and endothelial progenitors. For that Takebe et al. [2014] used
112
Chapter 4. Discussion
HUVECs as the endodermal epithelial, MSCs as mesenchymal epithelial and iPSC-
derived hepatic endoderm (HE) cells. We tried to reproduce this publication but without
success (data not shown). There seem to be too many stumbling blocks at the moment.
In the future we want to focus on the use of small molecules. Shan et al. [2013] published
a small molecule which activates the proliferation and one which induces the maturation
of hepatocytes. Additionally, an experiment done by a colleague indicates that definitive
endoderm (DE), the first step of HLC differentiation, can be achieved by the use of one
small molecule. This year Siller et al. [2015] published the successful differentiation
of iPSCs into HLCs by the use of small molecules. However, at this stage the HLCs
are comparable with cytokine-derived HLCs. That means they are immature as any
other generated HLC line. Using this protocol and further using the small molecules
published by Shan et al. [2013] could generate more mature HLCs comparable with PHH.
All together hold great promise that it will be possible to generate mature hepatocytes.
Another way to generate HLCs is the direct use of fibroblasts and manipulate them by
transfection with lentiviruses or synthetic modified RNA (Huang et al. [2014], Simeonov
and Uppal [2014]). The direct generation of HLCs from fibroblasts is much faster, low-
priced and more directed compared to the common procedure of iPSC derivation from
fibroblasts and then differentiate them into HLCs. It should be possible to find the right
cocktail of small molecules to derive directly HLCs from somatic cells. We want to focus
on this issue in the future.
HFF1-iPSC-derived HLCs were used to analyze the human hepatogenesis in details
and untangle human hepatogenesis-associated gene regulatory networks (Chapter 3.2.1).
We demonstrated the potential of using E-iPSCs as in vitro models for studying liver cell
fate decision making (Figure 3.23 - 3.27). One of the important pathway for hepatogene-
sis is the Hippo-signaling pathway which influences liver cell fate and size. Additionally,
the Hippo pathway is responsible for maturation and stabilization of the tight junctions
in hepatocytes. This pathway is over represented in HLCs, fetal liver and PHH. The
existence of tight junctions in E-iPSC-derived HLCs is shown by electron microscopy.
ABC transporters are also over represented in HLCs, fetal liver and PHH. These are
accountable for the uptake and efflux of e.g. bile acids. A measurement assay for bile
acid secretion shows that the HLCs excrete primary bile acids. Primary bile acids are
involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. Hep-
atocytes synthesize primary bile acids which then carried out by the gut microbiota
convert to secondary bile acids by several reactions including dehydroxylation, dehy-
drogenation and epimerization (Camargo et al. [2007], Varelas et al. [2010], Hofmann
and Hagey [2014], Lamba et al. [2014], Yimlamai et al. [2014]). A heatmap of bile acid
related transporter genes underlines the functionality of the HLCs and shows the highest
expression of NTCP, MRP2, ASBT and MDR2/3 in the HLC samples (Figure 3.25G).
The heatmap presented in Figure 3.27B implies that the HLCs also harbor cell pop-
ulations with bipotential properties similar to hepatoblasts. It is shown differential
expression of key cell fate regulating genes specific to the hepatic endoderm and in some
cases also in the HLCs. For example, the hepatic endoderm cells (HE) express exclu-
sively DLK2 and a set of transcription factors specific to this stage (Onecut1/HNF-6 ).
These set of transcription factors are putative candidates for directing biliary epithe-
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lial cells/cholangiocytes cell fate. However, HLCs express DLK1 and progenitor-related
genes such as PROX1 and LGR5 which are not expressed in HEs. Though, in both
stages are expressed genes such as WNT3A, NOTCH3, HNF1A, HNF1B and SOX9.
Our overall findings based on gene expression patterns supports the perception that
HE and HLCs in our hepatocyte differentiation protocol are equivalent to the DLK,
HNF6 and SOX9-positive bipotential hepatoblasts present in fetal liver and are com-
mon progenitors for hepatocytes and biliary epithelial cells/cholangiocytes. The Notch
signaling, hepatocyte nuclear factor-6 (HNF-6) and PROX1 are factors known to regu-
late lineage commitment in the bipotential hepatoblast progenitor cell population (Clot-
man et al. [2002], Tanimizu et al. [2003], Dudas et al. [2004], Vanderpool et al. [2012]).
This implicates that it should be possible to change the fate of HE cells by manipu-
lating the expression levels of e.g. PROX1, SOX9, and HNF6 or even by using small
molecules targeting for instance Notch signaling. Odom et al. [2006] used human hep-
atocytes from donors and compared these with healthy hepatocytes. They described
a core transcriptional regulatory circle in human hepatocytes consisting of six tran-
scription factors (ONECUT1/HNF-6, FOXA2, HNF1A, HNF4A, CREB1 and USF1).
These transcription factors bound promoters that are central for liver development and
function (Odom et al. [2006]). Our study shows the expression of the transcription fac-
tors ONECUT1/HNF-6, FOXA2, HNF1A and HNF4A in human E-iPSC-derived HLCs.
Furthermore, we have demonstrated that transcription factors HNF1A and HNF4A are
involved in orchestrating cell fate decision of bipotential hepatoblast cells to become
either hepatocytes or biliary epithelial cells/cholangiocytes (Figure 3.27C).
The generation of a transcription factor network via the oPOSSUM data base un-
covered transcription factors which are involved in cell fate decisions during hepato-
genesis (Figure 3.27C, Supplementary Table S9). MYC regulates numerous biological
processes such as glycolysis, cell proliferation and differentiation and is the most promi-
nent transcription factor in our network. It also regulates the expression of bipotential
hepatoblast-related genes (e.g. DLK1, PROX1 ), cholangicyte-related genes (e.g. ONE-
CUT1, WNT3A and SALL4 ) as well as hepatocyte-related genes (e.g. HNF1A). The
second prominent transcription factor is HNF4A which is a central regulator of hepato-
cyte differentiation and function. HNF4A regulates hepatocyte-related genes (e.g. ALB,
AFP), cholangiocyte-related genes (e.g. ONECUT1, SALL4 ) as well as the hepatoblast-
related gene PROX1 (Watt et al. [2003], Hay et al. [2008b], Cai et al. [2013], Dianat
et al. [2014], Seth et al. [2014], Qu et al. [2014]). This transcription network underlines
the bipotential progenitor-related characteristics of the HE and HLC stage in our differ-
entiation procedure. This implies that there are bipotential progenitors within HE and
HLC cell populations.
In summary, K-means clustering identified 100 clusters including developmental stage-
specific groups of genes, e.g. OCT4 expression at undifferentiated stage, SOX17 marking
the DE stage, DLK and HNF6 the HE stage, HNF4A and Albumin is specific to HLCs,
fetal liver and adult liver (PHH) stage gain an insight into hepatogenesis. Gene regula-
tory networks generated by oPOSSUM data base uncovered the presence of bipotential
progenitor populations in both stages in HE and HLC. This analysis should lay the
foundation for future efforts to generate long-term cultivable cholangiocytes and HLCs.
114
Chapter 4. Discussion
4.3 Generation of endodermal progenitors
The detection of progenitor cells uncovers information about the developmental process
of somatic cells and organs. Especially, the liver has a unique regenerative capacities.
After injury the proliferation becomes activated and the liver is able to regenerate.
Remarkably, the liver is able to regenerate itself in vivo. If up to two thirds are removed,
the cells start to proliferate immediately and the lost cell mass will be replaced. In vitro
the cells lose this ability and serveral experiments were conducted to activate the ability
for regeneration in vitro (Mitaka [1998]; Runge et al. [2000]; Mizuguchi et al. [2001];
Zhao and Duncan [2005]; Shan et al. [2013]; Chapter 1). This mechanism highlights
the role of adult liver stem cells. In recent years, stem and progenitor cells in liver
development and their cellular niche were identified. However, most studies concentrate
on the biliary tree and hepatoblast which can give rise to hepatocytes, cholangiocytes
and pancreatic cells (Cardinale et al. [2011], Carpino et al. [2012], Goldman et al. [2013],
Nissim et al. [2014]).
Using the protocol described by Cheng et al. [2012] in this study multipotent en-
dodermal progenitors (EPs) were derived (Chapter 3.3). Whose capability are more
comprehensive than that of cells from hepatoblast or biliary tree. The protocol de-
scribes three steps to generate EPs. Pluripotent stem cells are differentiate in 5 days to
definitive endoderm (DE), than to transient cells (TC) which takes 4 weeks and further
to EPs within one passage. In this study the E-iPSC line epiHFF1-iPS-B1 was used.
The protocol was slightly modified and separated into four steps (Figure 3.41). The first
step, differentiate E-iPSC to DE was the same as described for HLC differentiation and
EP derivation. The second step, differentiating DE to TC was done in 4 weeks as de-
scribed by Cheng et al. [2012] and was shortened to 2 and 3 weeks, too. The first passage
in EP maintenance medium is called here pre-EP stage. When organoids were formed
the fourth stage, the EP, was accomplished. All versions resulted in organoids. These
organoids are multipotent progenitors due to the fact that they express lineage-specific
markers at the same time point detected by qRT-PCR and immunoflurorescence-based




Summary of EP generation derived from epiHFF1-iPS-B1.
A multipotent endodermal progenitor (EP) cell line was generated and characterized. The cells express
at the same time LGR5 and ALCAM, liver-specific (ALB) and pancreas-specific (PDX1) marker, as
well as intestine-specific marker (CDX2). DAPI stained the nucleus. Scale bar: 200 µm, Alexa Flour
594 (red), Alexa Flour 488 (green).
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EPs express transcription factors related to early liver (TBX3 ), pancreas (ISL1,
RFX6 ), lung (FOXP2 ) and specific protein marker for liver (ALB), pancreas (PDX1 ),
intestine marker (CDX2 ), intestine- and lung (SOX2 ) as well as primitive streak-/
endoderm-specific genes such as CER1, MIXL1, EOMES, FOXA2, HNF4α, GATA6.
Definitive endoderm and primitive streak related genes were expressed most in DE and
pre-EP samples. Transcription factors related to early liver (TBX3 ), pancreas (ISL1,
RFX6 ), lung (FOXP2 ) as well as ID2 and MEIS2 were overexpressed in EP. The heat
map of progenitor related genes identified the EP as a panendoderm progenitor. A qRT-
PCR uncovered primitive streak associated genes, such as CER1, MIXL1 and EOMES,
were exclusively expressed at the definitive endoderm (DE) stage. However DE specific
genes, e.g. GATA6 and FOXA2 were also expressed in the transient cells (TC) and
pre-endodermal progenitor cells (pre-EP). Lineage specific genes such as GATA6 (DE),
TBX3 (early liver), ALB (mature liver), CDX2 (pancreas) as well as LGR5 (self-renew)
are most expressed in the endoderm progenitor (EP). Immunofluorescence-based protein
detection revealed that EPs express ALB as a marker for liver, PDX1 (Pancreas) and
CDX2 (intestinal). Additionally, they express SOX2, which is also a marker for neuronal
progenitors, and the self-renew marker LGR5 as well as the progenitor marker CD133
(Cheng et al. [2012]; Hannan et al. [2013]; Amador-Arjona et al. [2015]; Niu et al. [2015]).
This indicate that these progenitors could be able to differentiate into neurons or other
cell types.
The transcriptome profile analyses could not confirm all of results of immunofluo-
rescence-based protein detection and qRT-PCR analysis due to the fact that the sam-
ples of defined EPs have not hybridized correctly. At the moment we are waiting for the
results of the re-hybridized EP probes. Then the transcriptome profile of the defined
EPs as well as the developmental stages of EP generation as to be analyzed in detail.
Studies are planned involving the use of the E-iPSCs derived endodermal progeni-
tors to generate hepatocyte-like cells and pancreatic-like cells. These studies will en-
able uncovering the genes and associated pathways that specify a bipotential endo-
dermal progenitor to differentiate to either liver or pancreas. In order to investigate
whether or not the EPs will shift their identity when cultured in hepatocyte mainte-
nance medium the EPs were cultured in hepatocyte maintenance medium for 4 pas-
sages. Immunofluorescence-based protein staining was done to detect LGR5, PDX1,
ALB, CDX2 (Figure 4.5). The expression of CDX2 and PDX1 was decreased. However,
LGR5 and ALB expression has not changed. This is a first indicator for the ability of
EP differentiation. The next steps will be to culture the EPs in pancreas and hepatocyte
maintenance medium in parallel. To identify and analyze the changes of the expression
pattern qRT-PCR and transcriptome analysis will be performed. Furthermore, it should




Figure 4.5: Immunofluorescence-based detection of proteins in EP cultured in hepatocyte
medium.
Endodermal progenitor (EP) colonies were cultured in a comercial hepatocyte maintenance medium for
18 days. The detection of the protein LGR5 (self-renewal marker), PDX1 (pancreas marker), ALBUMIN
(liver marker), CDX2 (hindgut marker). DAPI stained the nucleus. Scale bar: 200 µm, Alexa Flour
594 (red), Alexa Flour 488 (green).
4.4 Mouse embryonic fibroblasts replaced by human
fetal mesenchymal stem cells
Today, it is still a common method to use mouse embryonic fibroblasts (MEFs) and/or
MEF conditioned medium (MEF-CM) to culture human embryonic stem cells (hESCs)
and induced pluriotent stem cells (iPSCs) (Jozefczuk et al. [2012a]; Kim et al. [2015];
Matz et al. [2015] under review; McKee et al. [2015]). To avoid overspending and killing
of mice this study analyzed the use of human fetal femur mesenchymal stem cells (fMSCs)
as an alternative for MEFs (Chapter 3.4). All cell lines (hESC and iPSC) which were
cultured on fMSC or in fMSC-CM maintained their pluripotent stage comparable to
these cultured with MEFs or MEF-CM. Additionally, they were all able to differentiate




The use of human fMSCs has a higher potential then only utilized for hESC and iPSC
cultivation. In order to detect whether or not other cytokines are secreted by fMSCs
a cytokine array was conducted by a colleague. Amongst others fMSCs secrete FGF2,
FGF19, VEGF, PDGF-AA and IL-11, which are involved in proliferation processes (Wu
et al. [2010]; Greber et al. [2007]; Cheng et al. [2012]; Lin et al. [2012]; Peterson et al.
[2013]; Yu et al. [2013]; Chen et al. [2015]; Kiso et al. [2015]; Nguyen et al. [2015]).
Fibroblast growth factor 2 (FGF2) modulates the activity of TGFβ superfamily members
and is one of the most critical factors for EP cell maintenance (Greber et al. [2007]; Cheng
et al. [2012]; Kiso et al. [2015]). FGF19 activates liver FGF receptor 4 (FGFR4) which
is the signal for enterohepatic regulation of bile acid metabolism and the activation of
liver FGFR4 is responsible for the enhanced hepatocyte proliferation (Wu et al. [2010]).
The vascular endothelial growth factor (VEGF) is involved in activation of hepatocytes
proliferation during liver regeneration, is important for endodermal progenitor (EP)
proliferation and maintenance. Additionally, VEGF is an important target gene of the
transcription factor hypoxia-inducible factor 1 (HIF1α/HIF1β) (Cheng et al. [2012]; Lin
et al. [2012]; Yu et al. [2013]). Platelet-derived growth factor-AA (PDGF-AA) together
with FGF2 have an synergistic effect on cell proliferation in vitro (Kiso et al. [2015]).
Interleukin 11 (IL-11) is involved in intestinal proliferation and maintenance of intestinal
homeostasis (Peterson et al. [2013]; Nguyen et al. [2015]). The secretion of FGF2, FGF19
and VEGF leads to the assumption that fMSCs could support the differentiation of iPSCs
to HLCs and further give rise to HLC maturation. Additionally, the fMSCs provide the
maintenance and proliferation of EPs. With a medium change fMSC secreted factors as
IL-11 could differentiate the EPs into intestinal cells and maintain them.
Furthermore, it seems that the fMSCs are stay in a self-renew stage because they is
an indication that they do not pass on to senescence. It is not confirmed yet, we have
to perform a senescence and other test for that. The fMSCs are the perfect alternative
to MEFs as well as to other human fibroblasts like HFF cells, if it is true that the
fMSC are an infinite source. Once you have them you can expand them as often as you
like. However, it is already published that the proliferation rate of fMSCs is enhanced
and, in addition, fMSCs display significantly lower doubling times in comparison with
adult-derived cells. In contrast to MEFs or other human fibroblasts such as HFF1 cells,
fMSCs can be expanded for longer periods. In addition, fMSCs are fully characterized as
mesenchymal stem cells and are already advocated for application in clinical approaches
(Mirmalek-Sani et al. [2006]). These attributes endow fMSCs as a perfect alternative to
MEFs routine and long-term propagation of pluripotent cells.
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When this study started using episomal vector-based method to generate integration-
free induced pluripotent stem cells (iPSCs) took the research of clinical approaches a
step forward. However, it will never become the gold standard of reprogramming. First,
the reprogramming efficiency is too low and second, the risk remains that foreign par-
ticles could integrate into the host genome. The future belongs to mRNA and small
molecules-based techniques. For this study we decided to use an episomal-based ap-
proach because we were still in trying to overcome the roadblocks to reprogram human
fibroblasts into iPSCs with mRNAs by then. We compared the episomal-derived iPSCs
(E-iPSCs) with viral-derived iPSCs (V-iPSCs) from the same genetic background, both
were derived from human neonatal foreskin fibroblasts (HFF1). The transcriptome pro-
file of E-iPSCs is more similar to that of human embryonic stem cells (hESCs) than that
of V-iPSCs. Furthermore, the E-iPSCs generated from human umbilical vein endothe-
lial cells (HUVECs) was faster than that of HFF1-derived E-iPSCs. Additionally, the
efficiency was higher and the transcriptome profile of HUVEC-iPSCs was more similar
to that of hESCs than the transcriptome profile of HFF1-iPSCs. This discloses that
not only the method of reprogramming is important furthermore the somatic cell line is
crucial, too.
In the context of analyzing hepatogenesis and maturation of hepatocytes the E-iPSC
differentiation to hepatocyte-like cells (HLCs) was demonstrated. E-iPSCs from both
genetic background, HFF1 and HUVEC, could be differentiated to HLCs. Both showed
morphology and functional characteristics of human hepatocytes. We uncovered gene
regulatory networks by analyzing the transcriptome profile of HFF1-iPSC-derived defini-
tive endoderm (DE), hepatic endoderm (HE) and HLCs. Additionally, the presence of
bipotential progenitor populations were uncovered in both stages in HE and HLC. Af-
terwards, a transcriptome profile analysis was performed of both HLC lines, derived
from HFF1-iPSCs and HUVEC-iPSCs. Supplementary, these transcriptome profiles
were compared to that of fetal liver and PHH and revealed that the iPSC-derived HLCs
are immature as well as more similar to fetal liver. Furthermore, to analyze the matu-
ration potential of HLCs a long-term culture experiment was performed using HUVEC-
iPSC-derived HLCs. This experiment implied the possibility for long-term culture of
HLCs while increasing maturation. Therefore, one future goal will be to increase and
push on the maturation while maintain the typical functional characteristics of hepato-
cyte, e.g. glycogen storage, uptake and release of ICG and CDFDA, bile acid and urea
secretion. Then they can serve as an improved source for drug screenings and toxicology
studies. In order to reach this aim co-culture with bone marrow fetal femur mesenchy-
mal stem cells (fMSC) could help to give rise to further maturation of the HLCs. They
secrete growth factors which are involved in proliferation and maintenance of hepato-
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cytes. Furthermore, small molecules could support the maturation and proliferation.
The fMSC and small molecules will be used in the next study.
Going a step back in the development, the endodermal progenitors (EP) generated
in this study hold a great potential to analyze the endodermal development far before
the biliary tree up to liver, bile duct and gallbladder, as well as pancreas, intestine and
lung development. This multipotent progenitors express lineage-specific markers of all
these named cell types at the same time point. Here as well could help the co-culture
with fMSCs due to the fact that they express growth factors support the proliferation
and maintenance of EPs. Additionally, they secrete amongst others factors which are
involved e.g. in differentiation of EPs into intestinal cells and maintain them. To em-
phasize the capabilities: fMSCs are versatile. They support the pluripotent maintenance
of hESCs and iPSC, could activate the proliferation of hepatocytes and EPs while main-
tanance them. In addition, fMSC secrete factors which are involved in differentiation
processes. In future studies the use of fMSCs will be increase.
The overall aim is to develop liver disease models in vitro and derive a whole liver
from patient specific cells in vitro. 2013, two promising methods were published which
will bring the research in disease modeling in vitro a huge step forward. One is called
transcription activator-like effector nuclease (TALEN) and the other clustered regularly
interspaced short palindromic repeat (CRISPR) and CRISPR associated 9 (Cas9) en-
donuclease systems (CRISPR/Cas9). They can work as a tool for reporter knockin, gene
knockout and gene correction. Healthy iPSC lines can be manipulated with these tools
to generate specific disease models in vitro or the other way around the correction of
mutation in patient-derived iPSCs can be conducted. The efficiency of genome modifi-
cation of both methods is very high and accurate (Hockemeyer et al. [2011], Choi et al.
[2013], Ma et al. [2013a], Mali et al. [2013], Osborn et al. [2013], Maetzel et al. [2014],
Ye et al. [2014], Sato et al. [2015]). A future step in our laboratory will be to use the
CRISPR/Cas9 method to derive a liver disease model from human iPSCs.
One million patient die each year from acute and chronic liver diseases worldwide.
While the number of patient who need a liver transplantation increases the number of
organ donors decreases since years. Deriving a whole liver from patient specific cells
in vitro would mean that the gap could be finally closed between needed and available
livers for transplantation. However, before generating a whole liver in vitro the liver as
a whole including its development needs to be understood. With this study more pieces
of this puzzle have been solved.
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6.1 Cell culture
The human embryonic stem cell (hESCs) lines H1 and H9 were bought from WiCell
Research Institute. From ATCC the following cell lines were bought: HFF-1 (HFF-1
(ATCC; SCRC-1041)), HEK-293 (293 [HEK-293] (ATCC; CRL-1573)) as well as HepG2
(Hep G2 [HEPG2] (ATCC; HB-806)). The HUVECs were bought from Life Technologies
(Gibco; C-003-5C). Human fetal femur mesenchymal stem cells (fMSCs) line H1536 was
got from a collaboration partner (Kindly provided by Dr. Emmajayne Kingham and
Prof. Richard Oreffo, University of Southampton, Southampton, United Kingdom). The
cells were obtained after day 55 post conception according to guidelines issued by the
Polkinghome Report and with ethical approval from the Southampton & South West
Hampshire Local Research Ethics Committee.
6.1.1 Culture conditions
Most cell lines were cultured at 37 ◦C and 5 % CO2 in an incubator (INNOVA CO-170
Incubator, New Brunswick Scientific) under humidified atmosphere. HUVECs, HUVEC-
derived iPSCs and endodermal progenitors (EPs) were cultured at 37 ◦C, 5 % CO2
and 5 % O2 in an incubator (INNOVA CO-170 Incubator, New Brunswick Scientific).
All treatments and maintenance procedures were carried out using a clean bench type
HeraSafe (Haereus Instruments).
6.1.2 Maintenance of human pluripotent stem cells
Humen embryonic stem cell (hESC) lines as well as induced pluripotent stem cell (iPSC)
lines were cultured on Matrigel-coated plates with mitotic inactivated mouse embryonic
fibroblast (MEF) cells and a defined medium called unconditioned medium (UM). UM
consist of KnockOut DMEM (Gibco/Life Technologies) supplemented with 20 % Knock-
Out Serum Replacement (Gibco/Life Technologies), 0.1 mM non-essential amino acids
(Invitrogen/Life Technologies), 0.1 mM L-glutamine (Invitrogen/Life Technologies), 0.1
mM -Mercaptoethanol (Sigma-Aldrich), 0.5 % penicillin and streptomycin and 8 ng/ml
basic fibroblast growth factor (bFGF, Invitrogen/Life Technologies) as described by
Wolfrum et al. [2010].
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6.1.3 Maintenance of non-pluripotent cells
Human foreskin fibroblast (HFF1) cells, mouse embryonic fibroblast (MEF) cells, fetal
mesenchymal stem cells (fMSCs), human hepatocellular carcinoma (HepG2) cells, hu-
man embryonic epithelial kidney (HEK-293) cells were maintained in Dulbecco‘s mod-
ified Eagle medium (DMEM, Gibco/Life Technologies) containing 10 % fetal bovine
serum (FBS, Invitrogen/Life Technologies) and 0.5 % penicillin and streptomycin (In-
vitrogen/Life Technologies) as described by Wolfrum et al. [2010].
Human umbilical vein endothelial cells (HUVECs) were cultured in Medium 200 (Gibco/
Life Technologies) with 2 % Low Serum Growth Supplement (LSGS; Gibco/Life Tech-
nologies).
Endodermal progenitors (EP) were cultured in Iscove’s Modified Dulbecco’s Medium
(IMDM; Gibco/Life Technologies) with 25 % Ham’s F-12 (Cellgro), 0.5 % N2-Supplement
100x (Gibco/Life Technologies), 1 % B-27 Supplement Minus Vitamin A 50x (Gibco/Life
Technologies), 0.1 % Bovine Serum Albumin (BSA; Sigma-Aldrich), 50 µg/ml ascorbic
phosphate magnesium (Sigma-Aldrich), 0.45 mM Monothioglycerol (Sigma-Aldrich), 50
ng/ml Recombinant Human BMP-4 (BMP-4, R&D), 10 ng/ml Recombinant Human
VEGF 165 (VEGF, R&D), 10 ng/ml Recombinant Human EGF, CF (EGF, R&D), 10
ng/ml basic fibroblast growth factor (bFGF, Invitrogen/Life Technologies), 0.5 % peni-
cillin and streptomycin.
6.1.4 Mouse Embryonic Fibroblasts Culture
To maintain the undifferentiated state of human embryonic stem cells they are grown
on a layer of mitotic inactivated mouse embryonic fibroblasts (MEFs) or on a feeder-free
Matrigel-coated plate with conditioned medium (CM).
Isolation of Mouse Embryonic Fibroblasts
A pregnant female mouse (CF-1, Harlan, USA) was sacrified at 13 or 14 days post-
cointum (d.p.c.) through cervical dislocation. After the uterine horns were separated
out they were rinsed briefly in 70 % (v/v) ethanol and placed into a falcon with PBS
(without Ca2+ and Mg2+, Gibco/Life Technologies). Then they were put into a petri-
dish where each embryo was cut from the placenta and embryonic sac. The head and
red organs (liver, heart, and gut) were dissected and discarded, the carcase was washed
in PBS and placed in a clean petri-dish. The tissue was minced with a sterile razor
blade until it become pipettable. One ml of 0.05 % trypsine/EDTA and DNase I (USB,
100 Kunitz units per ml of trypsine) was added per embryo. Afterwards the tissue was
transferred into 50ml falcon tubes and incubated for 15 min at 37 ◦C. Every 5 min the
cells were dissociated by pipetting up and down. By adding approx 1x volume of freshly
prepared MEF medium the trypsine was inactivated. Remaining pieces of tissue were
trashed. The supernatant were centrifuged by low-speed, the cell pellet was resuspened
in pre-warm MEF medium. Three or four embryos were plated in each T150 flask, which
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were coated with 0.2 % gelatine, for two hours. Only the passage 0 (P0) fibroblasts have
the ability to attach onto gelatine-coated flask. On the next day the cells were 80 - 90
% confluent. The major part of the P0 was frozen for future use. The rest of the T150
flask of P0 cells was expanded until passage three or four, inactivated and then used
as feeders for culturing human embryonic stem cells or to produce conditioned medium
(CM).
Freezing and Thawing Cells
MEFs or HFF1 cells were washed with PBS (amount according to the size of the culture
dish). The cells were trypsinised, centrifuged at 1,000 rpm for 5 min at RT and the pellet
was resuspended in freezing medium (MEF medium with 10 % DMSO). Then the cells
were aliquoted into cryovials, put in a freezing container (Nalgene) and placed at -80 ◦C
overnight. On the next day the vials were transferred to liquid nitrogen for long-term
storage.
The cells were stored in liquid nitrogen. They were removed, quickly defrosted in a 37
◦C water bath, the vial was sterilized by using 70 % ethanol, opened below the clean
bench and the cells were transferred into 10 ml pre-warmed medium in a 15 ml centrifuge
tube. After 5 min of centrifugation by 1,000 rpm at room temperature the cell pellet
was resuspended in fresh pre-warmed medium.
Inactivating and Plating of MEF
T150 flasks were coated with 0.2 % gelatine and incubated at room temperature for two
hours. During the incubation mitomycin C was diluted in PBS (1 mg/ml) and sterilized
by filtration. Thawed or fresh made mouse embryonic fibroblasts (MEF) were washed
with PBS (without Ca2+ and Mg2+, Gibco/Life Technologies). 20 ml of MEF medium
has contained 10 µg/ml of mitomycin C (Sigma-Aldrich; M4287-2MG) and were placed
on the MEFs. The MEFs were incubated two hours at 37 ◦C. Then the medium was
removed and the cells were washed twice with PBS. After the cells were trypsinised and
centrifuged they were resuspended in pre-warmed medium. The cells were counted and
plated in a concentration of 5.6 x 104 cells/cm2 in T150 flasks. The MEFs were used for
conditioned medium (CM) production for the next seven days.
Preparation of Conditioned Medium
One day after plating inactivated MEFs with a concentration of 56,000 cells/cm2 in
a T150 flask the MEF medium was exchanged with 0.5 ml/cm2 human ES medium
(unconditioned medium, UM) fresh supplemented with 4 ng/ml of FGF2. The T150
flask was incubated by 37 ◦C. 24 hours later arose CM was collected from the T150 flask
and fresh UM containing 4 ng/ml of FGF2 was added to the feeders. This procedure
was repeated the next six days. The collected CM of each day was placed at -20 ◦C.
The CM of seven days was combined and sterilized through filtration. 50 ml aliquots
were made and stored at -80 ◦C. To use the CM it was thaw and supplemented with 8
ng/ml of FGF2 (Peprotech) before adding to cells which are grown on Matrigel.
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6.1.5 Human ESCs and iPSCs Culture
To maintain the undifferentiated state of human embryonic stem cells they are grown
on a layer of mitotic inactivated mouse embryonic fibroblasts (MEFs) or on a feeder-free
Matrigel-coated plate. If human ebryonic stem cells (hESCs) or human induced pluripo-
tent stem cells (iPSCs) were cultured feeder-free on a Matrigel-coated plates the cells
were fed every day with CM (supplemented freshly with FGF2 to a final concentration
of 8 ng/ml) for each well of a 6-well plate. If the hESCs or iPSCs were cultured on
feeders they were fed every day with unconditioned medium (UM) supplemented freshly
with FGF2 to a final concentration of 8 ng/ml.
Passage of human ESCs and iPSCs
First the Matrigel-coated plates were prepared to plate cells after splitting. Matrigel
were diluted in KO-DMEM to a final concentration of 5 mg/ml. Matrigel were storaged
at -20 ◦C. One day before using Matrigel were diluted in cold KO-DMEM 1:30 and were
plated. The plates were storaged over night at 4 ◦C. Before using the plates, they were
warmed up at 37 ◦C. Second step the feeders were removed from liquid nitrogen, quickly
defrosted in a 37 ◦C water bath, the vial was sterilized by using 70 % ethanol, opened
below the clean bench and the cells were transferred into 10 ml pre-warmed UM in a
15 ml centrifuge tube. After 5 min of centrifugation at 1,000 rpm at room temperature
the cell pellet was resuspended in fresh pre-warmed medium (supplemented with FGF2)
and counted. The Matrigel solution was removed from the plates and 250,000 cells were
seeded into each well of a six-well-plate and kept at 37 ◦C. Afterwards the hESCs or
iPSCs colonies were cut manually into small pieces with a Microlance injection needle
(Becton Dickinson, Madrid, Spain). The cells were gently removed with a cell scraper.
The cell clumps were transferred to a 15 ml falcon tube. After centrifugation medium
(supplemented with FGF2) was added to the cell pellet. The hESCs or iPSCs were seeded
in an optimal split ratio of 1:3 into the wells of Matrigel-coated plate with feeders. The
plates were returned to the incubator and gently shook left to right and back to front
to obtain an even distribution of cells. One or two days after splitting undifferentiated
cells were recognisable as small colonies. During the culturing the cells got large and
compact. Due to the high density of the hESCs or iPSCs in this culture system the cells
were split normally once a week.
Freezing and Thawing of hESCs
The procedure for freezing human ESCs and iPSCs is identical to that for splitting
these cells. This time colonies were manually cut in bigger pieces than for seeding.
The colonies will get a higher chance to survive the procedure of freezing and thawing.
The cells were gently scraped with a cell scraper (Biochrom AG, Berlin), the clumps
were collected, centrifuged and resuspended gently in cold hESCs freezing medium (UM
with 10 % DMSO). Usually cells clumps collected from one well of a 6-well-plate were
suspended in 1 ml of freezing medium and placed into one cryovial. The cells were put
into a freezing container (Nalgene) and placed immediately at -80 ◦C overnight. The
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next day vials were transfer to liquid nitrogen for long-term storage.
A cryovial containing hESCs or iPSCs was removed from the liquid nitrogen storage tank
and thawed by gently swirling in a 37 ◦C water bath until only a small ice pellet remained.
Afterwards 70 % (v/v) ethanol was used to sterilize the cryovial and the vial was allowed
to air dry before opening. Cells were added dropwise, to reduce osmotic shock, into
a 15 ml falcon containing 10 ml of pre-warmed UM. Cells were briefly centrifuged,
resuspended in 2 ml of warm UM and added gently to a prepared plate (MEF plated on
Matrigel and UM). Around 3 - 4 days before thawing the cells, 6-well plate was coated
with Matrigel. One day before splitting 250,000 inactivated MEFs per well of 6-well
plate were seeded. The MEF medium was aspirate, wells were washed with PBS and
then pre-warmed UM supplemented with 8 ng/ml of FGF2 was pipetted on the MEF.
Usually cells from one cryovial are plated into three wells of 6-well plate. However, it
may take even 2 - 3 weeks before cells are ready to be expanded. These culture methods
and conditions were adapted from (Xu et al. [2001]).
6.2 Episomal Reprogramming by means plasmid
nucleofection
Figure 6.1: Episomal vector combination.
The used amount of plasmids for the nucleofection was 3.0 µg of pEP4EO2SEN2K, 3.0 µg of
pEP4EO2SET2K and 2.0 µg of pCEP4-M2L respectively in combination 7F-2. Figure adapted from
Yu et al. [2011].
To generate vector-free iPSCs three oriP/EBNA1 (Epstein-Barr nuclear antigen-1)-based
episomal vectors published by Yu et al. [2011] were used. These vectors expresses the
reprogramming factors OCT4, SOX2, NANOG, KLF4, LIN28, c-MYC and SV40LT. A
nucleofection was done by using a cell-specific Amaxa Cell Line Nucleofector Kit (Lonza)
and one single electroporation was sufficient. 1 x 106 of the cells of interest were used.
The cells were centrifuged and then diluted in 100 µl Nucleofectior Solution which con-
tained the vectors DNA. The used amount of plasmids for one nucleofection was 3.0 µg
of pEP4EO2SEN2K, 3.0 µg of pEP4EO2SET2K and 2.0 µg of pCEP4-M2L as described
by Yu et al. [2011]. The cells were mixed quickly and electroporated. Subsequently, 500
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µl of pre-warmed medium was added to the solution and rested in a water bath at 37
◦C for 10 min. The transfected cells were seeded on a Matrigel-coated 6-well-plate con-
taining the same medium the cells were cultured before the nucleofection. One day after
nucleofection the cells were treated with so called small molecules. A TGFβ inhibitor
(SB431245, Sigma, in a concentration of 2 µM), a MEK inhibitor (PD0325901, Sigma, in
a concentration of 1 µM) and a GSK3β inhibitor (CHIR99021, Sigma, in a concentration
of 0.5 µM) were used. The nucleofected cells were treated with the small molecules for 23
days. 7 days after nucleofection the cells were trypsinized, centrifuged, diluted in condi-
tioned medium (CM) and seeded on a Matrigel-coted and MEF-contained 6-well-plate.
From this day on CM was used and was changed every other day.
Figure 6.2: Scheme of reprogramming HFF1 cells into iPSCs.
Humanl foreskin fibroblast (HFF1) cells were transfected with three different vectors (Figure 6.1). The
reprogrammed HFF1 cells were picked and cultured on feeders. During the course of continous culturing
the iPSCs lose the vectors completely.
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6.3 Characterization of Reprogrammed Cells
Generally, the cells formed colonies, were picked and cultured as single clones. During
culturing the vectors were diluted out and the cells containing no ectopic material any
more (Figure 6.2). In order to show convincingly that these colonies have stem cell
characteristics and can be called induced pluripotent stem cells (iPSCs), a set of analysis
has to be conducted. As human embryonic stem cells (hESCs) human iPSCs have
the ability to self-renew and differentiate in all lineages of the three germ-layers. To
demonstrate these abilities the following analyses were carried out.
6.3.1 Morphology
Two weeks after nucleofection clusters formed and the cell shape differed from the orig-
inal cells. More and more these clusters grew and fromed iPSC-like colonies (Figure
6.2). Pictures as an overview of the development of the cells were taken (4,000 x 3,000
pixel; 180 dpi) through the ocular of the microscope at a 4-fold magnification with a
digital camera. Pictures of stained cells were taken by using a Zeiss, LSM 510 Meta
microscope with a connected camera for microscopy model AxioCam ICC3 controlled
by the software Axiovision 4.6.
6.3.2 Alkaline Phosphatase Staining
hESCs and iPSCs are characterised by the expression of high levels of alkaline phos-
phatase. The staining procedure to visualise alkaline phosphatase was performed using
the Stemgent Alkaline Phosphatase Staining Kit (00-0055, Stemgent). The cells were
washed once with PBS and fixed with the Fix Solution for 2 min at RT. After the fix-
ative was aspirated the cells were washed with PBS. The wash buffer was removed and
the freshly prepared Staining Solution (mixed Staining Solution A with B at the same
amount) was added to cover the cells. The cells were incubated in the dark at RT for 5
to 15 min. To stop the reaction the Staining Solution was aspirated and the cells rinsed
with PBS two times. The stained cells were stored in PBS to keep them moist. Pictures
were taken with a digital camera.
It is also possible to stain live cells with the Alkaline Phosphatase Live Stain from
molecular probes (Life technologies). The cells were washed two times with pre-warmed
DMEM/F-12 for 3 min. The 1x staining solution was made freshly from the 500x stock
solution diluted in DMEM/F-12. The staining solution was added to the adherent cells
and were incubated for 30 min at 37 ◦C. Afterwards the solution was removed and the
adherent cells were washed two times with PBS for 5 min per wash. Fresh DMEM/F12
was added to the adherent cells. The fluorescence were visualized by using a Zeiss LSM
510 Meta confocal microscope with a connected camera for microscopy model AxioCam
ICC3 and the software Axiovision 4.6. A standard FITC filter was used. Subsequently,
DMEM/F-12 was removed and fresh pre-warmed culture medium was added to the cells.
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6.3.3 Immunofluorescence-based Detection of Proteins
To detect protein expression, the cells were fixed with 4 % paraformaldehyde for 20 min
and washed twice with PBS. Afterwards the cells were permeabilised with 0.1 % Triton
X-100 in PBS for 10 min. Next, the cells were blocked with a solution consisting of 10 %
fetal bovine serum (Invitrogen), 0.1 % Triton X-100 (Sigma) in PBS for 45 min. Subse-
quently, the cells were washed with PBS twice for 5 min per wash. The primary antibody
was diluted in 10 % fetal bovine serum (Invitrogen), 0.1 % Triton X-100 in PBS. The
cells were incubated with primary antibody solution over night at 4 ◦C. Next day the
cells were washed three times with PBS for 5 min per wash. The secondary antibody
against the species in which the first antibody was produced, was diluted in 10 % fetal
bovine serum (Invitrogen), 0.1 % Triton X-100 in PBS. The cells were incubated with
the secondary antibody for 1 hour at RT in the dark. Then the cells were washed three
times with PBS for 5 min per wash. The nuclei of the cells were counterstained with
4,6-Diamidin-2-phenylindol (DAPI, Invitrogen) solution (200 ng/ml in PBS). 200 µl of
DAPI solution was added to the cells and incubated in the dark for 20 min at RT. Finally,
the cells were covered with PBS to keep them moist. The fluorophores on the secondary
antibodies were visualised by using a Zeiss LSM 510 Meta confocal microscope with a
connected camera for microscopy model AxioCam ICC3 and the software Axiovision 4.6.
The following primary antibodies were used in this study:
Table 6.1: List of primary antibody
Human antigene Species Company Product Code
ALB (ALBUMIN) mouse Sigma-Aldrich A-6684
ALCAM mouse Santa Cruz sc-74558
AFP (Alpha Fetoprotein) mouse Sigma-Aldrich WH0000174M1
A1AT (Alpha 1 Antitrypsin) mouse R&D Systems MAB1268
BSEP goat Santa Cruz sc-17292
CD133 (Prominin-1) mouse Millipore MAB4399
CD31 (PECAM-1) mouse R&D Systems BBA7
CDX2 mouse Santa Cruz sc-166830
c-MYC rabbit Santa Cruz sc-764
CK18 (Cytokeratin 18) mouse DakoCytomation M7010
CXCR4 mouse Invitrogen 35-8800
E-CAD (CDH1) mouse Santa Cruz sc-21791
FOXA2 (HNF3β) goat Santa Cruz sc-6554
HNF4α mouse Santa Cruz sc-8987
KLF4 rabbit Santa Cruz sc-20691
LGR5 rabbit Abgent ABIN389218
LIN28 rabbit Proteintech Europe 16178-1-AP
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Human antigene Species Company Product Code
NANOG goat R&D Systems AF1997
NES (NESTIN) mouse Millipore MAB5326
NTCP goat santa cruz sc-107030
OCT4 mouse Santa Cruz sc-5279
PAX6 rabbit Covance PRB-278P
PDX1 goat Santa Cruz sc-14664
PODXL rabbit Santa Cruz sc-33138
SMA (Smooth Mucle Actin) mouse DakoCytomation M0851
SOX2 goat Santa Cruz sc-17320
SOX17 goat R&D Systems AF1924
SSEA1 mouse Millipore SCR001
SSEA4 mouse Millipore SCR001
T (Brachyury) goat R&D Systems AF2085
TRA-1-60 mouse Millipore SCR001
TRA-1-81 mouse Millipore SCR001
TUJ1 (class III beta TUBULIN) mouse Sigma-Aldrich T8660
ZO-1 goat Santa Cruz sc-8146
The following secondary antibodies were used:
Table 6.2: List of secondary antibody
Human antigene Species Company Product Code
anti-goat IgG, Alexa uor 488 donkey Invitrogen A11055
anti-goat IgG, Alexa uor 594 chicken Invitrogen A21468
anti-mouse IgG, Alexa uor 488 goat Invitrogen A11001
anti-mouse IgG, Alexa uor 594 goat Invitrogen A11005
anti-rabbit IgG, Alexa uor 488 donkey Invitrogen A21206
anti-rabbit IgG, Alexa uor 594 chicken Invitrogen A21442
6.3.4 Karyotyping
The Chromosomal analysis was performed after GTG-banding by Prof. Dr. G. Thiel
(Praxis für Humangenetik, Friedrichstr. 147, 10117 Berlin, Germany). For each cell line
20 metaphases were counted and 10 karyograms analyzed.
6.3.5 Isolation of Genomic DNA
To isolate DNA, the cells were scraped from the well, transfered to a 15 ml tube and
centrifuged. The pellet was used for the DNA isolation. The DNA isolation was done
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by using the FlexiGene DNA Isolation Kit (Qiagen) according to the manufacturers
guidelines. Subsequently, DNA concentration and quality was assessed by NanoDrop
measurements. 1 µl was used for quality check by photometric quantification with a
spectrophotometer type NanoDrop ND-1.000 and measured at a wavelength of 260 nm
to determine concentration. For quality control the ratio of 260 nm and 280 nm was
measured.
6.3.6 Agarose Gel Electrophoresis
For the preparation of an agarose gel (1 - 3.5 % gels were used in this study) the
appropriate amount of agarose was dissolved in 100 ml 1x SB buffer. The solution was
boiled using a microwave until it got clear. 0.5 µg/ml ethidium bromide was added.
The solution was mixed and subsequently poured into an agarose gel tray. Finally, gel
combs with the appropriated number of teeth and size of the teeth were put into the
liquid gel solution. After 20 min the gel was polymerized. The gel combs were removed
and the agarose gel was covered with 1x SB buffer. 6x DNA-loading buffer was added
to each PCR sample and the agarose gel was loaded with the samples. The length of
the amplicons was determined in relation to a DNA ladder. The gels were run at 50
V for 30 min or longer, depending on the size of the amplicon and the pore size of the
agarose gel. The nucleic acids were visualised with UV light using the AlphaImager
(Alpha Innotech).
6.3.7 Polymerase Chain Reaction
The PCR reactions were used to perform DNA fingerprinting of iPSCs and to detect the
sequences of the episomal plasmid (Yu et al. [2011]).
Reaction mix for one DNA sample:
2.0 µl DNA
0.2 µl dNTP-Mix (dATP, dCTP, dGTP, dTTP each 25 mM)
1.0 µl forward primer and reverse primer mix (100 µM)
0.25 µl Polymerase





























Table 6.3: List of PCR primer for vector detection
Gene Size (bp) Symbol Sequence 5‘- 3‘ Annealing Temp.
T-Oct4 657 pOCT4 F AGTGAGAGGCAACCTGGAGA exogen 62 ◦C
pIRES R AGGAACTGCTTCCTTCACGA
T-NANOG 732 pNANOG F CAGAAGGCCTCAGCACCTAC exogen 62 ◦C
pIRES R AGGAACTGCTTCCTTCACGA
T-LIN28 447 pLIN28 F AAGCGCAGATCAAAAGGAGA exogen 58 ◦C
pSV40pA R CCCCCTGAACCTGAAACATA
T-SV40LT 491 pSV40LT F TGGGGAGAAGAACATGGAAG exogen 55 ◦C
pIRES R AGGAACTGCTTCCTTCACGA
Oct4 113 hOCT4 F AGTTTGTGCCAGGGTTTTTG endogen 58 ◦C
hOCT4 R ACTTCACCTTCCCTCCAACC
oriP 544 pEP4-SF1 TTCCACGAGGGTAGTGAACC exogen 58 ◦C
pEP4-SR1 TCGGGGGTGTTAGAGACAAC
EBNA1 666 pEP4-SF2 ATCGTCAAAGCTGCACACAG exogen 60 ◦C
pEP4-SR2 CCCAGGAGTCCCAGTAGTCA
The sequences were used as described from Yu et al. [2011].
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Example of a PCR-program:
Step 1 94 ◦C 5 min.
Step 2 94 ◦C 15 sec.
Step 3 58 ◦C 30 sec.
Step 4 68 ◦C 1 min.
Step 5 68 ◦C 7 min.
Step 4 4 ◦C forever
Step 2 till Step 4 were repeated 32 times before proceeding to step 5. The PCR was
carried out using a Thermocycler type PTC100 (MJ Research Inc).
6.3.8 DNA Fingerprinting
The DNA fingerprinting was used to analyse the relation between the generated iPSC
lines and the parental cell line. After isolation of genomic DNA from the iPSC lines
(as described before) different PCRs (as described before) with the primer set D7S796,
D10S1214, D17S1290 and D21S2055 were performed. The primers amplify different
VNTRs (variable number of tandem repeats). The amplicons were visualised by agarose
gel electrophoresis (as described before) with a concentration of 2 - 3 % agarose.
Table 6.4: List of primer sequences for DNA fingerprinting.









6.3.9 Isolation of RNA
To isolate RNA the cells were scraped from the well, transfered to a 15 ml tube and
centrifuged. The pellet was used for the RNA isolation. The RNA isolation was done by
using the Direct-zol RNA Miniprep (Zymo Research, R2050) or Universal RNA Purifi-
cation Kit (Roboklon, E3598-02) and according to the manufacturers guidelines. Subse-
quently, RNA concentration and quality was assessed by NanoDrop measurements and
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gel electrophoresis. 1 µl was used for quality check by photometric quantification with a
spectrophotometer type NanoDrop ND-1.000 and measured at a wavelength of 260 nm
to determine concentration. For quality control the ratio of 260 nm and 280 nm was
measured which should be > 2.0. 1 µl was used for the gel electrophoresis.
6.3.10 Generation of cDNA
RNA was isolated as described before. 1 µg of the RNA was mixed with Oligo dT
Primer (1 µg/µl; Invitek) and filled up with ddH 2O to a volume of 10 µl. This solution
was incubated for 10 min at 70 ◦C, cooled on ice and supplemented with a master mix
consisting of following components:
5.0 µl 5x reaction buffer (Promega)
0.5 µl dNTP-Mix (dATP, dCTP, dGTP, dTTP each 25 mM)
0.1 µl MMLV (Moloney Murine Leukemia Virus) reverse transcriptase (200 U/µl, USB)
9.4 µl ddH 2O
After 1 h incubation at 42 ◦C the reaction was stopped at 65 ◦C for 10 min. Afterwards
the cDNA was diluted 1:5 with distilled water. The incubation was carried out using a
Thermocycler PTC100 (MJ Research Inc).
6.3.11 Quantitative Real Time PCR
The qRT-PCR was performed in 384-well Optical Reaction Plates (Applied Biosystems).
Reaction mix for one cDNA sample:
3 µl SYBRGreen PCR Master Mix (Applied Biosystems)
2 µl cDNA (1:5 dilution)
1 µl forward primer and reverse primer mix (5 pmol/µl)
1 µl ddH 2O
Table 6.5: List of rtPCR primer
Gene Size (bp) Symbol Sequence 5‘- 3‘
GAPDH 81 forward CTGGTAAAGTGGATATTGTTGCCAT
reverse TGGAATCATATTGGAACATGTAAACC
OCT4 119 forward GTGGAGGAAGCTGACAACAA
reverse ATTCTCCAGGTTGCCTCTCA
SOX2 78 forward GTATCAGGAGTTGTCAAGGCAGAG
reverse TCCTAGTCTTAAAGAGGCAGCAAAC
NANOG 78 forward CCTGTGATTTGTGGGCCTG
reverse GACAGTCTCCGTGTGAGGCAT
134
Chapter 6. Material and Methods
Gene Size (bp) Symbol Sequence 5‘- 3‘
LEFTY1 76 forward AATGTGTCATTGTTTACTTGTCCTGTC
reverse CAGGTCTTAGGTCCAGAGTGGTG
GDF3 96 forward TTGGCACAAGTGGATCATTGC
reverse TTGGCACAAGTGGATCATTGC
FGF4 109 forward CCCTTCTTCACCGATGAGTGC
reverse CATTCTTGCTCAGGGCGATG
DPPA4 91 forward TGGTGTCAGGTGGTGTGTGG
reverse CCAGGCTTGACCAGCATGAA
DNMT3B 93 forward GCTCACAGGGCCCGATACTT
reverse GCAGTCCTGCAGCTCGAGTTTA
SOX17 86 forward ACGTGTACTACGGCGCGATG
reverse CTGGTGCTGGTGCTGGTGTT
FOXA2 97 forward TTCAGGCCCGGCTAACTCTG
reverse CCTTGCGTCTCTGCAACACC
HNF4 102 forward GTGCGGAAGAACCACATGTACTC
reverse GAAGCATTTCTTGAGCCTGCAGTA
AFP 88 forward AGCAGCTTGGTGGTGGATGA
reverse CCTGAGCTTGGCACAGATCCT
ALB 77 forward GCGCAGATGACAGGGCGGAA
reverse GTGCCGTAGCATGCGGGAGG
A1AT 76 forward GGTCACAGAGGAGGCACCC
reverse AGTCCCTTTCTCGTCGATGGT
TBX3 88 forward AGTCCTCCAGTGAACAAGCAG
reverse TCTTTGAGGTTCGATGTCCC
FAH 79 forward CGGGCCGGAGCCAGAAAAC
reverse ACCATTCCCCAGGTCTATG
TDO2 77 forward GGTGAAAGACGGCTGTCATACAG
reverse TGGAACCTAGGCTCTTCCCTG
PROM1 69 forward GACTTGCGAACTCTCTTGAATGA
reverse GGTAGTGTTGTACTGGGCCAAT
LGR5 118 forward TTTGGACAAGGGAGACCTGGAGAA
reverse AGAGGAGAAGGACAAGAAAGCCACA
CYP1A1 195 forward AAACAGGGCCACATAGATGC
reverse AGGGTCCTGGTTTGGCTAGT
CYP3A4 79 forward GTGACTTTGCCCATTGTTTAGAAAG
reverse CAGGCGTGAGCCACTGTG
CYP3A7 77 forward GATTCTGTACGTGCATTGTGCTC
reverse ATTTGGTCATCTCCTCTATATTACCAAGT
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Gene Size (bp) Symbol Sequence 5‘- 3‘
CYP3A11 forward TGGTCAAACGCCTCTCCTTGCTG
reverse ACTGGGCCAAAATCCCGCCG
CYP19A1 100 forward TGGCTGTGCAGGAAAGTACATC
reverse AACACACTGTCCTTGCAATGTCTTC
PDX1 145 forward CTCCACCTTGGGACCTGTTTAGAGA
reverse CGCCCGAGTAAGAATGGCTTTATGG
CDX2 100 forward TCCTGGTCTGGGAAGGGAAGAGAAA
reverse CGGAAGCCAAAGGCAGCTAAGATAG
CXCR4 79 forward CACCGCATCTGGAGAACCA
reverse GCCCATTTCCTCGGTGTAGTT
6.3.12 Embryoid Body-based Differentiation
The hESC or iPSC colonies were cut manually into pieces with a Microlance injection
needle (Becton Dickinson, Madrid, Spain). The cells were gently removed with a cell
scraper. The cell clumps were transferred to a 15 ml falcon tube. After centrifugation
DMEM medium was added to the cell pellet. The hESCs or iPSCs were seeded on ultra
low attachment dishes (Corning). The cells were cultured in 10 ml of medium per cell
culture dish. The cell pieces formed spheres, so called embryoid bodies (EBs), due to
the fact that the cells could not attach to the surface. Those which cannot form spheres
will die. The medium was changed every two days through transferring the EBs into a
15 ml tube. The EBs were settled by waiting 5 min. The medium was drawn off and
fresh medium was added. The EBs were transferred back to the ultra low attachment
culture dish and were put in the incubator (INNOVA CO-170 Incubator, New Brunswick
Scientific) at 37 ◦C and 5 % CO2 in a humidified atmosphere. The EBs were cultured
seven days. Afterwards the EBs were seeded onto 12 well cell culture dishes that were
coated with 0.1 % gelatin and the same medium (DMEM) was used. The EBs attached
onto the gelatin surface and differentiated. Three days after seeding on gelatin some
wells were fixed with paraformaldehyde to detect the early markers of the germ layers
Brachyury (mesoderm) and PAX6 (neuroectoderm). To detect the other markers the
EBs were fixed with paraformaldehyde 10 days after seeding on gelatin. Generally,
the EBs were stained by immunofluorescence-based staining of marker proteins of the
three germ layers. Stainings for SOX17, AFP and FOXA2 detecting the endoderm
differentiation. Staining for Brachyury and α-SMA detect differentiation into mesoderm
lineage. PAX6, β-TUJ and NESTIN were stained to detect differentiation of ectoderm
germ layer. The immunofluorescence-based detection of proteins was done as described
before (Chapter 6.3.3).
136
Chapter 6. Material and Methods
6.3.13 Teratoma Formation
The in vivo differentiation experiments (teratoma formation) were performed by EPO
Berlin GmbH (Germany, http://www.epo-berlin.de, accessed 26.02.2016). Approx-
imately 2 x 106 cells of the cell line were harvested by combined type IV collagenase
treatment and 0.05 % Trypsin/EDTA-treatment and washed. Cells were resuspended in
50 µl PBS, then mixed with Matrigel (1:2) and immediately injected subcutaneously into
NOD.Cg-rkdcscid Il2rgtm1Wjl/SzJ mice, commonly known as NOD scid gamma (NSG).
Teratoma formation was carefully monitored and sacrificed 63d after injection. The
teratomas were collected and processed by means of standard procedures for paraffin
embedding, then hematoxylin and eosin staining. Histological analysis was performed
by a pathologist.
6.3.14 Microarray-based gene expression profiling
Illumina bead chip hybridization
Total RNA was isolated for each sample as described in chapter 6.3.9. For global gene
expression analysis on a Illumina microarray platform quality-checked total RNA was
used. 500 ng RNA for each sample was used as input for the amplification and bi-
otin labeling reactions (Illumina TotalPrep RNA Amplification Kit, Ambion, Austin,
TX, USA), which precede bead chip hybridizations. The cRNA synthesis, BeadChip
hybridization and scanning was performed by ATLAS Biolabs GmbH (http://www.
atlasbiolabs.com, accessed 26.02.2016).
Data analysis
All gene expression data analyses were done in cooperation with the bioinformatition of
our group Wasco Wruck, Institute for Stem Cell Research and Regenerative Medicine,
Heinrich Heine University, 40225 Düsseldorf, Germany.
The gene expression data were background subtracted and normalized on the basis of
the rank invariant algorithm of the Gene Expression Module version 1.8.0 provided with
the GenomeStudio software (formerly BeadStudio, Illumina). An arbitrary cut-off value
was set to eliminate negative gene expression signals, which may have resulted from
background subtraction. GenomeStudio calculates a Detection p-value for every gene
by comparing its signal intensity with that of negative control beads to determine the
probability that this gene is expressed.
The quality of the experiments is controlled by calculation of the Pearson correlation
coefficient between all experiments vs. each other. These coefficients are summarized in
a table marking value ranges of the correlation coefficients in different colors to enable
detection of outliers. Additionally, a dendrogram is generated via the plotSampleRela-
tion from the Bioconductor lumi package to enable comparison of similarities between
experimental samples and outlier finding by obvious misalignments in the dendrogram.
For the generation of Venn Diagrams and to carry out correlation coefficient analy-
ses, the normalized data sets were filtered for genes present in either sample or in
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at least one of the samples under investigation (Detection p-value/pdet < 0.01, http:
//bioinfogp.cnb.csic.es/tools/venny/index.html, accessed 26.02.2016). The dif-
ferential gene expression was calculated using the Illumina Custom Model (Kuhn et al.
[2004]). The Diff p-values (p-value, describing the probability that a genes signal inten-
sity has changed between two samples or groups of samples) were adjusted by the Ben-
jamini and Hochberg false discovery rate (FDR) correction algorithm (Benjamini1995).
Genes had to be at least 1.5 fold up- or down-regulated between the samples of interest
and the corresponding FDR-adjusted Diff p-value had to be padj < 0.05, to be considered
differentially expressed.
Functional annotation and enrichment analyses were performed using the DAVID plat-
form version 6.7 (http://david.abcc.ncifcrf.gov/home.jsp (accessed 26.02.2016);
Dennis et al. [2003]; Huang et al. [2009]). Illumina ProbeIDs or official gene symbols
were used as input against the background of Homo sapiens; analyses were executed
based on DAVID default parameter settings. Expression profiles of all genes are an-
alyzed via k-means clustering. In order to achieve a sufficient granularity k =1 00
clusters are conceived. The k-means clustering algorithm from the R/Bioconductor en-
vironment is applied for this task. An association table of Illumina probes and genes
to the 100 clusters is the result of the clustering analysis. Plots of mean and standard
deviation of all genes expression over all HLC differentiation phases are condensed for
all clusters. Heatmaps of these clusters are generated via the heatmap2 function from R
(http://www.r-project.org/ (accessed 26.02.2016); Team [2010]; G. R. Warnes and
Venables [2010]).
Stage-specific clusters containing genes which are prominently expressed in dedicated
stages of the differentiation. These were extracted from the k-means clustering. Four
clusters were selected containing similar genes to OCT4 (POU5F1), SOX17, AFP and
ALB. The gene sets from these clusters were subjected to transcription factor analy-
sis via oPOSSUM3 single site analysis using default parameters with the exception of
restricting the amount of upstream/downstream sequence to 2000 / 2000 bases. To
detect pathways over representation in differentiation stages stage specific genes were
determined via comparisons of DE vs. iPSCs, HE vs. DE, HLCs vs. HE, Fetal liver
vs. HLCs and PHH vs. fetal liver. Differentially expressed genes in these comparisons
were found with the criteria a) Illumina detection p-value < 0.05 in at least one of both
conditions, b) ratio < 0.75 or ratio > 1.3333 and c) limma-p-value < 0.05 and limma-
q-value < 0.05. The differentially expressed genes are subjected to pathway analysis
via Consensus Path DB. For cluster analysis of expression of liver-specific metabolisms
cytochromes, ABC transporter genes and several other transporter genes were filtered
from the microarray experiments of iPSCs, definitive endoderm (DE), hepatic endoderm
(HE), hepatocyte-like cells (HLCs), fetal liver and primary human hepatocytes (PHH).
Heatmaps of these clusters are generated via the heatmap2 function from R using Eu-
clidean distance as distance measure. To detect differences and commonalities between
HLCs, fetal liver and PHH genes differentially expressed in HLCs vs. iPSCs, fetal liver
vs. iPSCs and PHH vs. iPSCs were compared via a Venn diagram. Differential expres-
sion was termed significant if a) limma-p-value < 0.05 and limma-q-value < 0.05, b)
detection-p-value < 0.05 at least in one of both conditions and c) ratio < 0.75 or ratio
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> 1.33. In order to detect differences between the three experiments in more detail an
analysis of variance (ANOVA) was employed to filter genes followed by pairwise t-tests.
Genes were termed significant if a) anova-p-value < 0.05 and anova-q-value < 0.05, b)
t-test p-value < 0.05 and t-test q-value < 0.05 and c) detection-p-value < 0.05 at least
in one of both conditions.
Opossum
The oPOSSUM database was downloaded in June 2014 and Single Site Analysis was
performed on this local instance to detect over-represented conserved transcription factor
binding sites in a set of progenitor associated genes (Kwon et al. [2012]). This analysis
was parameterized to use the species human, 2,000 base pairs upstream and downstream
each, use only JASPAR Transcription Factor Binding Site (TFBS) profile matrices which
belong to the tax group vertebrates, a minimum relative TFBS position weight matrix
(PWM) score of 0.85 and a minimum information content (specificity) of JASPAR TFBS
profile matrices of 8. The network was drawn based on the results of the oPOSSUM
analysis using only transcription factors surpassing a predefined for the Z-Score. The
Z-Score shows if in the investigated up- and downstream regions of the set of genes
there are more TFBS than in the background. We used a relatively restrictive threshold
of 10 to focus on the core regulatory network. For all transcription factors above this
threshold we extracted the conserved binding sites from the oPOSSUM analysis output
and connected them with the transcription factor itself as edges in the graph. For the
drawing and layout of the graph we employed the R package network (http://www.
jstatsoft.org/v24/i02/paper (accessed 26.02.2016)) which was instructed to draw
red circles for genes and green circles with sizes corresponding to the Z-scores for the
transcription factors. For a closer look into the stages we used a threshold of 3.
Pluritest
It is a robust open access bioinformatic assay of pluripotency in human cells (Mller et al.
[2011], http://www.scopus.com/inward/record.url?eid=2-s2.0-79953267538&
partnerID=40&md5=7108a16c223225f3d2443f06cbba4ace, accessed 26.02.2016). With
this tool the gene expression pattern of the new iPSC line will be compared to the
expression profile of several hundreds hESC and iPSC lines from multiple laboratories
all over the world.
Novelty Score: A score that is based on well-characterized pluripotent samples in the
stem cell model matrix. Samples are color-coded green (pluripotent), orange, red (not-
pluripotent) based on the probabilities given from the logistic regression model. Orange
and red samples are more dissimilar to the pluripotent samples in the model matrix than
the other pluripotent samples in the matrix. A low Novelty Score indicates that the test
sample can be well reconstructed based on existing data from other well-characterized
iPSC and ESC lines. A high Novelty Score indicates that there are patterns in the tested
sample that cannot be explained by the currently existing data from well-characterized,
karyotypic normal pluripotent stem cells. Partially differentiated pluripotent cells, ter-
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atocarcinoma cells or karyotypically abnormal embryonic stem cells may have a high
pluripotency score but cannot be reconstructed well with data from well-characterized,
normal pluripotent stem cells and thus are expected have a high Novelty Score.
A plot of hierarchical clustering generated by the Lumi package after the samples
were transformed with a variance stabilizing transformation (VST) and before robust
spline normalization (RSN). Outlier arrays with too much technical variation might be
spotted if they do not cluster with their respective technical or biological replicates
from the same sample or sample type. For example, if an array hybridized with the
RNA from an pluripotent cell clusters with fibroblasts on the same chip, but not with
other pluripotent samples, something might be wrong with technical aspects of your
experiment.
6.4 Hepatocyte-Like Cell Generation
For the differentiation of iPSCs into hepatocyte-like cells (HLCs) the three step proto-
col from Sullivan et al. [2010] was used. The cells have to be cultured feeder-free on
Matrigel-coated plates. The first step of differentiation starts at a cell colony density of
30 - 50 %. To generate the definitive endoderm (DE) stage the cells were treated with
the following medium:
Table 6.6: Medium for definitive endoderm
Amount Component Company Product Code
96 % RPMI medium Gibco 31870-025
2 % B27 Gibco 12587-010
1 % Glutamin Gibco 25030-081
1 % Penicillin and Streptomycin Gibco 15070-063
From day one to day three 100 ng/ml Activin A (R&D; 338-AC-010) and 50 ng/ml
Wnt-3A (R&D; 5036-WN-010) were added to the medium. Day four and five 100 ng/ml
Activin A only was added to the medium.
The next differentiation step is the hepatic endoderm (HE) stage which needed four
days of treatment with the following medium:
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Table 6.7: Medium for hepatic endoderm
Amount Component Company Product Code
76.5 % KnockOut DMEM medium Gibco 10829-018
20 % KnockOut Serum Replacement (SR) Gibco 10828-028
0.5 % Glutamin Gibco 25030-081
1 % Non-Essential Amino Acids Lonza BE13-114E
1 % Penicillin and Streptomycin Gibco 15070-063
0.01 % β-Mercaptoethanol Gibco 31350-010
Each day 1 % DMSO was added freshly to the medium.
The last step of HLC generation was modified. During the last step of differentiation
we used 25 ng/ml dexamethasone instead of 10 M hydrocortisone 21-hemisuccinate. The
following medium composition was used for five days:
Table 6.8: Medium for hepatocyte-like cells
Amount Component Company Product Code
82 % Leibovitz’s L-15 medium Gibco 11415-049
8 % Fetal Bovine Serum (FBS) Biochrom S 0115
8 % Tryptose Phosphate Broth solution Sigma 8159-100ML
1 % Glutamin Gibco 25030-081
1 % Penicillin and Streptomycin Gibco 15070-063
0.01 % Insulin Solution Sigma I9278-5ML
Each day 10 ng/ml HGF (Pepro Tech; 100-39), 20 ng/ml OSM (R&D; 295-OM-010)
and 25 ng/ml Dexamethasone (R&D; 1126/100) were added freshly to the medium.
6.4.1 Periodic acid-Schiff (PAS) Assay
To identify glycogen storage in iPSC-derived HLCs the Periodic Acid-Schiff (PAS) Stain-
ing System (Sigma; 395B-1KT) was used. The purpose of this method is to identify car-
bohydrate macromolecules through chemical reaction. Periodic acid oxidizes the glucose
residues and creates aldehydes, which react with Schiff reagent producing purple colour.
Cells were fixed with 4 % PFA for 15 min, washed with distilled water and incubated
with Periodic Acid solution for 5 min. Then washed 3 times with water and incubated
for 15 min with Schiffs reagent. Afterwards the cells were washed with distilled water
(5 min), stained with Hematoxylin (90 sec) and again washed with distilled water. The
result was examined under an Olympus CK2 phase contrast microscope and represen-
tative morphology was recorded at a magnification of X50 using a Canon 300D digital
camera.
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6.4.2 Indocyanine Green (ICG) Assay
Indocyanine Green (ICG) is an indicator dye used for assessing liver and cardiac function,
which after intravenous injection is bound to plasma protein (primarily albumin). This
substance is rapidly taken up by the liver and then secreted unchanged into the bile.
The cellular uptake and release of ICG (Cardiogreen, ICG, Sigma; I2633-25MG) was
performed to prove the presence of albumin in hepatocyte-like cells derived from human
iPSCs (Yamada et al. [2002]; Ho et al. [2012]). Stock solution (5 mg/ml) of reagent
was prepared in DMSO (Sigma; C6164-50ML) and freshly diluted in culture media to
1 mg/ml just before application. Cells were incubated in culture media supplemented
with ICG for 30 min at 37 ◦C. Afterwards, the cells were washed with PBS (Gibco;
10010-023) and fresh medium without substrate was added. The uptake of the dye
was documented. To examine the release of ICG the cells were cultured under normal
conditions for 6 h. Afterwards cellular release was analyzed. The result was examined
under an Olympus CK2 phase contrast microscope and representative morphology was
recorded at a magnification of X50 using a Canon 300D digital camera.
6.4.3 5 (and 6)-Carboxy-2,7-dichloroflurescein diacetate (CDFDA)
Assay
5 (and 6)-Carboxy-2,7-dichloroflurescein diacetate (CDFDA) is an indicator dye (fluo-
rescent substrate) used for assessing liver function (Zamek-Gliszczynski et al. [2003]).
This substance passively diffuses into hepatocytes where it is hydrolyzed to CDF or
hydrolized in the extracellular medium to CDF. CDF is taken up via an Oatp mediated
process and is excreted from the liver by Mrp2 on the canicular membrane and Mrp3 on
the basolateral membrane. The cellular uptake and release of CDFDA (Sigma-Aldrich;
21884-100MG) was performed to highlight canicular formation and prove the function-
ality of the HLCs derived from human iPSCs. CDFDA was diluted in DMSO (Sigma;
C6164-50ML) and was freshly diluted in culture medium to 1 µM just for application.
The Cells were incubated in culture media supplemented with CDFDA for 30 min at 37
◦C. Afterwards, the cells were washed with PBS (Gibco; 10010-023) and fresh medium
without substrate was added. The uptake of dye was documented by using a Zeiss LSM
510 Meta confocal microscope with a connected camera for microscopy model AxioCam
ICC3 and the software Axiovision 4.6. To examine the release of CDFDA the cells were
cultured under normal conditions for 6 hours. Afterwards cellular release was anal-
ysed by using a Zeiss LSM 510 Meta confocal microscope with a connected camera for
microscopy model AxioCam ICC3 and the software Axiovision 4.6.
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Figure 6.3: Scheme of CDFDA uptake and release.
CDFDA passively diffuses into hepatocytes where it is hydrolyzed to CDF or hydrolized in the
extracellular medium to CDF. CDF is taken up via an Oatp mediated process and is excreted
from the liver by Mrp2 on the canicular membrane and Mrp3 on the basolateral membrane.
Figure adapted from Zamek-Gliszczynski et al. [2003].
6.4.4 Urea Assay
Urea is the major end product of protein catabolism in the liver. The detection of
urea in the medium proves another functionality aspect of intact hepatocytes. This
QuantiChromTM Urea Assay Kit (BioAssay Systems; DIUR-500) is designed to measure
urea directly in biological samples without any pretreatment. The method utilizes a
chromogenic reagent that forms a colored complex specifically with urea. The intensity
of the color, measured at 520 nm, is directly proportional to the urea concentration in
the sample. The 5 µl of water (blank), standard row (50 mg/dl; 25 mg/dl; 12.5 mg/dl;
etc.) and samples were pipetted directly in wells of a 96-well-plate. Then 200 µl of
working reagent were added to the wells and taped lightly to mix. After an incubation
period of 10 to 20 min the optical density at 470 - 550 nm (peak absorbance at 520 nm)
was measured with a plate reader. Three biological replicates in technical triplicates of
each sample were analyzed. The levels of urea are presented as a percentage, considering
measured levels of urea in mg/dL/24 h.
6.4.5 Bile Acid Assay
The bile acid assay was performed by Dr. Diran Herebian, Department of General
Pediatrics, Neonatology and Pediatric Cardiology, Heinrich Heine University, 40225
Düsseldorf, Germany. Bile acids (cholic acid CA, chenodeoxycholic acid CDCA, de-
oxycholic acid DCA, ursodeoxycholic acid UDCA, lithocholic acid LCA) including their
glycine- and taurine derivatives were analyzed by UPLC-MS/MS. The system consisted
of an Acquity UPLC-H Class (Waters, UK) coupled to a Xevo-TQS tandem mass spec-
trometer (Waters, UK) which is equipped with an ESI source operating in the negative
ion mode. Quantitative data were conducted in the multiple reaction monitoring (MRM)
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mode. The chromatographic separation was performed on Waters UPLC BEH C18 col-
umn (100 mm, 2.1 mm ID, 1.7 m; Waters, UK) using acetonitrile and acidic water (0.1
% formic acid) as mobile phases. Analytes were separated by a gradient elution. The
injection volume was 5 µl and the column was maintained at 40 ◦C.
6.4.6 CYP3A4 Assay
The P450-GloTM CYP3A4 Assay (Promega; V9001) provides a luminescent method
to measure cytochrome CYP3A4 activity. This protein is localizes in the endoplasmic
reticulum and its expression is induced by glucocorticoids and some pharmacological
agents (Ek et al. [2007]). Luciferin-PFBE was freshly diluted in culture medium to a
concentration of 50 µM. Cells were incubated with culture medium supplemented with
Luciferin-PFBE for 4 h at 37 ◦C (normal culture conditions). Afterwards, 25 µl of the
culture medium supplemented with Luciferin-PFBE were pipetted to 96-well opaque
white luminometer plate. To initiate the luminescent reaction 25 µl of Luciferin Detec-
tion Reagent were added. This mixture was incubated for 20 min in the dark. For the
read out the GloMax-Multi+ Microplate Multimode Reader with Instinct (Promega) was
used. Three biological replicates in technical triplicates of each sample were analyzed.
The levels of CYP3A4 are presented as relative light units per milliliter (R.L.U./ml).
The error bars indicate the standard errors of the mean.
6.4.7 Electron Microscopy
EM was performed by Beatrix Fauler and Dr. Thorsten Mielke, Max Planck Institute
for Molecular Genetics, Microscopy & Cryo Electron Microscopy Group, 14195 Berlin,
Germany. Cells grown on Thermanox plastic coverslips (Nunc) were fixed in a modi-
fied Karnofsky solution, 2 % PFA/2.5 % GA in 50 mM Cacodylate buffer, pH 7.4 at 4
◦C. Cells were washed in 50 mM Cacodylatpuffer / 50 mM NaCl and post-fixed for 90
min at RT with 0.5 % OsO4 in the same buffer. After washing steps with water, cells
were incubated for 40 min with 0.1 % tannic acid in 250 mM Hepes pH 7.4 , washed
with water and stained with 2 % uranyl acetate, 90 min at RT. Cells were dehydrated
in a graded series of ethanol and embedded in Spurrs resin (Low Viscosity Spurr Kit,
Ted Pella, CA, USA). Ultra-thin sections (70nm) were prepared with an ultramicrotome
(Reichert Ultracut E, Leica) and mounted on pioloform-coated slot grids from copper.
Sections were counterstained with uranyl acetate and lead citrate.
Ultrathin-sections were first examined using a Philips CM100 transmission electron mi-
croscope operated at 100 kV and finally imaged using a FEI Tecnai Spirit transmission
electron microscope operated at 120 kV, which was equipped with a 2kx2k Eagle CCD
camera (FEI). The MSI-Raster application within the Leginon Software package (Su-
loway et al. [2005]) was used to automatically image selected regions of interest at a final
nominal magnification of 15,000 x applying a defocus of -4 µm. Raw micrographs were
stitched using the Trakem2 plugin implemented in the Fiji software platform (Saalfeld
et al. [2010]; Schindelin et al. [2012]).
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6.5 Endodermal Progenitor Generation
For E-iPSC differentiation into endodermal progenitors (EPs) the three step protocol
from Cheng et al. [2012] was used. The cells have to be cultured feeder-free on Matrigel-
coated plates. The first step of differentiation starts at a cell colony density of 30 - 50 %.
To generate the definitive endoderm (DE) stage the cells were treated with the following
medium for the first day:
Table 6.9: Medium for definitive endoderm part 1
Amount Component Company Product Code
89 % RPMI medium Gibco 31870-025
10 % SFD-Medium - -
1 % Penicillin and Streptomycin Gibco 15070-063
40 ng/ml Wnt3a R&D 5036-WN-010
100 ng/ml ACTIVIN A R&D 338-AC-010
The next two days the cells were treated with the following medium:
Table 6.10: Medium for definitive endoderm part 2
Amount Component Company Product Code
99 % RPMI medium Gibco 31870-025
1 % Penicillin and Streptomycin Gibco 15070-063
100 ng/ml ACTIVIN A R&D 338-AC-010
10 ng/ml VEGF R&D 293-VE-050
10 ng/ml FGF Peprotech 100-18B
0.5 ng/ml BMP4 R&D 314-BP-050
The next two days the cells were treated with the following medium:
Table 6.11: Medium for definitive endoderm part 3
Amount Component Company Product Code
99 % SFD-Medium - -
1 % Penicillin and Streptomycin Gibco 15070-063
100 ng/ml ACTIVIN A R&D 338-AC-010
10 ng/ml VEGF R&D 293-VE-050
10 ng/ml FGF Peprotech 100-18B
0.5 ng/ml BMP4 R&D 314-BP-050
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The SFD-Medium was prepared with the following components:
Table 6.12: SFD-Medium
Amount Component Company Product Code
74 % IMDM medium Gibco 21980-065
25 % Ham‘s F12 medium Cellgro 10-080-CV
1 % Penicillin and Streptomycin Gibco 15070-063
0.1 % BSA Sigma-Aldrich A7979
0.5 x B27 A Gibco 12587-010
0.5 x N2 Gibco 17502-048
50 µg/ml L-Ascorbic Acid Phosphate Wako 013-19641
0.45 mM 1-Thioglycerol Sigma-Aldrich M6145
After five days the DE stage achieved. To get the next stage of transient cells (TCs)
the cells were treated in a special medium for two, three and four weeks. The original
protocol from Cheng et al. [2012] described this period for 4 weeks. The medium to
generate TC consists of the following components:
Table 6.13: Medium for transient cells
Amount Component Company Product Code
99 % SFD-Medium - -
1 % Penicillin and Streptomycin Gibco 15070-063
1 % DMSO Santa Cruz sc-202581
100 ng/ml HGF Pepro Tech 100-39
50 ng/ml BMP4 R&D 314-BP-050
20 ng/ml TGFα Pepro Tech 100-16A
10 ng/ml VEGF R&D 293-VE-050
10 ng/ml EGF R&D 236-EG-200
10 ng/ml FGF Peprotech 100-18B
0.1 µM Dexamethasone R&D 1126/100
After two, three or four weeks the medium was changed to the maintenance medium
of EPs. After one passage culturing the TC in EP maintenance medium the pre-EPs
were generated. The following components constitute the EP maintenance medium:
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Table 6.14: Medium for endodermal progenitor maintenance
Amount Component Company Product Code
99 % SFD-Medium - -
1 % Penicillin and Streptomycin Gibco 15070-063
50 ng/ml BMP4 R&D 314-BP-050
10 ng/ml VEGF R&D 293-VE-050
10 ng/ml EGF R&D 236-EG-200
10 ng/ml FGF Peprotech 100-18B
The EPs were generated when organoids were formed.
6.6 Activin A Assay
The TGF-β superfamily is an huge protein group including the transforming growth
factor β (TGF-βs) and Activins. Members of the TGF-β superfamily are involved in
embryonic development, maintenance and differentiation of embryonic stem cells, so-
matic stem cells and cancer stem cells as well as in development and maintenance of
various organs (Massagu et al. [1987]; Massagu [1992]; Wilson and Hemmati-Brivanlou
[1995]; Brandenberger et al. [2004]; Qi et al. [2004]; Clotman and Lemaigre [2006];
Xu et al. [2008]; Watabe and Miyazono [2009]; Wu and Hill [2009]). The Quantikine
Human/Mouse/Rat Activin A Immunoassay (R&D; DAC00B) employs a 3-step quanti-
tative sandwich enzyme immunoassay technique. The capture antibody is biotinylated
and bound to streptavidin-coated plates. First, the plate was washed once and 100 µl
Assay Diluent was pipetted into each well. Second, 100 µl standard (1,000 pg/ml; 500
pg/ml; 250 pg/ml; etc.), water (blank) and samples were pipetted to the Assay Diluent.
The plate were incubated for 3 hours on a horizontal orbital microplate shaker set at 500
rpm. After washing away any unbound substances, an HRP-conjugate specific for the
A subunit is added to the wells. Following a wash to remove any unbound conjugate, a
substrate solution is added to the wells and color develops in proportion to the amount
of Activin A bound. The color development is stopped and the intensity of the color is
measured.
6.7 Cytokine Assay
The cytokine assay was done by Lucas Spitzhorn using the Proteome Profiler Array
(Human XL Cytokine Array Kit; R&D Systems, Minneapolis, USA). The medium for
the analysis was collected from fetal MSCs after they had reached a confluency of about
95 %. Therefore the cell culture supernatant was centrifuged at 500 x g to remove
particles. The membrane was analysed by detecting the emitted chemiluminescence
with the camera Fusion FX (Fusion FX; Vilber Lourmat) and the software Fusion-FX
(Fusion-FX Fischer Biotec, Australia). The images were further analysed for the different
pixel densitys using ImageJ (ImageJ; JAVA, National Institutes of Helath, USA).
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Figure S1: Immunofluorescence-based detection of surface markers in H1.
A) Staining of the surface protein alkaline phosphatase (AP) overwiev of the well, microscopy image
and live stained cells (from left to right). B) All protein stainings for the surface markers SSEA-4,
TRA-l-60 and TRA-1-81 were positive, SSEA-1 was negative. DAPI stained the nucleus. Scale bar:
200 µm, Alexa Flour 594 (red), Alexa Fluor 488 (green).
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Figure S2: Immunofluorescence-based detection of pluripotency markers in H1.
All protein stainings for pluripotency markers OCT4, NANOG, SOX2, KLF4, c-MYC, LIN28 and




Figure S3: Summary of k-means clustering.
A) Listing of 100 k-means cluster of HLC differentiation compared with fetal liver and PHH generated
by transcriptome profile analysis. The used k-means cluster for Figure 3.24B are marked with asterisk.
One asterisk = iPSC k-means cluster, two asterisk = DE k-means cluster, three asterisk = HE k-means
cluster, four asterisk = HLC k-means cluster, five asterisk = fetal liver k-means cluster and six asterisk
= PHH k-means cluster. B) Heat map of the selected k-means cluster in A. Abbreviations: PHH =
primary human hepatocytes; iPSC = induced pluripotent stem cells; DE = definitive endoderm; HE =
























continued on next page
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continued from previous page
Figure S4: Summary of k-means clustering.
Transcription factor over-representation analysis via the oPOSSUM data base (Kwon et al. [2012]).
A) The network for iPSCs shows the regulatory relations between OCT4 (POU5F1), SOX2, NANOG,
KLF4. B) The network for DE demonstrates the regulatory relations between SP1, INSM1, MZF1,
KLF4 and REST. C) The network for HE represents the regulatory relations between LHX3, MIZF
and CTCF. D) The network for HLC illustrates the regulatory relations between PLAG1, EWSR1-
FLI1 and IRF2. E) The network for fetal liver shows the regulatory relations between TAL1::GATA1,
HNF1A, ZFN143, GATA1 and HNF1B. F) The network for PHH represents the regulatory relations
between HNF1A, CTCF, ZFX, HNF4A, FOXA2, FOXA1 and CEBPA. Abbreviations: iPSC = induced
pluripotent stem cells; DE = definitive endoderm; HE = hepatic endoderm; HLC = hepatocyte-like
cells; PHH = primary human hepatocytes.
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Figure S5: Illustration of pathways.
EpiHFF1-iPSC derived HLCs were used for transcription factor over-representation analysis via the
oPOSSUM data base (Kwon et al. [2012]).
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Figure S6: Summary of k-means clustering.
EpiHFF1-iPSC derived HLCs were used for transcription factor over-representation analysis via the
oPOSSUM data base (Kwon et al. [2012]).
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Figure S7: Immunofluorescence-based detection of proteins in iPSC derived from HU-
VEC.
A) Destection of successful nucleofected HUVEC with GFP-Vector control. B) The positive detection
of the surface marker in differentiated iHUVEC. SSEA-1 as a differentiation marker of human stem
cells, SSEA-4 as a pluripotency marker is still detectable and CD31 as a marker of HUVEC. DAPI
























Figure S8: Comparative immunofluorescence-based detection of liver specific markers AFP and ALB.
Comparison of protein stainings of the liver specific marker α-Fetoprotein (AFP) and Albumin (ALB) in HLCs generated under different conditions
and long-term culture. HLCs were generated with the treatment of cytokines (epiHUV-3a HLC 5d) or without cytokines and small molecules
(epiHUV-3a HLC SM 5d). Additionally, HLCs which were generated with the common procedure (treatment with cytokines) were cultured longer,
15 days (epiHUV-3a HLC 15d) and 18 days (epiHUV-3a HLC 18d). In all HLCs the expression of AFP and ALB was detectable. DAPI stained
























Figure S9: Immunofluorescence-based detection of pluripotency markers in hESC-H1.
All protein stainings for pluripotency markers OCT4, SOX2, NANOG, and the surface marker TRA-1-60 were positive. The culture of H1 on
mouse embryonic fibroblasts (MEFs) is depicted on the left hand side and the culture of H1 on human fetal mesenchymal stem cells (MEFs) is
























Figure S10: Immunofluorescence-based detection of pluripotency markers in epiHUV-iPS-3a.
All protein stainings for pluripotency markers OCT4, SOX2, NANOG, and the surface marker TRA-1-60 were positive. The culture of epiHUV-
iPS-3a on mouse embryonic fibroblasts (MEFs) is depicted on the left hand side and the culture of epiHUV-iPS-3a on human fetal mesenchymal

























Figure S11: Immunofluorescence-based detection of pluripotency markers in epiHUV-iPS-1f.
All protein stainings for pluripotency markers OCT4, SOX2, NANOG, and the surface marker TRA-1-60 were positive. The culture of epiHUV-
iPS-1f on mouse embryonic fibroblasts (MEFs) is depicted on the left hand side and the culture of epiHUV-iPS-1f on human fetal mesenchymal




Figure S12: Quantitative real-time PCR of pluripotency markers.
Expression pattern of pluripotency markers relative to HFF1 from hESC-line H1, the iPSC-line
epiHFF1-iPS-B1 and the iPSC-line epiHUV-iPS-3a are shown. The cells were cultured in conditioned
medium (CM) made from mouse embryonic fibroblats (MEFs), which is the common used CM, and
fetal mesenchymal stem cells (fMSCs) made CM (fMSC-CM). Three biological replicates in technical
























Figure S13: Immunofluorescence-based detection of pluripotency markers in hESC-H1.
All protein stainings for pluripotency markers OCT4, SOX2, NANOG, and the surface marker TRA-1-60 were positive. The culture of H1 on
Matrigel with mouse embryonic fibroblasts (MEFs) made conditioned medium (CM) with additional FGF is depicted on the left hand side (H1
MEF-CM +FGF) and the culture of H1 on Matrigel with human fetal mesenchymal stem cells (MEFs) made CM with additional FGF is depicted
























Figure S14: Immunofluorescence-based detection of pluripotency markers in hESC-H1.
All protein stainings for pluripotency markers OCT4, SOX2, NANOG, and the surface marker TRA-1-60 were positive. The culture of H1 on
Matrigel with mouse embryonic fibroblasts (MEFs) made conditioned medium (CM) without additional FGF is depicted on the left hand side
(H1 MEF-CM -FGF) and the culture of H1 on Matrigel with human fetal mesenchymal stem cells (MEFs) made CM without additional FGF is

























Figure S15: Immunofluorescence-based detection of pluripotency markers in epiHUV-iPS-3a.
All protein stainings for pluripotency markers OCT4, SOX2, NANOG, and the surface marker TRA-1-60 were positive. The culture of epiHUV-
iPS-3a on Matrigel with mouse embryonic fibroblasts (MEFs) made conditioned medium (CM) with additional FGF is depicted on the left hand
side (iHuv3a MEF-CM +FGF) and the culture of epiHUV-iPS-3a on Matrigel with human fetal mesenchymal stem cells (MEFs) made CM with
additional FGF is depicted on the right hand side (iHuv3a fMSC-CM +FGF). DAPI stained the nucleus. Scale bar: 200 µm, Alexa Flour 594
























Figure S16: Immunofluorescence-based detection of pluripotency markers in epiHUV-iPS-3a.
All protein stainings for pluripotency markers OCT4, SOX2, NANOG, and the surface marker TRA-1-60 were positive. The culture of epiHUV-
iPS-3a on Matrigel with mouse embryonic fibroblasts (MEFs) made conditioned medium (CM) without additional FGF is depicted on the left
hand side (iHuv3a MEF-CM -FGF) and the culture of epiHUV-iPS-3a on Matrigel with human fetal mesenchymal stem cells (MEFs) made CM
without additional FGF is depicted on the right hand side (iHuv3a fMSC-CM -FGF). DAPI stained the nucleus. Scale bar: 200 µm, Alexa Flour
594 (red), Alexa Fluor 488 (green).
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Supplementary Tables are located on the second pdf.
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einen Doktorgrad beworben und besitze keinen entsprechenden Doktorgrad.
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